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ABSTRACT
INTRODUCTION Colorectal cancer (CRC) is the UK’s second most common 
carcinoma and remains a significant cause of mortality despite impressive medical 
advances over the last two decades. Survival outcome is related to histological stage 
of disease at diagnosis, as well as the mode of clinical presentation, be it emergency 
or elective. Same-stage CRC’s do not necessarily harbour a similar prognosis or 
clinical course, nor is the stage at presentation related to the duration of symptom 
suffered. Additionally, over a third of CRC present as an emergency or with late 
stage disease, conferring a poor prognosis. This heterogeneity has been attributed to 
differences in underlying tumour biology, and has driven the search for useful 
biomarkers of disease and prognosis.
The aim of this project was to undertake a global examination of the proteome of 
colorectal cancer tissue, investigating novel differences between protein expression 
profiles of emergency and elective tumours.
METHODS Dukes C tumour was taken from the left colon from 6 elective and 6 
emergency surgical cases and cryo-preserved. Following cryosectioning, proteins 
were extracted and resulting lysates were separated by two-dimensional gel 
electrophoresis. Gels were then stained with colloidal Coomassie blue and images 
analysed for differences in spot intensities. Protein spots of interest were isolated and 
subjected to in-gel trypsin digestion and resulting peptides were analysed by mass 
spectrometry. Proteins were identified by searching the NCBI database with 
MASCOT software.
Identified proteins were further analysed using immunohistochemical staining of a 
CRC tissue microarray. Scores taken from the staining intensities were added to a
II
customised database and cross-referenced to common clinicopathologic parameters 
for statistical analyses.
RESULTS Several differentially regulated proteins were identified between 
emergency and elective patient groups, including glutathione-S-transferase pi (GST- 
pi), ubiquitin carboxyl-terminal esterase (ubiquitin thiolesterase), haemoglobin beta, 
heat shock protein 27 (Hsp27) and S100A8. Two proteins thus identified, Hsp27 and 
S100A8, were further analysed.
Hsp27 was expressed within tumour cells, whilst S100A8 was confined to myeloid 
cells throughout the stroma. High Hsp27 expression and emergency type presentation 
were significantly associated with a positive surgical resection margin (p=0.01 and 
p=0.034 respectively).
In node positive CRC (Stage III), expression of Hsp27 was associated with a 
significantly worse prognosis compared to node positive tumours that did not express 
Hsp27 (p=0.03).
Emergency tumours containing lower levels of S100A8 expressing cells within the 
stroma were associated with a poor outcome when compared to cancers with higher 
levels of SI00A8 (p-0.03),
CONCLUSION This study provides an insight into the biology of clinically 
distinct CRC groups. The expression of Hsp27 and S100A8 may represent potential 
prognostic biomarkers within a subset of clinically high-risk patients, which may be 
useful in guiding or tailoring existing treatment options.
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Section 1 Introduction
1.1 Incidence and Mortality
1.1.1 Incidence
Each year, 1.2 million individuals worldwide will develop bowel cancer accounting 
for 9.7% of all new cancers diagnosed.1 Large bowel cancer is the third most 
commonly diagnosed carcinoma and the fourth most frequent cause of cancer-related 
mortality worldwide.2
In 2008, 39 998 new cases of large bowel cancer were registered in the UK giving rise 
to an incidence of 47.2 per 100 000 population with a male to female ratio of just over 
one (11 : 10). The incidence has remained relatively stable over the last three 
decades, except for a slight increase observed in men.3 The lifetime risk of 
developing colorectal cancer in the UK is currently 1 in 14 for men and 1 in 19 for 
women3 with the incidence increasing with age; approximately 70% of patients with 
CRC are over 65 years of age.4
Across the globe the incidence of colorectal cancer displays wide geographical 
variation, with the age adjusted rates on either end of the spectrum differing by up to a 
factor of 15.5 Industrialised nations tend to experience the highest incidence whereas 
South American and African countries enjoy a relatively low incidence.6 This 
geographical discrepancy may be partially accounted for by differences in the national 
diet, as exemplified by the contrast in incidence between the native Japanese 
population and descendants of Japanese immigrants who settled in North America; 
they, like the Americans have a higher incidence of CRC.5 The change in incidence 
approximating to that of the host country has been observed within the time frame of 
one generation.7
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1.1.2 Mortality
Survival is measured as the percentage of those individuals with the diagnosed 
condition that are still alive at a given time from the diagnosis. Overall 5-year 
survival for colorectal cancer varies between just over 60% in North America to less 
than 50% in UK and Denmark.8
Following surgical resection, survival rates in the United Kingdom lag behind those
observed in Europe, although there is some evidence to suggest that this may be due
to later disease stage at clinical presentation in the UK.9’10 Indeed, one of the factors
upon which survival is dependant is the spread of disease at the time of diagnosis.
Studies in England and Wales have demonstrated that 55% of CRC patients present
with advanced colorectal cancer (Stage III or IV) with an average five year survival of
45% 11, whilst others have shown that up to 53% of UK patients with colorectal
12cancer have metastatic disease at the time of diagnosis.
The quality of treatment, extent of surgical clearance, service provision and volume of 
caseload at specialist units also contribute to overall survival. Studies have shown 
that centres with higher caseload volume and specialisation are associated with better 
outcome.13 This has made a particular impact on the surgical treatment for rectal 
cancer14,15, and over the last decade the age standardised mortality rates have fallen 
by 13%3 with improved treatment, increased awareness and early detection.16
Other factors intimately related to survival are the mode of clinical presentation 9’ 17 
and inherent tumour biology.18"22
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1.2 Aetiology and Pathophysiology 
1.2.1 Sporadic Colorectal Cancer
The majority of colorectal cancer occurs sporadically and accounts for 88-94% of all 
cases.2 Colorectal cancers arise from pre-malignant polyps, known as adenomas, 
which are areas of proliferative mucosa lining the bowel. As these polyps grow 
beyond a certain size, they loose their differentiated cellular architecture and become 
dysplastic.23 A well-described adenoma-carcinoma sequence has been postulated 
encompassing genomic theory24, and forms the basis of progressive chromosomal 
instability as a consequence of an accumulation of errors (see Vogelgram pi5). The 
resulting dysregulation of molecular pathways controlling cell migration, 
differentiation, proliferation and apoptosis25 are responsible for the sequential 
phenotypical changes from overgrowth of colonic mucosa to colon cancer.26 Roughly 
85% of all sporadic cases exhibit chromosomal instability (CIN) whereas the 
remaining 15% demonstrate microsatellite instability (MSI).27
These biological factors may be associated with dietary and lifestyle risk factors in the 
development of CRC.28 Importantly, lifestyle factors are amenable to modification 
with potential influence on disease incidence.
Although hereditary CRC accounts for the remaining 5-10% cases, up to 20% of 
affected individuals have a familial component to their disease that does not fulfil the 
strict hereditary criteria.29
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1.2.1.1 Risk Factors
1.2.1.1.1 Environment and Lifestyle
CRC is a disease of the Western World and as such can be correlated to ‘developed’ 
lifestyles from the following work:
• There seems to be an inverse relation between physical activity performed 
during the day and likelihood of developing CRC.30,31 This may be related to 
the increase in gut transit time32 associated with the more active individual, 
thereby reducing intra-mural epithelial carcinogen exposure.33
• Heavy tobacco use has also been shown to increase the lifetime risk of CRC 
by as much as two to three times.34,35
• The consumption of tea and coffee has been implicated in CRC with varied 
results. A recent study found that there was no direct relation between tea and 
the risk of colon or rectal cancer, but a cohort of coffee drinkers had a reduced 
pooled relative risk.36
• Alcohol has been implicated as a risk factor for developing distal bowel 
cancer, and it is thought that the mode of action is antagonism of methyl- 
group metabolism37 and has been associated with a decreased intake of 
folate.38
In developing countries such as China a correlation has been demonstrated between 
schistosomiasis and the development of colorectal cancer.39
1.2.1.1.2 Diet
Diet varies throughout the world and several observations have been made:
• The postulated protective effect of dietary fibre has long been a source of 
much debate. A protective role has been shown, mainly by observational 
studies.40,41 The type, rather that quantity, of fibre ingested has been shown to
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be of greatest importance, with cereal fibre of least value and vegetable and 
fruit fibre offering the most protection.42 However, a Cochrane review of 
randomised controlled trials concluded that there was insufficient evidence 
linking increased dietaiy fibre intake with a reduction in incidence or 
recurrence of adenomatous polyps.43
• Increased consumption of meats has been shown to be associated with CRC.44, 
45 When meat is seared during cooking, the carbonaceous products contain 
aminoimidazoazarenes or AIA’s, which are mutagenic 46 They have been 
shown to be carcinogenic in both bacterial and mammalian species.47
• Bile acids secreted into the gut are subject to bacterial metabolism and have 
been implicated as carcinogens48 As bile secretion increases after 
cholecystectomy, there is some evidence that there is an increased post- 
operative risk of bowel cancer in this population.49,50 Diets high in fat may 
cause an excess of bile secretion, and may promote growth of bacteria that 
degrade bile salts to carcinogens51 and so may also be implicated.
• Dietaiy calcium binds to bile salts in the gut and previous work has shown that 
supplemental calcium brings about a reduction in the risk of recurrent colonic 
adenomas.52
• Fatty acids have been studied to reveal both protective and promotional with 
regards to carcinogenesis. Work done on linoleic acid (a n-6 polyunsaturated 
fatty acid), a derivative of arachadonic acid, reveals that a diet high in content 
of this acid tends towards cancer formation.53, 54 On the other hand, low fat 
diets containing eicosapentaenoic acid (a n-3 polyunsaturated fatty acid) have 
shown an inhibitory effect on CRC.55
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1.2.L 1.3 Contributing Medical Co-Morbidities
Inflammatory Bowel Disease (IBD) increases the risk of developing malignancy later 
in life and accounts for 1-2% of all CRC.2 Crohn’s disease and ulcerative colitis are 
associated with a higher risk of malignancy due to prolonged mucosal inflammation.56 
Around one third of all IBD deaths are cancer-related and the increased risk depends 
on the duration of the disease (2% of affected people by 10 years, 8% by 20 years, 
and 18% by 30 years), the degree of inflammation, and the presence of primary 
sclerosing cholangitis and backwash ileitis.57,58
The underlying mechanism appears to be related to the host immune response to 
intraluminal bacteria in conjunction with genetic alterations.59 The process involves 
complex interplay between factors such as cyclo-oxygenase 2 (COX-2), nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB), and tumour necrosis factor 
alpha (TNF-a)60 and the resulting expression of inflammatory cytokines, anti 
apoptotic factors and angiogenic factors.
As mentioned previously, removal of the gallbladder is implicated in CRC.50
Diabetes mellitus predisposes to a higher risk of developing bowel cancer due 
elevated levels of faecal bile and autonomic neuropathy causing slow gut transit.
1.2.2 Hereditary Colorectal Cancer
Hereditary CRC accounts for 5-10% of all cases. The two main hereditaiy disorders 
that give rise to CRC are familial adenomatous polyposis (FAP) and hereditary non­
polyposis colon cancer (HNPCC)29. Both are inherited with an autosomal dominant 
pattern and a germline mutation in the APC gene is identifiable in 80% of FAP 
cases.61
6
FAP manifests its phenotype as multiple small adenomas throughout the intestine 
(more than 100), usually by the age of 15. If left untreated, cancer inevitably occurs 
by the age of 40 attributed to progressive chromosomal instability. The APC gene 
may be responsible for other phenotypic changes such as desmoids tumours and 
osteomas and if these are present, the term Gardner’s Syndrome is applied.
HNPCC, or Lynch syndrome is caused by a germline mutation of Mismatch Repair 
genes such as MLH1, MLH2, PMS1, PMS2, and MSH6. MLH1 and MSH2 are 
mutated in around 35% of HNPCC cases27, 62. Its diagnosis is aided by the 
identification of microsatellite instability, which occurs in 95% of cases. The 
instability is defined as frequent mutations in short repeated sections of DNA63, and is 
also associated with an increased risk of developing other types of tumours including 
those of the pancreas, small intestine, biliary system and central nervous system.29,61, 
64 HNPCC patients tend to develop carcinoma by the age of 44, most of which is 
right-sided.65 The diagnosis is often difficult to make as there are no type specific 
phenotypic manifestations (as seen in FAP) and as a result several clinical criteria 
have been developed to aide such a purpose. These are known as the Amsterdam 
criteria64, all of which must be satisfied to confirm the diagnosis. These are:
• One individual diagnosed with CRC who is younger than 50 years
• Two successively affected generations
• Three affected relatives, one a first-degree relative of the other two
• FAP should be excluded
• Tumours should be verified by pathological examination.
This condition is associated with a 30% risk of developing synchronous or 
metachronous tumours and, in women who cany the mutation, a 20-40% chance of 
endometrial cancer.62,66,67
7
1.3 Basic Anatomy and Physiology
The colon extends from the terminal ileum to the rectum at the recto-sigmoid 
junction, located 15cm from the anal verge, which then joins the anus in continuity. 
The colon is divided, according to its position, into the caecum (to which the appendix 
is attached), the ascending colon, the transverse colon, the descending colon and the
z: o
sigmoid colon (Figure 1).
Transverse Colon (5%) Inferior
Figure 1: Anatomy of The Large Bowel
Anatomical divisions of the large bowel are displayed with the frequency of 
associated tumours at that site in brackets.3
The anatomical and clinical discrepancy between colon and rectum has lead to much 
difficulty in differentiation between colon and rectal carcinoma - the rectum can be 
defined as beginning where the sigmoid colon enters the lesser pelvis at the pelvic 
brim where it continuous with the rectum at the third piece of the sacrum.
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1.3.1 Blood Supply
The arterial blood supply is distributed in keeping with the embryonic development of 
the mid and hindgut. The proximal arteries are derived from branches of the superior 
mesenteric artery; the ileocolic, right and middle colic arteries. These supply the right 
side of the colon from caecum to the splenic flexure, the point where the hind and mid 
gut join. Following on distally, the descending and sigmoid colon are supplied by 
branches of the inferior mesenteric artery, namely the left colic and sigmoid arteries. 
The blood supply of the entire colon is in communication via an anastamosed loop 
that extends from the distal ileum to the distal sigmoid colon about 1cm from the 
bowel wall and allows for adequate perfusion in an event such as proximal 
obstruction. This is known as the marginal artery of Drummond.68
The venous drainage corresponds to its arterial counterpart and the tributaries that 
form the superior mesenteric vein join the splenic vein to form the portal vein. The 
inferior mesenteric vein drains into the splenic vein and thence into the portal vein.68
1.3.2 Digestive Function
The colorectum is uniformly described as “the large bowel” and averages 1.5 meters 
in length. The main function of the large bowel is involved with the final stages of 
digestion, and includes salt and water re-absorption, bacterial activity, storage and 
evacuation of faeces. During a 24-hour period, about 1500ml of water, 200mmol of 
sodium and lOOmmol of chloride pass through the ileocaecal valve. The colonocytes 
absorb up to 95% of the sodium and water in this period using active transport 
through the cell membrane on the luminal epithelial surface.69,70
The large bowel is a muscular tube consisting of distinct layers, the innermost being 
the mucosa, followed by sub-mucosa, then the two muscular layers (circular and 
longitudinal) which is finally encapsulated by the serosa. The muscular layers have
9
longitudinal condensations or thickenings at three points around the gut and are 
displayed as longitudinal bands running along its length. These are termed taenia 
coli. 68’ 69 Staging of bowel cancer relies on the depth of tumour invasion through 
these layers.71
The mucosa, which forms the smooth lining of the gut, is further divided into 
epithelium (a one cell thick layer mainly made up of columnar cells), the lamina 
propria, and the muscularis mucosae. This layer has a distinct structure and gives rise 
to the colonic ‘crypts’ (Figure 2),
The submucosa lies below and in contact with the mucosa, and is predominantly made 
up of loose connective tissue containing the necessary lymph and blood vessels that 
supply the mucosa.
The serosal lining of the gut is formed by loose areolar tissue that is encapsulated by a 
single layer of squamous mesothelial cells that allow the visceral organs to glide past 
one another in the abdominal cavity.
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1.3.3 The Colonic Crypt
• 73A colonic crypt is formed by the invagination of epithelium into the lamina propria.
The crypt is the site of epithelial cell production, which originates from pluripotent 
stem cells. As they differentiate and migrate up the crypt structure they are eventually 
shed at the surface of the epithelium. The progenitors are committed to differentiate 
at the crypt-villus junction after which they migrate in collinear bands towards the tips 
of the colonic epithelium. The proliferative cells occupy the bottom two thirds of the 
colonic crypts whereas differentiated cells constitute the top third and surface 
epithelium (Figure 2).72
Surface
epithelium
crypt
colon
Figure 2: Histological appearance of normal colonic crypt and epithelium
The colonic cells are stained with the cell cycle marker Ki67 to identify 
proliferative cells 72, demonstrating differentiation along the crypt villus axis. 
(Reproduced with permission)
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The precursor cells are responsible for producing three distinct types of differentiated 
cell found within the large bowel: columnar epithelial cells, goblet cells and 
enteroendocrine cells. They can be classified into two functional lineages, secretory 
and absorptive. Colonocytes are absorptive cells whilst the secretory lineage 
encompasses goblet and enteroendocrine cells (Figure 3).
Differentiated cells
Crypt-villus
junction
Goblet Entero- Absorptive 
cells endocrine epithelial cells 
cells
* • #
\ f t 
*
\ f Proliferative
progenitors
Stem cell
•Vi'* 1 Paneth cell
Figure 3: The Colonic Crypt (schematic)
A schematic representation of the lineage of stem cells and their differentiated 
products. The position of the cells at each stage in their development correspond 
to the relative position along the crypt-villus axis.72 (Reproduced with 
permission)
Goblet cells are designed to produce mucus, which protects the gut and aids passage 
of motion, enteroendocrine cells produce neuro-active peptides and the epithelial cells
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perform a digestive function. The average life span of the epithelial cell is between 3 
to 8 days before it is extruded and sloughs off into the luminal content.69 From this 
description one can appreciate the very high turn over of cells in the large bowel, and 
it is here in the crypts that mutations of a clonal cell line may give rise to the 
beginnings of neoplasia - from aberrant crypt foci progressing to adenomatous polyps, 
growing and acquiring mutations; changes which may further progress to cancer.74 It 
is this observation that has driven the investigation of stool in a quest for disease 
biomarker discovery.75'77
1.4 Colorectal Cancer and the Adenoma-Carcinoma Sequence
Histological observations have lead to the theory that colorectal cancer develops as a
result of worsening dysplasia originating within normal colorectal epithelium.78 
Classically, colorectal cancer develops as a consequence of a series of mutations 
acquired in a multistep process that affect molecular pathways, often evolving over 
several years or decades.26 These accumulated genetic aberrations cause a step wise 
tumourigenic progression of bowel epithelium leading to the development of 
cancerous tissue within adenomatous polyps, as described by Voglestien in the late 
1980’s (Figure 4). The age distribution of adenomatous polyps and CRC show that 
prevalence of both increases with increasing age, but the highest prevalence for 
adenomas was, on average, 5 years earlier than that of CRC79, with a similar 
distribution of both throughout the colon.80 Furthermore, histological examination 
has shown that large adenomatous polyps were observed to have more dysplatic 
changes, cellular atypia and genetic abnormalities than their associated smaller 
counterparts 26 and that a proportion of adenomas contain carcinomatous foci.81
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Normal epithelium Early adenoma / 
dysplastic crypt
Late adenoma Carcinoma Metastasis
© KRAS
Genetic Instability: CIN or MIN
TPS3
20-40 years
Figure 4: Progressive phenotypic changes of CRC and associated genetic 
aberrations
Genetic instability occurs as a consequence of a series of mutations ultimately 
leading to CRC. This progression described by Vogelstein and Fearon, is 
represented by the ‘VogelgranT displaying phonotypical changes.
Several phenotypic classifications of CRC exist. " The majority of sporadic CRC, 
accounting for 85% of all cases, develops as a result of chromosomal instability 
brought about by an allelic imbalance at several chromosomal loci (typically 5q, 8p, 
17p and 18q), chromosome amplification and translocation, which ultimately 
precipitate tumour aneuploidy.*3, 84 The remaining 15% exhibit high frequency
or
microsatellite instability phenotypes ‘ brought about by mutations of the DNA
oz:
mismatch-repair system. The genes affected include MLH1, MSH2, and MSH6 ; all 
of which have been implicated in familial CRC (HNPCC) as discussed in Section 
1.2.2. The loss of function, which can be brought about by epigenetic silencing of the 
DNA mismatch repair genes, typically displays a phenotype characterised by 
proximal location, poor differentiation, mucinous histology, and lymphocytic 
infiltration.87
These alterations form the basis of the two classical pathways of developing CRC, 
namely chromosomal instability (CIN) and microsatellite instability (MIN). The
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genomic instability and underlying molecular biology of developing CRC have been 
reviewed by Markowitz and Bertagnolli.88
1.5 Presentation, Treatment and Related Survival in CRC 
1.5.1 Presentation of Colorectal Cancer
The symptoms and signs associated with Colorectal cancer are well documented89,90 
and consequent clinical presentation, either elective or emergent, is dependent on 
these. Efforts in reducing delays between symptomatic presentation and definitive 
treatment have been undertaken in a bid to improve clinical outcome.91 In 2001 the 
Government implemented the NHS Cancer Plan in an attempt to improve statistics 
relating to hospital delays and treatment of suspected cancer patients. It incorporated 
a policy that was based on several assumptions. It has long been thought that 
reducing the symptomatic delay in treatment by early diagnosis improved the 
prognosis in CRC.92 The disease was also considered to be associated with certain 
easily identifiable symptoms and risk factors.93 This formed the basis of the UK 
government guidelines that prompted ‘at risk’ patients to be seen by a specialist 
within two weeks, and has since been a topic of much debate.94"97
Several factors have been implicated in CRC disease outcome, but the most 
reproducible predictors are pathological stage at diagnosis, and mode of 
presentation.17, 98 Prognostically implicated histopathological risk factors include 
degree of differentiation, presence of vascular invasion, depth of tumour invasion, 
lymph node yield and involvement.99 Originally the English pathologist Cuthbert 
Dukes described histological staging of rectal cancer in 1932 (Figure 5). This was 
later modified by Astler and Coller in 1954100, but around the same time another 
classification system was described by Pierre Deniox categorising the tumour size, 
lymphatic involvement and metastatic spread of solid cancers, thereby classifying
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disease progression.101 This has since been developed as the TNM (tumour, node, 
metastasis) classification and has been utilised, world wide, to describe tumour stage 
and guide treatment plans. The American Joint Committee on Cancer (AJCC), set up 
in 1992, has produced the 7th edition of the TNM classification system for CRC which 
was published in 2009. This is displayed in Figure 6 with associated prognostic 
outcomes for each classified stage of the disease modified from Cunningham et. a!.21.
STAGE HISTOLOGY 3 YR SURVIVAL
A Growth limited to rectal wall 93%
B Extension of growth into extra rectal tissue but not 77%
lymph nodes
C Tumour in regional lymph nodes 48%
Figure 5: Dukes Staging of Rectal Cancer
Stages were dictated by tumour spread through distinct structures. This was 
later modified to include stage D in patients presenting with distant metastasis
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T - primary tumour
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades through the muscularis propria into subserosa
or into nonperitonealised pericolic or perirectal tissues 
T4a Tumour penetrates the surface of the visceral peritoneum
T4b Tumour directly invades or is histologically adherent to other
organs or structures 
N - regional lymph nodes
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
Nla Metastasis in one regional lymph node
Nib Metastasis in two to three regional lymph nodes
N2a Metastasis in four to six regional lymph nodes
N2b Metastasis in seven or more regional lymph nodes
M - distant metastasis
MX
MO
Mia
Mlb
Stage
Stage
Distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis to one site 
Distant metastasis to more than one site
T N M
5-year overall 
Survival
I T1,T2 NO MO 97.1%
IIA T3 NO MO 87.5%
IIB T4 NO MO 71.5%
IIIA Tl, T2 N1 MO 87.7%
IIIB Tl, T2 N2 MO 75.0%
IIIB T3 N1 MO 68.7%
me T3 N2 MO 47.3%
me T4 N1 MO 50.5%
me T4 N2 MO 27.1%
IV Any T Any N Ml 0-7%
Figure 6: The TNM staging of CRC
Table displaying the stages of CRC with associated 5 year survival figures.
Surgical outcome has been directly related to the stage of disease at presentation2,
79, 103 and the earlier stage diseases (Stage I and II) are associated with the best
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prognosis. It follows that if CRC could be identified at an earlier stage then curative 
surgical intervention should enable subsequent improvement in outcome; a concept 
that underpins the basis for the implementation of the UK national bowel cancer 
screening programme104, and the driver for continued research into biomarkers for the 
early detection of disease.
In reality, patients presenting with symptoms of CRC often have locally advanced 
disease or metastases at the time of presentation, and only half of those who undergo 
apparently curative resection survive for 5 years,105 although this figure is 
progressively improving". Patients suffer their symptoms for varying lengths of time 
before presenting themselves for medical opinion. These delays are multifactorial but 
include, amongst others, unwillingness to attend the doctor, personal fears and 
anxieties, inequalities in health provision, incapacity or cultural influences. Whatever 
the underlying cause, studies have shown that symptom duration is unrelated to stage 
of disease at diagnosis103,106, whilst paradoxically, others report that a shorter duration 
of symptom is associated with more advanced stage of disease.98,107 Speculation has 
therefore arisen attributing more biologically aggressive tumours with increasingly 
severe symptoms, such as pain for example, precipitating an earlier presentation. No 
clinical reason for this association has been ascertained, but further investigation into 
the protein makeup of these more aggressive tumours may shed light on novel 
findings that could account for biological behaviour.98
The type of clinical presentation is also significantly implicated in CRC outcome and 
survival.17 Emergency presentations account for between 20% and 40% of all CRC 
admissions, a figure which has remained consistent over the last three decades.17,108' 
110 There is no one particular symptom that is associated with emergency 
presentation, but intestinal obstruction, perforation or bleeding account for the
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overwhelming majority of cases, often requiring immediate or expedited surgery. 
Both immediate post-operative mortality, and cancer specific mortality are higher for 
emergency cases when compared to matched elective cases.9' I7, ll1, 112 A study by 
McArdle and Hole of 3200 CRC patients who underwent curative resection 
demonstrated a cancer specific 5 year survival rate of 56.3% for elective patients 
compared to 38.5% for emergency CRC patients (Figure 7).
£ 0 8 -
0 7 -
§ 06 -
Elective
Emergency
Time after surgery (years)
Figure 7: Cancer specific survival for emergency and elective CRC
Overall survival in a study of 3200 patients in Scotland according to mode of 
presentation taken from McArdle etal.xl (Reproduced with permission).
Although 30-day postoperative mortality was higher in emergency patients (8.2%
emergency vs 2.8% elective), they found that the hazard ratio for cancer specific
survival for emergency relative to elective surgery (adjusted for age, sex, site and
Dukes stage) was 1.81 (95 per cent c.i. 1.54 to 2.13, p=<0.001) excluding the 30 day
post operative deaths. The authors postulated that poorer outcomes in the emergency
group may be associated with the presence of occult hepatic metastases and increased
levels of circulation cytokines.
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Another study undertaken by Fulham’s group in New South Wales demonstrated the 
poor long term outcome in emergency CRC patients compared to stage matched 
concurrent elective cases.113 Emergency patients also presented with a more 
advanced stage of cancer. The surgical department at Glasgow Royal Infirmary noted 
the association between emergency CRC presentation and systemic inflammation as 
measured by the C-Reactive Protein level (CRP)114, and confirmed an inferior cancer 
specific survival for the emergency CRC group independent of TNM stage.
Little is known about the underlying mechanism linking the clinical findings of 
emergency presentation and associated poor long-term survival, but several groups 
have alluded to the inherent and distinct biology of the underlying CRC. Others have 
suggested that a proteomic investigation might uncover novel findings accounting for 
the differences observed in the clinical course of similar stage tumours.98,115
1.5.2 Treatment of Colorectal cancer
Surgery is the treatment of choice for colorectal cancer. Grinnel suggested that a 
resection margin constituting 5 cm of macroscopically normal bowel should be 
observed in order to obtain sufficient clearance.116 The resected specimen should be 
taken with its anatomical blood supply (see Section 1.3.1) and a high ligation will aid 
adequate lymph node harvest; the current minimum standard enabling adequate 
staging is 12 nodes117, and understaging of the tumour may occur with a lower yield, 
affecting further potential treatment. Complete microscopic resection (designated as 
RO) may require en-block resection of surrounding organs if there is a suspicion that 
the tumour has penetrated the serosa (graded as T4) involving adjacent structures. 
Rectal dissection is undertaken within the mesorectal plane (total mesorectal excision- 
TME) as described by Heald118, and is associated with a reduced risk of local
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recurrence with or without pre operative chemoradiotherapy.119 Surgical outcome has 
also been associated with hospital volume and surgeon caseload for rectal resection.120
Recurrent disease, or relapse, mostly occurs within the first three years and 
significantly affects survival outcome, commonly occurring within the liver or 
lung.121 The current standard of care, if feasible, is resection of oligometastatic 
disease27 which improves the 5 year survival figures substantially.
Stage III (node positive) CRC has been shown to benefit from six months fluorouracil 
based adjuvant treatment, which reduces the risk of death by 30%; equivalent to a 
survival gain of 10-15%122, and its oral alternative, capecitabine, has displayed similar 
efficacy.123 Oxaliplatin, a third generation platinum, has also been used in addition to 
fluoropyrimidines with improved overall survival124, 125but its use must be balanced 
against the potential toxic complications, patient preference, fitness and age. 
Furthermore, genetic polymorphisms have been shown to be of importance in drug 
metabolism.126 The fluoropyrimdines inhibit the enzyme thymidylate synthase and 
polymorphisms of this gene are related to the individual response to adjuvant or neo­
adjuvant CRC treatment.127
Adjuvant chemotherapy for node negative CRC (Stage II) is more controversial. 
Small gains in survival benefit were observed in subgroup analysis of studies with 
combined stage II and III tumours, but high risk cancers (such as T4 tumours, 
emergency presentation, positive resection margins, and inadequate lymph node 
harvest), are often offered treatment.128 The QUASAR study demonstrated a 3.6% 
overall survival gain for stage II disease treated with fluorouracil and folinic acid 
compared to observation alone.129 However, tumour phenotype has been shown to be 
of predictive significance for adjuvant treatment of stage II cancers; high 
microsatellite instability was associated with a poor response to therapy.130
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Targeted therapies with monoclonal antibodies (edrecolomab and bevacizumab) in 
addition to chemotherapy have not been shown to improve disease free survival for 
non metastatic cases (stage II and III)131, 132 but are employed in the treatment of 
advanced metastatic disease. Palliative chemotherapy can improve survival, 
symptoms and quality of life for patients with stage IV disease, as well as downsize 
liver or lung metastasis for those with potentially resectable disease. Target therapy 
has been shown to be efficacious when used in chemorefractory patients either alone 
or in combination with chemotherapy (fluoropyrimidines and platinums)133 although 
this is only offered to patients with wild type KRAS tumours. Several studies have 
demonstrated that mutation of this gene has been a predictor of poor response to 
Epidermal Growth Factor Receptor (EGFR) directed monoclonal antibody therapy134 
and the status of this predictive marker is widely used in a multidisciplinary team 
setting.
Resection of hepatic metastases can lead to a 5-year survival of 35-58% 135 in contrast 
to less than 10% without intervention. Around 15% of unresectable hepatic 
metastases will become resectable after appropriate chemotherapy, and with the 
advent of advanced treatment modalities such as preoperative portal vein embolisation 
and two-stage hepatectomy, even more patients may benefit from this therapy.136
1.6 The Case for Early Detection
Detection of CRC at an early disease stage is paramount if curative intervention is to 
take place. From the information outlined in the Figure 6, displaying disease stage 
and projected survival, it is evident that the 5-year survival figures range from 90% to 
less than 10% depending on what stage clinical intervention occurs.
Several studies have shown that screening using faecal occult blood and colonoscopy
1 T*7 1 TOcan reduce mortality by 15-33% , increase the detection of Stage I and II
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lesions,140 and reduce the number of emergency type presentations.141 Despite this, 
approximately 70% of all CRC are detected at advanced tumour stages (III and IV) 
and thus harbour a poor prognosis.142
In addition to sensitivity and specificity issues, this method of screening has suffered 
poor compliance (it involves not only the handling of faeces, but the unattractiveness 
of colonoscopy). As a consequence, innovative tools and methods for the early 
detection of cancer are being sought, aiming to identify unique biological markers that 
could be incorporated into clinical practice.
1.6.1 Clinical Investigations
A thorough history is of paramount importance as symptoms are varied and familial 
components should be identified (see 1.2.2). There are no blood tests that are specific 
to the diagnosis of colorectal cancer and the gold standard investigations are 
colonoscopy 143or double contrast barium enema.144 The former offers not only the 
diagnostic benefit of obtaining a tissue sample for histological examination during the 
investigation, but may be therapeutic if the lesion is small enough to completely snare 
and excise. Barium studies represent tumours as filling defects, areas of narrowing, or 
strictures. False positive and false negative results may occur in up to 1 % and 7% of 
all cases respectively, occurring most commonly in the sigmoid colon or caecum.145 
These errors can be attributed to a number of factors and can be categorised into 
perceptive errors, technical errors and limitations of barium radiology.
Perceptive errors occur if the films demonstrate a positive lesion, but identification 
went umioticed by the reporter. If too few films are taken, or if suboptimal volumes 
of air insufflated for the ’double contrast’ effect causing a relative overfilling of the 
gut with barium, then the failure is technical. The limitations of barium radiology are 
most obvious when the bowel has been poorly prepared or there is a marked presence
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of diverticular disease. This condition makes identification of small lesions especially 
difficult.
Colonoscopy allows for a more thorough examination of the gut and can supply 
supplementary information, especially in the case of diverticular disease where 
neoplasia may be detected in up to 25 per cent of ‘normal’ barium enemas.146, 147 
With this in mind, it would seem more appropriate to investigate all patients with 
colonoscopy, however, the procedure is not without associated risks. Cardiac events 
(1.1%), bleeding (0.16%), perforation (0.09%) and death (0.007%) have been reported 
following intubation148. Although risk of perforation is present in barium studies, the 
chances of this happening are much higher during endoscopy. Technically, 
colonoscopy is a difficult procedure and even in the most skilled hands total colonic 
examination i.e. viewing the caecum, is unlikely to be achieved in up to ten percent of 
all cases.144 Absolute location of a lesion is also difficult at colonoscopy due to the 
fact that the only fixed points of reference are the terminal ileum and anus.
More recently, CT (computerised tomography) has been used in conjunction with 
careful bowel preparation to produce a ‘virtual colonoscopy’ that is effective in 
detecting polypoid lesions down to 6 mm in diameter.149 This investigation has the 
added benefit of radiological staging; any disease affecting the lungs or liver may be 
imaged at the same time as detecting local tumour extension.148 The disadvantages, 
aside from radiation dose, are that lesions measuring less than 6mm or those with low 
projection will be missed, and any pathology identified will need following up with 
colonoscopy.150
Sigmoidoscopy has been trailed as a screening tool, as up to 75% of all cancers occurs 
in the left colon.143 The procedure is better tolerated than colonoscopy and full bowel 
preparation is not required. Studies have obseived a reduction of CRC incidence and
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mortality151,152 and sigmoidoscopy may lend itself to screening methodology given its 
acceptable compliance.
1.6.2 Non-invasive Testing for Cancer of the Colorectum
In 1969 a large glycoprotein was discovered that was believed to be a sensitive and
specific marker for CRC.153 Known as carcinoembryonic antigen (CEA), it was 
easily detectable in the patient serum and as such its application as a biomarker of 
disease has been extensively investigated. Unfortunately, further studies could not 
demonstrate adequate sensitivity or specificity to justify its use as a screening tool 154, 
155, but this did pave the way for research into useful biomarkers that reflected disease 
status, response to treatment and could be utilised in the early detection of cancer. 
Currently CEA is utilised in clinical practice as a marker of disease recurrence or 
progression in CRC follow-up.156
Current screening methods incorporate non-invasive testing for faecal occult blood 
(FOB). The test identifies the presence of haemoglobin within the excreta, and two 
different methods of testing are available. The UK national bowel cancer screening 
programme uses the guaiac based FOB enzymatic test, which relies on the peroxidase 
like activity of haemoglobin for its detection. This method can produce false 
positives if certain foods or drugs are consumed as the test does not differentiate 
between other non human sources of haemoglobin. Sensitivity increases when using 
the immunological method for human haemoglobin detection, but a reduced 
specificity is still seen as the test does not differentiate between upper or lower 
gastrointestinal bleeding.157 Overall the sensitivity of the available tests has been 
documented as 85-90%, but the specificity has a much wider range of 40-90%.143
With the discovery of genetic alterations in CRC24, and the knowledge that malignant 
colonocytes are shed into the gastrointestinal lumen at a higher rate than healthy
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Severalones158, stool samples have been the subject of molecular testing.159, 160 
genetic mutations, including APC, KRAS and p53, can be assessed in one test and can 
improve detection of tumours when compared to faecal occult blood testing161, 
although there is still a low pick up rate when compared to the invasive test of 
colonoscopy. Validation of these findings has yet to be undertaken using large cohort 
studies, which may also assess their cost effectiveness.162
Several proteins isolated from the stool have also been investigated as biomarkers of 
disease. These included faecal calprotectin (a cytosolic protein in leukocytes), alpha- 
1-antitrypsin, lysozyme, and albumin. None of these, however, displayed any better 
results than those seen with the use of faecal occult blood.163
1.7 Overview of Proteomics 
1.7.1 Proteomic Investigation
With completion of the human genome project, new opportunities and challenges 
have arisen in biomedicine. In addition to profiling tumour tissue at a genomic and 
transcriptional level, the functional product of cellular systems can be investigated; 
the protein. Proteomics is the term used to describe the study of the proteome 
(PROTEin complement to the genOME) and has become one of the leading 
technologies of the postgenomics era,164
Proteome analysis has been used in the detection of disease-associated proteins.165 
However, one of the biggest difficulties posed by current tumour and biomarker 
studies is one of tumour heterogeneity. Evidence indicates that tumours having the 
same histological classification can subsequently have entirely different clinical 
outcomes.166 The genetic make-up of both the individual patient and that of the 
tumour will have an effect on the outcome of a treatment.167 As disease processes are 
complex and involve multiple factors, the search for an individual biomarker related
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to a particular condition is unlikely to yield any one protein that is adequately 
sensitive or specific. As such, a global approach is needed to investigate the dynamic 
range of cellular processes that may reflect the multiple prognostic and diagnostic 
markers associated with the diseased state. Proteomic investigation allows 
identification of functional products of the genome that may aid understanding of 
disease progression and development, as well as giving rise to new drug targets and 
diagnostic markers.168 Ideally, a clinically useful biomarker should be able to detect 
the presence of disease at an early stage (diagnostic) or predict a tumour’s response to 
treatment, thereby providing the patient with individually tailored therapy as well as 
treatment that is tumour specific (predictive).115
Technological advances in proteomics, including 2D gel electrophoresis and mass 
spectrometry, have demonstrated that this science is an invaluable tool with regards to 
understanding how cells behave and interact during a pathological process. Several 
examples of the application of 2D electrophoresis in a variety of malignancies were 
evident at the time of this study. Urological malignancies were recognised to exhibit 
differentially expressed proteins between malignant and benign prostate tissue.'69, 170 
Other malignancies investigated using this technology included bladder171, 172,
i rif\ I ha i nc t ,7/r
oesophagus , breast ’ , and the pancreas.
Although several tumour types have been investigated using proteomics, it is difficult 
to pool their results for cross analysis on account of small sample size and differences 
in techniques. Proteomic research design must therefore be carefully undertaken as 
there are several vital factors involved if the results are to be comparable and 
reproducible.177
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1.7,1.1 Sample Preparation and Selection
The quality and complexity of protein samples are important parameters in proteomic 
investigation. Every step in the process is crucial to the success of the protein 
identification, from tissue collection via biopsy or surgery, to isolation and lysis of the 
target population, and these variables affect the end result. Standardisation of 
procedure improves outcome, and the generation of standard operating procedures 
(SOPs) are being generated by the Human Proteome Organisation.178
Samples have to be prepared under controlled conditions. Once tissue specimens 
have been resected, they must be analysed and cut by an experienced pathologist. 
Although the time taken for the fresh tissue to be preserved in fixative is kept to a 
minimum, the microscopic morphology will be affected as proteolysis begins from 
the time of resection 179. Tissue morphology is maintained through specimen fixation, 
though again, care must be taken at this stage as incorrect fixation can destroy certain 
macromolecules; the cross-links produced by formalin alter the detection of both 
proteins and RNA in the tissue. To circumvent this problem, the use of non-formalin 
alcohol based fixatives allows the protein mechanisms and RNA quality to remain 
intact180’181.
In order to obtain accurate and representative data, molecular analysis of cells is best 
performed within their respective tissue environment. Difficulties in cellular 
procurement arise as samples are often complex and the relevant cell type may only 
comprise a very small proportion of the tissue’s total volume 169,182. Several solutions 
are available to aid cellular acquisition. Cultured cell lines have been used to enhance 
the protein yield from cells of interest, but often do not represent the in vivo 
environment of the original tissue and results are often varied as a result183.
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In a global survey solution, gene expression is examined by extracting the protein 
from the heterogeneous piece of tissue, thus capturing the information of the 
interacting populations of tissue cells in a sample at a given time. The disadvantage 
with this method is that the proportion of diseased subpopulation is not known. 
Sample heterogeneity can be minimised by various enrichment methodologies. 
Microdissection profiling addresses this issue and allows for isolation of the diseased 
population or comparison amongst several subpopulations from a given patient. 
Previous procedures combined manual microdissection l84> 185 with laser ablation of 
areas of tissue that were not needed.186, 187 More current methods involve laser- 
assisted microdissection techniques. Laser beam microdissection cuts out areas of 
interest from the tissue using a laser and transfers it using laser pressure catapulting 
188 or a needle.189
A preferential procedure is known as laser capture microdissection (LCM), originally 
designed at the National Institute of Health in America. Arctums Engineering 
(Mountain View, CA, USA) developed the approach commercially. It involves 
exposing the acquired stained tissue sample to a cap that has a layer of thermo-labile 
ethylene vinyl acetate film. A focussed laser beam melts the film locally over chosen 
cells, causing the tissue immediately below to fuse to the cap. These cells of interest 
can then be removed when the cap is lifted. Thousands of the relevant cell type can 
be captured on one cap from which DNA, RNA, or proteins can be solubilised, once 
an extraction buffer is applied to the film.190
LCM does have its drawbacks, which include process-induced alterations from 
staining and cell procurement, as well as resource constraints. Certified pathologists 
need to select the cells for microdissection, which requires specialist training and 
expensive equipment - not to mention the labour intensive time involved. However,
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in spite of these rather negative aspects of the LCM, it does have an advantage over 
the global survey strategy: it can accurately profile the transition stages, at a 
microscopic level, from normal cells through carcinoma in-situ to invasive carcinoma. 
Indeed, the profiling of these transitional stages could be of great importance with 
regards to cancer prevention.181
Another cell separation method is fluorescence-activated cell sorting or FACS, which 
utilised the technology of flow cytometry. Cell populations are sorted based on 
immunolabeling, providing a fast and quantitative record of fluorescent signals from 
individual cells and a physical separation of cells of interest.191
Affinity or immunocapture purification using antibodies immobilised on a solid phase 
has been used to separate proteins of interest from complex mixtures, whilst protein 
enrichment technology uses anybodies to remove high abundance proteins (depletion) 
or collect low abundance proteins of interest using beads coated with specific ligand 
(enrichment).192
1.7.1.2 Two-Dimensional Electrophoresis (2DE)
Two-Dimensional Electrophoresis (2DE) is a proteomic analysis technique developed 
in the 1970s that involves separating proteins by charge in the first dimension and 
then by molecular weight in the second.193 This is undertaken on a poly-acrylamide 
gel (PAGE), and is sensitive to protein concentrations in the micro to nanomolar 
range 194. Once these variables are separated, the gels are stained so that a 
comparison in protein expression can be made visually between two samples. One 
2DE gel can resolve as many as 10,000 protein spots and, together with mass 
spectrometry, can be used to identify post-translational modifications as well as the 
level of protein expression.195 The disadvantages of 2DE have prompted exploration 
and development in techniques that do not use electrophoresis. A major weakness is
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due to overly complex mixtures of protein, each of which has different 
physiochemical properties and abundances.177 Because of this, 2DE is not efficient 
for detecting extremely acidic or basic proteins (3 < pi < 11) or those less than lOkDa. 
Additionally, a broad range of solubility makes it next to impossible to identify the 
proteomes completely, as low abundant or poorly soluble proteins are lost.196 Even if 
enrichment or prefractionation methods were used to pick up the proteins in lesser 
abundance, ten to fifteen percent of total proteins would still be undetectable.
A modification of 2D PAGE described by Unlu et al is two-dimensional differential 
in-gel electorophoresis (2D DIGE). Different protein samples are labelled with 
different fluorescent dyes and analysed in the same 2DE gel. Three separate samples 
can be run per gel, typically labelled with Cy2, Cy3 and Cy5 dyes (GE Healthcare, 
Little Chalfont, UK)197 and allows assessment of two samples with an internal 
standard. The gels are scanned at the specific wavelengths to reveal the separated 
proteins and allow quantification of their relative abundance using the fluorescent 
intensity. The main advantage of this method is the minimisation of spot pattern 
variability, as co migration of spots between samples is identical.
1.7.1.3 Alternatives to 2DE
In view of 2DE’s inherent weaknesses, different techniques are being researched 
which do not incorporate isoelectric focussing. The term ‘shotgun’ proteomics has 
been used to denote gel free approaches. Procured protein is digested without 
fractionation, and separated by multi-dimensional liquid chromatography.198 These 
separation methods are coupled to mass spectrometry based techniques for differential 
quantification of separated peptides.199 The differential labelling of proteins with 
stable isotopes can create a mass shift, distinguishing identical peptides from different 
samples within a single MS analysis. Methods include stable isotope labelling by
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amino acids in cell culture (SILAC)200, isobaric peptide tags for relative and absolute 
quantification (iTRAQ)201, and isotope coded affinity tags (ICAT).202
ICAT involves chromatographic analysis on cysteine-containing peptides, which are 
labelled with isotopes. Both qualitative and quantitative data can be acquired when 
this is used in conjunction with mass spectrometry 202, however, ICAT has only a 
small dynamic range for detecting differences in protein expression due to the fact 
that one protein in seven does not contain cysteine.203
Label free quantification is becoming more popular, and is based on the precursor MS 
signal intensity of a protein sample. The spectral count of protein peaks is used to 
differentiate between different biological samples, and the resultant quantified 
proteins samples can then be integrated aiding high throughput analysis.205
Multi-dimensional protein identification technology (MUDPIT) uses columns of 
strong cation exchange material back to back with reverse phase material inside fused 
silica capillaries. The chromatography occurs in cycles, with each consisting of an 
increase in salt concentration to release peptides from the strong cation exchange, 
followed by a gradient of increasing hydorphobicity. This progressively elutes the 
peptides from the reverse phase into the mass spectrometer.
1.7.1.4 Protein Visualisation
Once the proteins are separated using 2DE, they are then stained with Coomassie blue
206 207 208, fluorescence staining , or silver staining. The most sensitive method for 
protein detection is silver staining, which can detect a lower limit of 0.1 ng per spot 
209, although it has a number of shortcomings. In addition to some proteins staining 
poorly or not at all, it is poorly reproducible upon subsequent stains, is labour 
intensive, and has limited dynamic range. Although less sensitive, fluorescent
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staining is easier to cany out and more reproducible but can give rise to protein 
charge modifications if used pre-electrophoretically. This can be avoided by the use 
of post-electrophoretic dyes such as SYPRO Red and SYPRO Ruby, which bind in a 
non-covalent fashion to the SDS (sodium dodecyl sulphate) surrounding the protein 
and do not exhibit protein to protein variation. They do not require destaining.209
Colloidal Coomassie brilliant blue staining has been utilised widely due to its ease of 
use, low cost and compatibility with microchemical characterisation methods such as 
mass spectrometry. The proteins have a higher affinity for the dye than the gel and 
this results in a visual map with well-labelled protein spots and minimal background 
gel “noise”. Gel to gel reproducibility is aided by a definite end point to the staining 
process. The detection range is 8-100 nanogrammes of protein, and Coomassie Blue 
provides a linear response to protein concentration range of up to 30 fold.210
1.7.1.5 Protein Identification
Mass spectrometry is the focal technology for identification of proteins. After 
visualisation, targeted proteins are cut out and subject to peptide cleavage by specific 
endopeptidases. A matrix assisted laser desorption/ionisation time of flight mass 
spectrometer (MALDI-TOF MS) then obtains a peptide mass fingerprint.211 The 
sample is mixed with a matrix molecule that absorbs electromagnetic waves at a 
predetermined wavelength. A laser is used to irradiate the crystalline matrix, 
converting it into a gas and ionising the peptides. These ions are ejected from the 
matrix surface and directed down a vacuum tube 212, the time of flight chamber 
(TOF). A digital to analogue converter then processes the signal, the results of which 
can be compared against a database of proteins which have had theoretically 
generated masses.176 If this returns a confident result then the target protein can be 
identified using tandem mass spectrometry (MS/MS) whose purpose is to determine a
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partial sequence or an analysis of fragment ions of a specific precursor.213 Even 
though there have been advances in the implementation of mass spectrometry, the 
vital step of sample preparation remains all important as it leads to efficient laser 
desorption of the sample.214
The peptide sequences derived from the MS data are subject to database searching 
and probability based scoring in order to confer protein identification. Commonly 
used resources include Mascot215 and SEQUEST, which compare experimental 
tandem MS data with theoretical spectra obtained from standard protein datasets.
1.7.2 Proteomics and Colorectal Cancer
Several workers have investigated protein alterations involved in colorectal 
carcinogenesis over recent years with the aim of identifying new biomarkers or 
therapeutic targets. ’ ’ “ Each has involved different proteomic strategies to
address different objectives, with varying numbers of patients. An early attempt to 
pool data on proteomic and transcriptiomic studies and integrate their results was 
undertaken by Sagynaliev et al. 218. Unfortunately, they noted very little overlap and 
reproducibility in gene expression results, and thus they emphasised the need for the 
development of standardized processes given the different technologies involved in 
collection of samples, storage, retrieving and querying gene expression data if 
transitional research is to be undertaken effectively.
Many researchers have chosen to undertake investigations using protein-profiling 
studies i.e. 2D PAGE and MALDI-TOF. Mazzanti et al reported 32 differentially 
expressed proteins between diseased and normal mucosa in eight CRC patients.219 
These proteins were involved with glucose metabolism and provided molecular 
evidence for preferential aerobic metabolism in normal tissue versus glycolysis as the 
energy source in tumour cells. A similar trend was noted by others with enhanced
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glycolysis and decreased gluconeogenesis in CRC tissue suggesting the possibility 
that this is a crucial mechanism in colorectal carcinogenesis.220 A group based in 
Aberdeen noted the expression of liver fatty acid binding protein (L-FABP) was 
reduced in tumour tissue compared to normal colonic mucosa, and that it’s 
immunohis to chemical staining was inversely related to the degree of tumour 
differentiation.221
In a combined study of gene and protein expression in colorectal cancer progression 
Kwong et al found the up regulation of Hsp70 and Hsp60, and a decreased production 
of aldehyde dehydrogenase family 1, phosphoglycerate dehydrogenase and vimentin 
between samples of normal and cancerous tissue.222
Friedman et al also investigated the differential protein expression profile between 
CRC and adjacent normal mucosa, but adopted a variation of 2D PAGE that involved 
differential fluorescent staining of multiple protein samples on the same gel 
(DIGE). They identified 52 distinct proteins whose expression significantly 
differed between the diseased and normal mucosa.
In a bid to follow on from the genetic Vogelstein model of colorectal carcinogenesis, 
Roblick et al investigated the proteome from 15 patients at different stages of the 
adenoma-carcinoma sequence. They analysed the global proteome using 2D 
Electrophoresis in conjunction with MS, and simultaneously measured DNA content 
to ascertain the degree of genomic instability. They noted 112 protein spots that 
displayed at least a two fold differential expression between stages, and went on to 
identify 72 of these by mass spectroscopy. Forty-six of these proteins were 
exclusively expressed in the cancerous state and in metastases.224
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The numbers of patients assessed are small in global profile experiments owing to the 
labour-intensive nature of protein extraction and 2D PAGE, as well as the difficulties 
encountered with gel analysis. Once a protein of interest has been identified, its 
significance to diseases states can be readily investigated with the use of a tissue 
microarray and a well-developed database as demonstrated by Dundas et al.225. Here 
a differentially expressed protein noted between 20 cases of Dukes C carcinoma and 
matched pairs of normal mucosa, was identified using mass spectrometry as 
mitochondrial Hsp70 (also known as Mortalin). A tissue microarray was constructed 
using random samples taken from 264 CRC cases and immunohistochemically 
stained using anti-mitochondrial Hsp70 monoclonal antibody. Clinicopathological 
data was available for all of these cases, and staining intensity was correlated with 
these using multivariate analyses. They successfully demonstrated that expression of 
Hsp70 (Mortalin) was an independent prognostic marker in disease specific survival.
Similarly, in a bid to investigate predictive markers, a report by Allal et al. described 
the response of seventeen advanced rectal cancers to preoperative adjuvant 
radiotherapy using proteomics.226 They identified several proteins that were 
associated with resistance to treatment with radiotherapy (several of which have 
already been described as playing a role in radioresistance), so demonstrating the use 
of proteomics as a valid research tool.
Although many exciting discoveries have been made from the proteomic investigation 
of CRC, there is not enough multi-centre independent evidence to confidently identify 
a specific useful biomarker for use in today’s clinical practice. Nevertheless, research 
continues for a protein, or panel of proteins, that will hopefully be able to serve as a 
marker for early disease recognition, a prognostic indicator, or a predictive marker 
with the aim of improving the outcomes of CRC treatment in the future.
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1.8 Heat Shock Protein 27 and S100A8
Following 2D PAGE analysis of experimental CRC samples, several protein spots of 
interest were identified. Two of these were validated and further investigated using 
immunohistochemistry and tissue microarray techniques. A brief introduction to 
these proteins is undertaken herein.
1.8.1 Introduction to Hsp27
Heat shock proteins are a highly conserved group of proteins present within all 
cellular compartments that function as molecular chaperones. Categorised according 
to their approximate molecular weight, HSPs can be divided into distinct groups; one 
incorporating molecules ranging from 34 - 110 kiloDaltons (kDa), and a low 
molecular weight group consisting of hsp27, ubiquitin and alpha-crystallin. They are 
involved in protein-protein interactions and regulate folding of tertiary and quaternary 
stincture.254 Several physiological conditions induce heat shock protein expression. 
They act on several pathways including apoptosis, cell division and differentiation, 
growth factor activity and tissue development. Although normal physiological 
processes can induce their expression, certain stressors acting upon the cell result in a 
marked increase in protein production. These include exposure to heat, cold, 
ischaemia, ultra violet light, heavy metals, and a change in acid base balance.255
The stimulation of a heat shock response induces transmembrane signalling pathways, 
which promote transcription factors that support a survival benefit to the cell. This 
adaptive response is known as “induced thermotolerance” and allows the cell to 
respond under challenging and diverse conditions.256
Several HSPs have been implicated in pathological and diseased states ’ and an 
understanding of their basic structure and function may be of clinical importance in 
treatment and survival outcome.
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1.8.1.1 Molecular Structure and Function
Cellular stress and subsequent disruption of the cellular microenvironment tends to 
denature proteins. The accumulation of denatured proteins is the initial stimulus for 
HSP induction258 and results in the activation of heat shock factor 1 (hsf-1). This is a 
member of the heat shock factor (HSF) family, which is a potent transcriptional 
activator of the genes encoding lisp 110, hsp90, hspVO and hsp27 and causes their 
mass expression in response to the stressor.259 Hsf-1 is present in the cytoplasm as a 
monomer, which is unable to bind to DNA. Following a stress fill stimulus, Ras 
dependent phosphorylation of the monomer results in the formation of trimeric 
compounds, which are able to translocate to the nucleus. These trimers then bind to 
heat shock element (HSE) at the promoter region of the HSP gene.260
HSPs function as chaperone molecules and interact in a stochiometric fashion with 
their substrate, re-organising the structure of denatured proteins into one of 
conformational and functional order. The chaperone molecules not only restore 
conformational derangement, but also act on apoptotic and cell cycle pathways. 
Hsp27, hsp70 and hsp90 are the key molecules involved in these processes. They 
inhibit cytochrome c and apoptosis-inducing factor (AIF) produced in the 
mitochondrion thus preventing proteolysis. The transcriptional activity of hsf-1 is 
regulated by a negative feedback loop from the expressed heat shock proteins and 
hence the initial response, although rapid, is a controlled event.256 In particular, this is 
a consequence of elevated levels of hsp70 and heat shock protein binding factor.261
Although important players in the measured physiological response to aberrant 
conditions acting on the healthy cell, HSPs seems to become over expressed in the 
pathological cancerous state. This may be as a direct result of an alteration in the 
tumour microenvironment, such as a change in the pH or glucose levels, thus allowing
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a cytoprotective state in otherwise lethal conditions. It has also been suggested that 
genetic mutations encountered during carcinogenesis (i.e. mutated p-53) may give rise 
to conformationally altered oncoproteins, which elicit the same response via the hsf-1 
pathway.262
Elevated levels of Hsp27, Hsp70 and Hsp90 either in isolation or combination have 
been reported in renal, uterine, breast and endometrial carcinoma as well as leukaemia 
and osteosarcoma.263,264
Such alterations have caused speculation that targeting heat shock proteins either at a 
functional or expressional level may be an effective anticancer strategy, as higher 
levels of chaperone activity are protective against cell death and provide a survival 
benefit against treatment strategies.257
This pro survival state has also been attributed to the process of tumourigenesis. Over 
expression of Hsp27 and Hsp70 in transformed cell lines introduced into syngenic 
mice showed tumourigenic potential265 and transgenic mice over expressing Hsp70 
developed T cell lymphomas.266
Exactly how HSPs enhance uncontrolled cell growth is not well understood beyond 
the fact that chaperones are associated with the control of cell cycle regulators and 
components of signal transduction pathways. They could contribute to 
tumourigenesis by suppressing apoptosis allowing oncogenic transformation of 
acquired mutations, from a gain of function mutation at the promoter region. 
Alternatively, this could be secondary to the expression of sub optimally folded 
variant proteins eliciting a direct response from activation of HSF. Either way, this 
adaptive response allows cells to configure cellular transduction in favour of 
unrestrained proliferation 257
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1.8.1.2 Hsp27 and Cancer
Hsp27 is encoded by a gene located at chromosome 7q. Unlike the larger HSPs, it is 
ATP independent but does rely on interactions with the ATP-dependent hsp70 for 
protein folding. As with the other chaperone molecules it also inhibits apoptotic 
pathways and contributes to thermotolerence.
The basic structure constitutes a well-preserved sequence of 88-100 residues known 
as the a-crystallin domain, which is located at the C terminus.268 Physical analysis of 
the sequence has shown the secondary structure to be predominantly a (3-sandwich 
with two antiparallel (3-sheets. The C terminus extension offers solubility and 
contributes to chaperone activity. Hsp27 contributes to several cellular functions 
including cell proliferation, immune response, intracellular protein movement, 
cytoskeletal dynamics, and drug sensitivity. It binds to F-actin which interferes with 
cytochalasin D and heat stress induced disruption of actin microfilaments and hence 
the cytoskeleton.269
Many cancers show varying expression of HSPs.264 High expression of Hsp27 has 
been shown to be associated with an inverse relation to prognosis, and resistance to 
chemoradiotherapy in breast, endometrial, ovarian and prostate cancer, but this trend 
is not observed in other cancer tissue types as reviewed by Ciocca et al
The expression of HSPs (including Hsp27) in relation to histopathological 
characteristics of tumour has been investigated in a bid to identify diagnostic, 
prognostic and predictive clinical implications. As HSPs are generally expressed in 
numerous cancerous states, there is very little to be gained from their use as a disease 
specific diagnostic marker.
Several studies have investigated the implication of Hsp27 as a prognostic marker. 
Thor et al. noted a reduction in disease free survival in lymph node positive breast
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cancer cases that expressed Hsp27270, whilst Tetu et al found no such correlation.271 
Other authors found no consistent significant correlation between Hsp27 expression 
and overall survival in either early or late breast cancer.272, 273 Geisler et al noted a 
better outcome in terms of overall survival in cases of endometrial carcinoma that 
expressed Hsp27274 and in ovarian cancer 275 Work undertaken on prostate cancer in 
Liverpool by Comford et al revealed poor clinical outcome in relation to Hsp 27 
expression levels , which was also noted by Bostwick.
Other studies have shown correlations between Hsp27 expression and predictive 
implications. Seymour et al demonstrated an improved response to combination 
chemotherapy in oestrogen receptor positive breast tumours that expressed Hsp27278 
whilst Langdon et al. observed chemo resistance in ovarian cancers expressing 
Hsp27.279 The expression of Hsp27 is unrelated to chemoradiotherapy response rate 
in tumours of the central nervous system according to Hermission et alm)
This evidence suggests that alterations in expression levels of Hsp27 relate to its 
different cellular functions, although to date, no confirmation of transcriptional 
regulation or post translational modifications have been characterised.
1.8.2 Introduction to S100A8
The SI00 proteins are a group of small acidic proteins, ranging between 10-12 kDa 
found exclusively in vertebrates.234 They constitute a family of calcium binding 
proteins of which 20 have been identified in humans. Sixteen of these are known to 
cluster at chromosome lq21, also known as the epidermal differentiation complex.235 
SI00 proteins have the ability to form homodimers, heterodimers or oligomers, and 
have been associated with a range of intra- and extra-cellular functions acting through 
the calcium binding EF-hand motif. These include regulation of protein 
phosphorylation and enzyme activity, cytoskeletal regulation, calcium homeostasis
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and regulation of transcription factors. The nomenclature of these proteins can be 
confusing as each protein is known by several names.
The extracellular functions of some members of the SI00 family act as macrophage 
activators, leukocyte chemoattractants, and modulators of cell proliferation.236 These 
functions have linked SI00 proteins with a variety of pathological states including 
inflammation, cardiomyopathy and cancer. SI00 proteins have been shown to act as 
both tumour suppressors and tumour activators. In colorectal cancer, associations 
have been demonstrated between the pathological state and S100A4237'241, S100A6242, 
243, S100A8244,245, S100A9244,245 and S100A1 1.246>247
S100A8, also known as Calgranulin A, forms a heterodimer complex with S100A9, 
known as Calgranulin B.248 This covalently bound complex is also known as 
Calprotectin and has been shown to be up regulated in several cancers including 
gastric249, prostate250 and colorectal.245, 251 Both these proteins are expressed on the 
surface of myeloid cells and have been implicated in the host inflammatory response, 
and include leukocyte trafficking, migration and adhesion.252 These cells often form a 
component of the peritumoural stroma and, as this molecule has been shown to 
display both immunomodulatory and antimicrobial effects, may be related to 
antitumour immune response.253 Furthermore, Calprotectin can be measured in other 
media such as patient sera and faeces.
Associations between S100A8 and CRC have not been studied as extensively as other 
members of the family e.g. S100A4 in CRC. As it is measurable in tissues, serum, 
and faeces, it has attracted recent attention as a biomarker of CRC disease
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1.9 Project Overview
Throughout the last three decades many advances have been made in the medical and 
surgical treatment of colorectal cancer, but this has not been matched by a similar 
improvement in overall survival. To date, the most reliable prognostic factors shown 
to reflect the five-year survival of colorectal cancer cases are the stage of disease at 
clinical presentation2, n’79, l03, and the mode of that presentation (i.e. emergency or 
elective).9, !7, in’ 112 One study reported a postoperative mortality following 
emergency surgery of 8.2 % - more than three times the figure documented for 
elective surgery, 2.8%. Furthermore, the adjusted hazard ratio for overall survival 
after emergency relative to elective surgery was 1.68 (95% confidence interval [Cl] 
1.49 to 1.90; pO.OOl) and that for cancer specific survival was 1.90 (95% Cl 1.62 to 
2.22; pO.OOl).17 Other groups also verified the poor outcome of emergency CRC 
when compared to stage matched elective cases, citing various clinical reasons.9, n3,
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Little is known about the underlying mechanism linking the clinical findings of 
emergency presentation and associated poor long-term survival, but several groups 
have alluded to the inherent and distinct biology of the underlying CRC. Numerous 
studies have revealed differentially expressed genes and their related protein products 
in association with the diseased state, but these have not been established for use in 
routine clinical practice to date.
As up to 40% of all colorectal cancer related hospital admissions are emergencies17, 
ios-i m measures have been undertaken to try and improve this figure in a bid to reduce 
the impact of its effect on the public health. In 2001 the Government implemented a 
Cancer Plan in order to identify ‘key symptoms’ that were associated with 
malignancy, and fast track sufferers into hospital for urgent assessment, investigation,
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diagnosis and treatment. The overall aim was to reduce pre-hospital delays and, 
hopefully, intervene at an earlier stage in the disease in an attempt to improve 
outcome. This plan was known as the “Two-Week Rule”, the time in which patients 
should be seen by a specialist, and despite compliance from the majority of GP’s and 
primary care workers, no changes in the outcome statistics were noted.
Work undertaken in the Department of Surgery in the Royal Liverpool Hospital 
revealed that 43% of all CRC patients presented as emergency admissions. 
Emergency patients suffered their symptoms for less time than elective patients prior 
to seeking medical advice, but no significant relation was identified between the 
duration of symptoms and the Dukes stage.106
As CRC prognosis is reflected by tumour stage, but stage matched tumours perform 
very differently depending upon their mode of presentation, it is proposed that there 
may be distinct biological differences between emergency and elective type tumours 
which could account for their different clinical course and outcome.
Various differentially regulated proteins have been noted in the progression of 
adenoma through to carcinoma. ’ To date, there has been no literature describing 
the differences in protein expression profiles between similar stage emergency and 
elective colorectal cancers that may reflect discrepancies in tumour biology and 
propensity to metastasise.
We therefore proposed and designed a novel research project aiming to further 
investigate the underlying biology of these clinically distinct CRC tumours. 
Proteomic technology was previously applied to pancreatic cancer research within our 
department yielding exciting findings ' ’ This project extended its application
to CRC, with our aims and objectives outlined below.
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The project was undertaken between March 2004 and March 2006 in the Division of 
Surgery and Oncology, University of Liverpool having been set up from first 
principles by myself, and both clinical and scientific supervisors, Mr. Paul Rooney 
and Dr. Eithne Costello. The preliminary months were involved with project design 
and securing ethical approval, after which our aims and objectives were addressed by 
the laboratory work that followed.
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1.10 Aims and Objectives 
1.10.1 Aims
1. To map the proteomic profile of elective and emergency colorectal tumours, 
identifying differences within and between groups
2. To undertake protein identification of differentially expressed spots of interest
3. To investigate the significance between differentially expressed proteins and 
clinicopatbological parameters in colorectal cancer
1.10.2 Objectives
1. To extract protein from stage matched elective and emergency colorectal cancer 
and undertake 2D PAGE using standardised protein lysates.
2. To identify different spot intensities between emergency and elective groups using 
electronically scanned gel maps and visual analysis by two independent scientists
3. To identify the protein represented by the mapped gel spot using MS/MS TOF 
spectroscopy and peptide database search tools
4. To validate the identified differentially expressed proteins with 
immunohistochemical techniques in conjunction with a paraffin embedded tissue 
microarray consisting of CRC specimens from the Cancer Tissue Bank Research 
Centre (CTBRC), University of Liverpool.
5. To construct a colorectal cancer database incorporating the immunohistochemical 
stain scoring and clinicopathological data for statistical analysis.
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Section 2 Materials and Methods
2.1 Project design and ethical approval
This project was designed and initiated from first principles during a two-year 
academic research contract between myself and, jointly, the NHS (Royal Liverpool 
University Teaching Hospital) and The University of Liverpool between April 2004 
and March 2006.
Supervisors, Dr. Eithne Costello and Mr. Paul Rooney, identified a novel topic of 
interest within the field of proteomic colorectal cancer research, which could be 
investigated utilising research methods practiced within the Division of Surgery and 
Oncology that had already been shown to yield valuable data in the field of pancreatic 
cancer research ,76.
Funding for the project was provided in part by the Division of Surgery and 
Oncology, as well as contributions from and charitable donations. A surgical Royal 
College general research grant (Small Research Support Grant) application was 
submitted (See Appendix 1), but was unsuccessful.
Meetings between myself, clinical and scientific supervisors and Divisional 
researchers culminated in the construction of a preliminary project design (based on a 
background literature search and ongoing departmental projects) with clearly defined 
aims and objectives (see section 1.10).
Following the finalisation of project protocols, research governance registration was 
applied for via the R&D Department at the Royal Liveipool University Hospital and 
resulted in the issue of a registration number and construction of a site file. The 
project was identified as Trust Study No. 2881.
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Several factors relating to this project required formal application to and approval 
from the Research Ethical Committee, then known as the Central Office for Research 
Ethics Committees (CoREC), as outlined in the Department of Health document 
“Governance arrangements for NHS Research Ethics Committes” (GafREC).230 
Ethical approval was warranted as there were potential implications relating to 
patients treated by the NHS past and present, and methodology involving the handling 
and storage of human tissue.
Ethical application was undertaken using an on-line account following registration 
with the COREC website, now known as the National Research Ethics Service 
(NRES) fwww.mes.nnsa.nhs.uk). The application form (AB/7622/1 version 4.1) was 
comprised of a three-part document containing discrete fields relating to project 
particulars. These sections were completed by myself and covered issues such as 
project aims and objectives, research methodology, inclusion and exclusion criteria, 
consent procedure, data storage and protection, and principle investigator details. A 
copy of the application document (reference 04/Q1505/64) is provided in Appendix 2. 
Before this document could be finalised and issued to the Local Ethical Review 
Committee (LREC) for consideration, the project first required approval from the 
Royal Liverpool University Teaching Hospital Trust’s R&D Directorate and Clinical 
Trials Unit, who were research sponsors for the study. As stated above, the Hospital 
R&D Department had already received the preliminary research protocol (identified 
as Trust Project No.2881).
Following Trust approval of Project No. 2881, the completed LREC application form 
was printed out, signed and issued with supporting documents on 14/06/04 to 
Hamilton House, Pall Mall for consideration by the peer-reviewed Regional Ethical 
Committee (held on 07/07/04). A favourable opinion was reached by the panel with
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conditions as outlined (see Appendix 3). Before work could begin on the sponsor’s 
premises, however, final Trust R&D approval had to be sought and the protocols, 
ethics forms and favourable opinion were re-submitted to the sponsors for final 
review. Formal confirmation of Trust requirement satisfaction was obtained on 
27/09/04 (see Appendix 4) and laboratory work commenced thereafter.
2.2 Acquisition, preparation and staining of tissue
Samples were obtained from the CTBRC at the University of Liverpool. Briefly,
fresh tissue was collected by the tissue bank from resection specimens in the 
operating theatre of the Royal Liverpool University Teaching Hospital following full 
ethical approval and patient consent. A consultant histopathologist undertook 
macroscopic examination of the resection specimen and dissected samples of whole 
tumour, which were then immediately cryofixed in liquid isopentane cooled to -160°C 
with liquid nitrogen. This process enabled controlled cooling and subsequent freezing 
of the fresh tissue, preserving the integrity and architecture of the tissue, which can be 
lost during the step of snap freezing with liquid nitrogen alone. Frozen tissues were 
stored, until required, in Nunc cryotubes (Thermo Fisher Scientific) at -80°C in the 
Cancer Tissue Bank Research Centre.
Blocks of frozen tumour were placed at -19°C to equilibrate to this temperature and 7 
pm thick frozen sections were cut, using a Bright OTF 5000 cryostat (Huntingdon, 
Cambs, UK), onto glass slides (pre-cleaned with detergent, rinsed with de-ionised 
water and oven-dried at 45°C) and immediately fixed in formyl alcohol (95% ethanol, 
5% formaldehyde) for 30 s. Haematoxylin and eosin (H&E) staining was carried out 
to ensure the quality of the sectioned tissue, H&E staining was carried out as follows; 
fixed sections were washed in deionised water and immersed in Ehrlich’s 
haematoxylin for 45 s, Scott’s tap water for 5 s, acid water for 5 s, and then
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dehydrated in 70 % ethanol. Sections were then stained with eosin for 10 s after 
which they were washed thrice in 100% ethanol and dehydrated twice in xylene for 5 
min. One complete protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis 
IN, USA) was added for each 80 mL of staining solution. H&E stained tissue 
sections were examined by a specialist histopathologist for monitoring purposes.
2.3 Extraction of protein from tissue
Whole-tissue sections from frozen tumour blocks were used for preparation of protein 
lysates. Forty sections, each 7 pm thick, were cut using a Bright OTF 5000 ciyostat, 
with every 10th section subject to H&E staining for monitoring purposes. Sectioned 
tissue was solubilised in 250 pL lysis buffer (7 M urea, 2 M thiourea, 40 mM Tris 
base, 1% DTT and 4% CHAPS) kept on ice and homogenised for 1 min. Aliquots 
were centrifuged at 15,000 g for 30 min and the supernatant removed and stored at - 
80°C for subsequent use.
2.4 Standardisation of protein quantity prior to analysis
Absolute protein quantification methods using calibrated assays, such as the Bradford
assay, were unsuitable for assessment of our protein lysis solution. The lysis buffer 
contained high concentrations of reducing agent (Urea, Thiourea) which could 
interfere with the assay and prevent the acquisition of accurate results, according to 
the manufacturer’s specifications
Relative concentrations were therefore assessed against a standard protein solution as 
outlined by Shekouh et ah (2003).176 In brief, a standard protein lysate was prepared 
by solubilising 120 sections (each 7 pm thick) of normal colon tissue in 500 pL lysis 
buffer, homogenising for 1 min and centrifuging for 30 min at 15000 g. This standard 
lysate stock was subjected to a two-fold dilution series using lysis buffer until a 
dilution of 1 in 16 was attained. Each aliquot was separated by two-dimensional gel
50
electrophoresis (2DE), (as described in 2.6) and the resulting gels were stained using 
both silver and colloidal Coomassie blue methods. The dilution of lysate producing 
optimum gel resolution of between 800-1000 individual protein spots (when a 
specified quantity i.e. 250 pL was used) was identified and this solution was stored at 
-80°C for further use.
All subsequent experimental protein loads intended for assessment by 2DE were first 
normalised against this standard. This was achieved by separating the standard 
solution (at the concentration determined to produce adequately resolved gels) against 
the test sample solution (and its dilution series) using one dimensional gel 
electrophoresis (undertaken as described in section 2.5). Following Coomassie blue 
staining of gels, the relative intensities of bands in the dilution series were compared 
to those of the reference standard and used to estimate the dilution of the test sample 
solution required to produce a well-resolved 2DE assessment gel. Similar protein 
loads were also ensured between the batches of sample run together and allowed for 
concentration standardisation for comparative and analytical purposes between 
samples, as outlined below.
2.5 Separation of proteins by one Dimensional gel electrophoresis
For one dimensional gel electrophoresis on small format gels (10 % SDS running and
4 % SDS stacking) 5 pL aliquots from each of the sample and standard lysates were 
mixed with the same volume of loading buffer (1 M Tris HC1 Ph 6.8, 10% SDS, 25 % 
v/v glycerol, trace bromophenol blue) to produce a two-fold dilution series (until a 
dilution of 1 in 8 was achieved) and heated to 95 °C for 10 min. Samples were made 
up to 10 pL with Laemmli buffer (62.5mM TRIS, pH 6.8, 25% w/v glycerol, 2% 
SDS, 5% beta-mercaptoethanol, trace bromophenol blue). Samples were loaded onto 
the ID gel and a constant voltage of 150 V was applied for 40 min. Gels were
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removed and fixation was carried out by agitating the gels in a fixing solution (40% 
methanol and 7% acetic acid) for 30 min.
Fixed 1-D gels were stained with colloidal Coomassie blue (as described in Section 
2.7) and scanned using a scanner (BioRad GS 710, Hercules, CA, USA). 
Densitometric readings were attained and enabled each sample to be normalised for 
protein load by comparison against the standard solution concentrations, which were 
run with the sample batch.
2.6 2-Dimensional gel electrophoresis
One hundred pL protein lysate was mixed with 250 pL of rehydration solution (9 M 
Urea, 2 % w/v CHAPS, 2 % w/v DTT, bromophenol blue trace) containing 2 % w/v 
immobilised pH gradient (IPG) buffer (possessing earner ampholytes for non-linear 
pH range 3-10; Amersham Biosciences, Uppsala, Sweden). The total volume of 350 
pL was added to IPG focusing strips (18 cm strips, non-linear immobilised pH 
gradient [pH 3-10]; Amersham Biosciences) and passive rehydration was earned out 
at room temperature for 12 h in mineral oil sealed re-swelling chambers. Iso-electric 
focusing (IEF) of the IPG strips was undertaken using the Multiplier II system 
(Amersham Biosciences) with the Voltage increasing in a linear gradient from 0-500 
V over 1 min, 500-3500 V over the following 1.5 h, and then maintained at a steady 
potential difference of 3500 V for 5 h and 40 min. Following first dimension 
separation, the strips were washed twice in equilibration buffer (1.5 M Tris-HCl, pH 
8.8, 35 % v/v glycerol, 6 M urea, 2 % w/v SDS, trace of bromopheol blue). The 
primary wash also contained 1% DTT w/v, and the secondary wash contained 
iodoacetamide at 2.5 % w/v. During each wash, the strips were agitated in 10 mL of 
solution for a total of 15 min after which they were rinsed in electrophoresis buffer 
(25 mM Tris base, 192 mM glycine, and 0.1 % w/v SDS in water). Rinsed strips were
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applied to 12% poly-acrylamide gels and sealed with molten agarose (consisting of 
electrophoresis buffer with 0.5% w/v agarose and a trace of bromophenol blue).
Second dimension separation was earned out using an Ettan Dalt II electrophoresis 
chamber (Amersham Biosciences) at 25°C with a constant 5 W per gel for half an 
hour, followed by 20 W per gel until the bromophenol blue marker had migrated 18 
cm. Gels were removed and agitated in fixative (7% acetic acid, 40% methanol) for 1 
h prior to staining as described below.
2.7 Colloidal Coomassie blue staining of polyacrylamide gels
Fixed gels were washed twice in 250 mL de-ionised water and stained as described by
Neuhoff et al (1988). Briefly, gels were incubated in 250 mL of staining solution (a 
4:1 mixture of [0.1% w/v G-250 Coomassie brilliant blue dye, 2% orthophosphoric 
acid and 10% w/v ammonium sulphate] and methanol) in a large Tupperware 
container, which was agitated at 42 cycles per min for 4 h. Gels were then de-stained 
for 30 s in 250 mL of destaining solution (10% v/v acetic acid and 25% v/v 
methanol), after which they were washed overnight in 250 mL of a ILO-based 
solution containing 25% Methanol. Gels were then placed in a fresh solution of 25% 
Methanol (250 mL) and stored at 4°C for up to two weeks. Long-term storage of gels 
was achieved by encasing (well hydrated) gels in heat-sealed plastic bags which were 
subsequently maintained at 4 °C.
2.8 Silver staining of polyacrylamide gels
Silver staining was performed essentially as described by Yan et al. 231. Gentle 
agitation of gels on a rotary platform was used throughout. Gels were fixed in a 
solution containing 10% acetic acid and 40% ethanol, before equilibration for 30 min 
in sensitisation buffer (containing 30% v/v ethanol, 0.2% sodium thiosulphate and 
0.83 M sodium acetate). Gels were then subjected to three 5 min washes with
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deionised water and subsequently equilibrated with a solution containing 0.25% w/v 
silver nitrate for 20 min, rinsed twice in water and then developed in a solution 
containing 2.5% w/v sodium carbonate containing 0.04% v/v formaldehyde (37% 
solution). Development was stopped after 40 s by immersing in 250 mL 40 mM 
EDTA after which gels were washed three times in water, scanned as described below 
(section; 2-D Gel Scanning) and stored at 4 °C.
2.9 2DE Gel scanning and protein spot analysis
Coomassie Blue-stained gels were scanned using a GS-710 scanner at 300 dots per 
inch (dpi) (Bio-Rad, Hercules, CA, USA) and the data acquired using PDQuest 
software (Bio-Rad, v6.2). Gel spot analysis was undertaken manually after transfer 
onto acetates using TIFF format images and evaluated objectively by two independent 
researchers. Gels were further subjected to automated analysis using Melanie II 
software v6.0 (Geneva Bioinformatics, Geneva, Switzerland) and compared with the 
manually visualised findings.
2.10 Protein spot identification using Mass Spectrometry
Protein spots were excised from Coomassie Blue-stained 2DE gels using a
micropipette tip cut to size, and were destained and dehydrated by incubation in a 
solution containing 50% acetonitrile (ACN) and 50 mM ammonium bicarbonate for 
15 min at room temperature, followed by vacuum drying in a SpeedVac (Eppendorf 
Concentrator 5301). The gel pieces were rehydrated by incubation in a solution 
containing 50 mM ammonium bicarbonate containing 40 ng/pL modified trypsin 
(Promega) for 16 h at 37 °C (Leec Mk II Oven). Peptides were extracted from the gel 
by incubation with 2 changes of a solution containing 60% acetonitrile and 1% 
trifluoroacetic acid (TFA), and the resulting supernatants were again dried in a
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SpeedVac. Final resuspension was in a solution of 10 pL 5% acetonitrile with 0.1% 
trifluoroacetic acid.
Aliquots of 0.5 pL sample were spotted onto a matrix assisted laser desorption 
ionisation (MALDI) target plate together with an equal volume of 5 mg/mL a-cyano- 
4-hydroxycinnamic acid (LaserBiolabs, France) in 50% ACN and 0.1% TFA. Peptide 
mass fingerprinting was undertaken on a Voyager DE Pro MALDI instrument 
(Applied Biosystems, California, USA) in positive ion reflector mode and the data 
were submitted for database screening via the Mascot search engine (Matrix Science, 
London). The mass tolerance was set to 100 ppm, and 1 missed cleavage and no 
modifications were allowed. For liquid chromatography tandem mass 
spectroscopy/mass spectroscopy (LC-MS/MS) analysis, aliquots of 5 pL sample were 
delivered into a QSTAR Pulsar i hybrid mass spectrometer (Applied Biosystems) by 
automated in-line liquid chromatography (integrated LCPackings System, 5 mm CIS 
nano-precolumn and 75 pm x 15 cm CIS PepMap column (Dionex, California, USA)) 
via a nano-electrospray source head and 10 pm inner diameter PicoTip (New 
Objective, Massachusetts, USA). A gradient from 5% ACN/0.05% TFA (v/v) to 48% 
ACN/0.05% TFA (v/v) in 60 min was applied at a flow rate of 300 nL/min, and mass 
spectroscopy (MS) and MS/MS spectra were acquired automatically in positive ion 
mode using information-dependent acquisition (IDA) (Analyst, Applied Biosystems). 
Database searching was performed using Mascot with mass tolerances set to 1.2 
Daltons (Da) for MS and 0.6 Da for MS/MS, and with deamidation as a variable 
modification.
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2.11 Immunohistochemical analysis of a colorectal cancer tissue 
microarray.
Tissue microarrays were constructed from specimens of 110 consecutively resected 
colorectal carcinomas at the Royal Liverpool University Teaching Hospital between 
the years 2000 - 2002, adopting the methodology described by Kononen et al l82. 
Sections measuring 4 pm were excised from the tissue microarray block onto poly-L- 
lysine coated glass slides and de-paraffmised using xylene. Subsequent rehydration 
was undertaken through graded ethanol solutions. Endogenous peroxidase activation 
was prevented by washing the sections in a 3% w/v solution of H2O2 for 15 min and 
then in distilled water. Following equilibration with fresh Tris buffered saline (TBS) 
(0.05 M Tris (pH 7.6), 0.12 M NaCl), the sections were incubated with primary 
antibodies at room temperature for 1 h.
Antigen retrieval was achieved using microwaves at 850 W for 15 min in a 10 mM 
EDTA solution (pH 7.0) followed by cooling for 15 min at room temperature. 
Antibodies were diluted to the manufacturer’s specification using TBS containing 5 % 
w/v BSA.
Antibody localisation was visualised by incubation with a horseradish preoxidase 
conjugated secondary antibody for 30 min followed by 10 min with 
diaminobenzidine. Haematoxylin was used to counterstain the sections, which were 
then dehydrated using 100% ethanol and xylene. Coverslips were fixed with DPX 
mountant (BDH, Poole, Dorset, UK). Negative controls were incubated with labelled 
secondaiy antibodies only.
Scoring of the stained tissue microarray was undertaken by two independent 
clinicians, one of whom was a specialist histopathologist. Data gathered were entered 
onto a database and consisted of intensity of staining (graded; 0[negative], l[weak],
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2[moderate], 3 [strong]) and proportion of tumour demonstrating positive 
immunoreactivity (graded; 0 [no cells stained], 1 [<20% cells stained], 2 [20-50% 
cells stained], 3 [>50% cells stained]). These scores were multiplied together, 
producing a combined index ranging between 0-9. The combined index was 
dichotomised using the median value, about which the degree of protein expression 
was categorised as either high or low. Data analysis was undertaken using both the 
combined index (high or low expression), and absolute intensity (positive or negative) 
categories.
2.12 Statistical analysis
All data were analysed using StatView v. 5.01 (SAS Institute) with significance levels 
set at jo-value <0.05. Clinicopathological variables were gathered from 
histopathological reports and included the individual’s age, date of surgery, gender, 
tumour size, tumour grade, disease stage, lymph node status, resection margins and 
smoking habits. Tabulated data were subject to Fisher’s two-sided exact test or x2 
test, as appropriate, in order to assess associations between categorical data. Non- 
parametric continuous data were examined using the Mann Whitney U test. Life 
tables were constructed from survival data and Kaplan-Meier curves plotted to 
evaluate the effect of protein expression on patient survival. Overall survival was 
calculated from the date of surgery to the date of death, (death from any cause was 
counted as an endpoint) or if date of death was not available, then the end point was 
taken as the last documented clinical entry at follow up. Death from any cause was 
used as the anonymisation of data made further differentiation impossible; the patient 
case notes would require cross referencing with the tissue bank database in order to 
achieve cancer specific endpoints. The log-rank test (Mantel-Cox) was used for 
comparison between the groups displayed by Kaplan-Meier survival curves.
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Section 3 Results
3.1 Two-Dimensional gel analysis of colorectal cancer
3.1.1 The standard Gel
3.1.1.1 Production of a standard protein solution
Protein was procured as described previously (sections 2.2 and 2.3 above). One 
hundred sections of normal colon, each 7 pm thick, were cut using the microtome 
from a frozen block of tissue. Every tenth section underwent haematoxylin and eosin 
staining as a record of specimen material collected and to ensure the appropriate cell 
population was selected (Figure 8).
Figure 8: H&E stained normal colon
40x light microscope magnification of a 7 pm section through the frozen block of 
normal colon mucosa. Normal crypt architecture is displayed; colonocytes (A) 
and goblet cells (B) are easily recognised.
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The protein solution was then subject to serial dilution as described in section 2.4. 
Each resulting solution was subsequently separated using one-dimensional 
electrophoresis on 10 x 6 cm 10% SDS gels, stained with Coomassie Brilliant Blue 
and electronically scanned (Figure 9).
Figure 9: Serial dilution of standard protein solution
Densitometric scan of Coomassie Blue stained one-dimensional electrophoresis 
gel displaying dilutional series of the procured normal protein solution
Each diluted protein solution was then loaded onto IPG strips, rehydrated overnight 
and separated by 2D PAGE as described in section 2.5 and 2.6. The resulting gels 
were stained with silver stain (Figure 10 A-E) or Coomassie Brilliant Blue (Figure 10 
F), scanned and inspected in order to investigate the optimum concentration of protein 
required to produce a well-resolved gel adequate for the purpose of visual analysis.
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Figure 10 (A-F): 2D PAGE separation of standard protein solutions
Gels (A-E) are silver stained and represent a dilution factor of 1, 2, 4, 8 and 16 
respectively. Gel (F) displays dilution factor 4 stained with Coomassie Blue.
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For reasonable experimental gel resolution (displaying approximately 800 identifiably 
distinct polypeptide spots), concentrations between one half and one eighth of the 
standard protein solution were deemed to be acceptable. The more sensitive silver 
stain produced the best results between dilution factors 4 to 16 (Figure 10 C-E) with 
overstraining seen in the undiluted sample (Figure 10 A). An optimal resolution was 
achieved using dilution factor 4 in conjunction with Coomassie Blue stain (Figure 10 
F), although it should be noted that the relative protein concentration was twice that 
required to achieve the same visual 2D PAGE representation using the silver stain. 
We opted to use Coomassie blue staining for subsequent analytical gel comparisons 
on account of its definitive staining endpoint. This minimised experimental variation 
and improved gel reproducibility.
For the purposes of quality assurance and gel orientation, the resulting 2DE images 
were compared to the reference images on the Swiss 2DE proteomics website, 
www.Expasv.ch/ made available by the Swiss Institute of Bioinformatics232. The gels 
produced by our diluted stock solutions demonstrated good reproduction of high 
abundance protein spots in a similar distribution when compared to the reference gel 
on the Swiss server derived from human colonocytes. Figure 11 displays this 
reference gel with several identified protein spots labelled, and our gel below it. The 
Expasy gel was silver stained and overloaded, resulting in a much darker appearance 
than our diluted gel stained with Coomassie blue, but general layout was similar.
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Figure 11: 2D PAGE reference map of human colonocytes from Expasy.
Silver stained 2D PAGE from Expasy (top) displaying normal colon epithelium 
. For the key to protein identities see http://world-2dpage.expasv.oni/swiss- 
2dpage/map=cec human. The layout is similar to our experimental gel displayed 
beneath it.
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A stock solution of procured ‘normal* colonic protein dilution factor 2 was stored at - 
80 °C as a reference for future use. This reference sample was used to assess the 
concentration of subsequently procured experimental cancer samples and acted as our 
protein standard. Procured experimental samples were subjected to serial dilution and 
separated using 1 D electrophoresis alongside the standard stock solution and its 
dilution series, thus enabling relative comparisons between protein loads. Selection 
of procured experimental sample concentration within the relative concentration range 
known to produce a well-resolved 2DE gel was undertaken, whilst also allowing for 
standardisation of the protein load between the experimental samples. This method 
was adopted from Shekouh et aL as described in Section 2.4.
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3.1.2 Patient samples
Twelve tumour samples were identified by the Cancer Tissue Bank Research Centre 
(University of Liverpool) for the purposes of proteomic investigation. Six samples 
each of emergency and elective CRCs were selected and coded, having been 
processed by a consultant pathologist. All tumour samples were from patients aged 
over 60 years, with Dukes C carcinoma from the left colon. A summary of tumour 
samples with CTBRC codes with their respective assigned numbered key (1-12) is 
provided in Table 1.
Table 1: Emergency and Elective Cases
Coded numbers identifying emergency and elective tumour cases
EMERGENCY ELECTIVE
Tumour Key Tumour Key
177/96A1 1 236/00A1 7
20/03A1 2 165/02A1 8
22/05A1 3 408/01A1 9
02/03A1 4 185/96A1 10
76/04A1 5 04/03A1 11
268/03A1 6 47/97A1 12
3.1.2.1 Extraction of protein from cancer tissue
Protein extraction was undertaken as described in section 2.3. Histological 
assessment of samples was carried out for quality assurance on eveiy tenth section 
cut. This allowed examination of each section, ensuring inclusion of samples 
containing greater that 50% cancer tissue; sections containing less than this were 
excluded (Figure 12 A-C).
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Figure 12 A-C: Light microscope view of 7 pm H&E sections through 
experimental colon cancer specimen (xlO), (x40) and (xlOO) respectively.
Figure 12A demonstrates a low power view of colorectal cancer displaying 
villous architecture. The majority of the section is made up of neoplastic 
colonocytes and it contains very little stroma. Figure 12B is a typical image of a 
cancer specimen taken from every tenth section used for protein procurement. 
This facilitated quality assurance of captured cell population. Figure 5 C is a 
high power magnification view of a cancer specimen. Note the cellular atypia 
when compared to the healthy villus displayed in Figure 8. Nuclear 
heterochromasia and lack of cellular polarisation are evident (arrowed).
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3.1.2.2 ID assessment of procured experimental protein lysate
The sample protein lysate was separated using one-dimensional 10% SDS gel
electrophoresis and subsequently compared against the standard solution as described
in section 2.4. The standard solution was paramount in controlling experimental
variables, and enabled quantitative comparison between our tumour samples. Similar
concentrations of experimental protein had to be loaded onto the IPG strips if
meaningful evaluations were to be made. Unfortunately, the high concentration of
reducing agent in our lysis buffer rendered conventional means of protein
quantification inaccurate and irreproducible (at the time of experimentation). A
subjective visual comparison was therefore relied upon for relative quantification and
standardisation between experimental samples.
Scamied images of stained 1 D gels are displayed in Figure 13. The dilution factors 
selected for loading the IPG strips prior to 2D PAGE are summarised in Table 2, and 
are indicated by the arrows in Figure 13.
Table 2: Relative concentrations of cancer protein lysate used for 2DE 
separation
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1248 1248 1248
Figure 13: Scanned images of experimental protein lysate dilutional series 
separated by one dimensional gel electrophoresis.
Gels were stained with Coomassie blue and dilution factors are indicated below 
each image. Arrows indicate the relative protein concentration selected for IPG 
loading following visual analysis.
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3.1.2.3 Two Dimensional PAGE of tumour samples
Procured experimental samples, standardised for concentration following ID 
separation, were loaded onto IPG strips and rehydrated overnight prior to 2D PAGE 
as outlined in section 2.6.
Samples were run in batches of six to control experimental conditions. Scanned 
images of Coomassie blue stained tumours 1-6, the emergency group, are depicted in 
Figure 14 . Tumours 7-12 representing the elective group are displayed in Figure 15.
68
• -jK..
* •
1 2
i
4
5 ........7 6
Figure 14: 2D PAGE of Emergency tumours
Images 1-6 depict Coomassie blue stained 2D PAGE of tumours 1-6.
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Figure 15: 2D PAGE of Elective tumours
Images 7-12 depict Coomassie blue stained elective tumours 7-12 respectively.
70
3.1.2.4 Computer assisted assessment of gels
Scanned images of 2D PAGE gels were loaded onto a flexible computer interface to 
aid comprehensive visualisation and spot analysis using Melanie II software (Geneva 
Bioinformatics, Switzerland). This enabled the overlaying of gel images and relative 
spot concentration assessment, with the benefit of absolute spot volume analysis using 
the normalised spot volume.
Ten to twenty consistent protein spots were ‘mapped’ on each gel, using the Expasy 
gel as a guide. These acted as reference points for the computer to contort, or ‘warp’ 
each gel into an image that would allow uniform comparison between gel overlays.
Gel 1 was arbitrarily selected to act as our reference point by which all other spots 
were mapped and subsequently assessed using total spot value normalisation 
methodology. Briefly, normalised spot volume represents the volume of a given spot 
on a gel as a ratio of the total volume of all spots. This value can then be used for 
relative comparison of discrete spots between tumour cases.
A summary of spots representing a relative up or down regulation in intensity by a 
factor of 1.5 is displayed in Figure 16. Spots highlighted in green demonstrate up 
regulation whilst yellow spots represent down regulation.
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Figure 16: Melanie II software analysis of 2DE gels.
Up (green) and down (yellow) regulation in intensity of protein spot staining are 
highlighted. Each highlighted spot represents a relative differential expression 
by a factor of at least 1.5 x between respective normalised spot ratios.
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Gel spot pattern analysis was undertaken with the aim of identifying differences 
between cases that may reflect variation in cellular functional activity. Although the 
sample protein solutions were prepared adopting controlled protocols and resolved 
using gels cast and run in the same experimental batch, difficulties arose during inter 
gel interpretation. Gel alignment was paramount in order to accurately compare 
samples, both visually and electronically. Various factors affected this process, 
including loss of protein during IPG loading, and variation in gel casting.
Our gels were visually analysed by two independent scientists and, in conjunction 
with the computer analysis, several spots of interest were identified for further 
analysis. Between 50-80 differentially regulated spots were identified Using Melanie 
II software, but after careful visual inspection only 15 to 20 of these were consistently 
correctly mapped between all 12 experimental gels. We selected 5 for further analysis 
that were easily identifiable, well resolved and consistently variable.
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3.1.3 Investigation of differentially expressed spots of interest
Following visual and computer assisted analysis of 2DE gels, five spots of interest,
labelled A-E, were identified for further assessment (Figure 17).
Emergency (Tumour 4) Elective (Tumour 10)
S 4 % ft 7 H « 1C Mf 14 ft ft lift 10
E C
Figure 17: Spots of interest
Identification of differentially expressed proteins between cases, represented by 
spot intensities, are demonstrated by the colour-coded circles. Spots of interest 
were arbitrarily labelled A-E for the purposed of further investigation. Staining 
intensity differences between these two gels are easily appreciated.
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Differential protein expression between tumour samples was quantified using the 
normalised spot volume, calculated as a ratio of sample spot intensity to total spot 
intensity (Table 3). Visual representations of theses differences are displayed in 
Figure 18.
Table 3: Normalised spot volumes
Tumour Spot A Spot B Spot C Spot D Spot E
1 0.139 0.33 0.186 0.422 0.015
2 0.001 0.176 0.099 0.731 0.012
3 0.131 0.114 0.206 0.757 0.01
4 0.036 0.032 0.079 0.642 0.012
5 0.186 0.177 0.636 0.497 0.011
6 0.094 0.314 0.16 0.703 0.019
7 0.165 0.143 0.284 0.423 0.027
8 0.001 0.208 0.148 0.827 0.035
9 0.13 0.098 0.176 0.696 0.017
10 0.638 0.46 0.391 0.737 0.042
11 0.136 0.187 0.126 0.368 0.015
12 0.179 0.191 0.227 0.65 0.019
75
0.8
0.7
^ Spot A
0.5 ■ Spot B
0.4
■ Spot D
■ Spot E0.2
Tumour
Figure 18: Graph displaying variation between normalised spot volumes
This bar chart plots the normalised spot volumes on the y axis for spots A-E 
against each tumour on the x axis. Tumours 1-6 represent emergency cases, 
whilst 7-12 are elective.
3.1.3.1 Spot intensity variations
Further analysis of protein expression was undertaken using the normalised spot 
volumes, investigating inter group (Emergency and Elective) and inter individual 
(case) differences. Absolute values were displayed using a bar chart to demonstrate 
inter-case variability, whereas inter-group comparison was undertaken using the 
median value for each group displayed as a box and whisker plot (Figure 19 to
Figure 23). Only spot E varied significantly between emergency and elective groups 
(p=0.015), however there was marked variation in expression of all spots between 
individuals. Protein validation using a tissue microarray was undertaken, increasing 
sample size and allowing for meaningful statistical analysis.
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Figure 19: Variation of Spot A (arrowed) between tumour samples 1-12
The bar chart demonstrates a visual representation of the individual normalised 
spot volumes, whilst the box and whisker diagram displays the average spot 
volumes for emergency and elective groups.
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Figure 20: Variation of Spot B (arrowed) between tumour samples 1-12
The bar chart demonstrates a visual representation of the individual normalised 
spot volumes, whilst the box and whisker diagram displays the average spot 
volumes for emergency and elective groups.
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Figure 21: Variation of Spot C (arrowed) between tumour samples 1-12
The bar chart demonstrates a visual representation of the individual normalised 
spot volumes, whilst the box and whisker diagram displays the average spot 
volumes for emergency and elective groups.
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Figure 22: Variation of Spot D (arrowed) between tumour samples 1-12
The bar chart demonstrates a visual representation of the individual normalised 
spot volumes, whilst the box and whisker diagram displays the average spot 
volumes for emergency and elective groups.
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Figure 23: Variation of Spot E (arrowed) between tumour samples 1-12
The bar chart demonstrates a visual representation of the individual normalised 
spot volumes, whilst the box and whisker diagram displays the average spot 
volumes for emergency and elective groups.
81
3.1.3.2 Spot and protein identification
Spots of interest were excised, subjected to tryptic digestion and analysed using Mass 
Spectrometry as per section 2.10. Results of the MALDI-TOF/QSTAR are displayed 
in Table 4.
Table 4: Spot results following mass spectrometry and SwissProt database 
search
Spot SwissProt 
Accession No.
Mr Pi Peptide Mass Fingerprint 
Result
A P09936 24.8 5.33 Ubiquitin thiolesterase
B P04792 22.8 5.98 Heat Shock Protein-27 
(Hsp 27)
C P05109 10.8 6.51 S100A8 
(calgranulin A)
D P09211 23.3 5.44 Glutathion S-transferase Pi 
(GST-pi)
E P68871 15.9 6.81 Haemoglobin Beta
Hps27, S100A8 and GST-pi were selected for further investigation and validation 
utilising cancer tissue microarray sections and immunohistochemical staining.
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3.2 Validation of proteins Hsp27 and S100A8
3.2.1 Protein Validation; Immunohistochemistry and Tissue Microarray 
Analysis
Tissue microarray sections were immunohistochemically stained using antibodies 
against Hsp27 (Figure 24), S100A8 (Figure 25) and GST-pi as described in section 
2.11 and scored for staining intensity. Unfortunately, the resulting GSTpi 
immunohistochemical staining process produced uniformly overstained tissue cores 
that were unusable for further analysis.
Figure 24: Light microscope view (x40) of TMA core subject to immunostaining 
for the detection of Hsp 27.
Image A represents normal colon tissue and demonstrates no Hsp27 expression 
in normal colonocytes. Image B is CRC tissue that does not express Hsp27. 
Image C and D demonstrating light and heavy staining in CRC, which would be 
represented by a staining score of 1 and 3 respectively (as described in Section 
2.11). All sections displayed a light stromal staining for Hsp 27.
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Figure 25: Light microscope view (x40) of TMA core immunohistochemically 
stained with antibodies against S100A8.
S100A8 staining (arrowed) was scattered throughout the tumour stroma and was 
concentrated within myeloid cells. Section A demonstrated low numbers of 
S100A8 positive cells, whereas section B shows high numbers.
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Of the original 110 CRC cases making up our TMA, the final number of intact 
duplicate cores, successfully stained for Hsp27 with comprehensive 
clinicopathological data totalled 81. Sixty-Six (81%) cases were admitted electively 
whereas 15 (19%) presented as an emergency. This represents a lower than 
anticipated number of emergency cases, and is further discussed on page 106.
Median patient age was 70 years, ranging from 34 -89 years. Of the 81 cases, (35 
were female, 46 male) the median follow up was 53 months (range 0 — 72 months). 
Event time was taken as either the date of death (38 cases) or last clinic follow up 
appointment (43 cases). Patient clinicopathological factors are presented in Table 5.
Hsp27 scoring was carried out as described in Section 2.11. Hsp27 intensity scores 
for the cases can be broken down as follows; 15/81 cases were negative (score of 
zero), 25/81 cases had weak staining (score=l), 28/81 were moderate (score=2), and 
13/81 were strong (score=3). For the 66 cases positive for Hsp27, the proportion of 
cells staining were: 11 had <20% cells stained (score=l), 7 had between 20%-50% 
stained (score=2), and 48 had >50% stained (score=3).
The intensity and proportion scores were multiplied to produce a combined index 
ranging from 0-9. This score was dichotomised using the median combined value 
of 4 to denote high or low intensity Hsp27 staining. Associations were sought using 
both the absolute presence of Hsp27 expression (positive or negative) and the 
combined index (high or low).
S100A8 immunostaining produced a uniformly consistent low intensity staining of 
colonic cellular cytoplasm throughout the tissue micro array and was therefore not 
subject to further analysis. Cells staining positively for S100A8 were located within 
the stroma and were myelocytic in origin. The number of positively staining cells per
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core were counted within a x40 power magnification field and ranged from 0-300. 
The median number of S100A8 positive cells per core was 6, about which the group 
was dichotomised into high and low expression.
Table 5: Patient characteristics of Tissue Microarray cases
Clinical parameter All cases
n=81(%)
Gender
Female
Male
35 (43)
46 (57)
Age
^60 years 
>60 years
11 (14)
70 (86)
Tumour size
^3 0mm
>3 0mm
Unrecorded
23 (28)
57 (70)
1(2)
Resection margin
Clear
Involved
72 (89)
9(11)
Degree of Differentiation
Well/Moderate
Poor
79 (98)
2(2)
Nodal status
Negative (NO)
Positive (Nl/2)
44 (54)
37 (46)
Depth of Invasion 
(T Stage)
T1
T2
T3
T4
6(8)
10(12)
52 (64)
13 (16)
Site of Tumour
Right colon
(caecum, ascending, transverse)
Left Colon
(Descending, sigmoid, rectum)
21 (26)
60 (74)
Colon/Rectum
Colon
Rectum
49 (60)
32 (40)
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Factors know to be of prognostic importance in colorectal cancer include lymph node 
status, mode of presentation (emergency or elective) and resection margin 
involvement. Our patient sample was subject to regression analysis in relation to 
these factors to investigate if the TMA reflected a true representation of the 
population. Both mode of presentation (p=0.04, logrank test) (Figure 26) and lymph 
node status (p=0.03, logrank test) (Figure 27) were significantly associated with 
survival. Patients with resection margin involvement tended to have a worse survival 
outcome, although this did not reach statistical significance (p=0.36) (Figure 28).
Correlations were sought between the protein scoring parameters and survival using 
univariate Cox regression analysis. No statistical significance was demonstrated 
between Hsp27 intensity (high or low using combined index) (p-0,29) or Hsp27 
expression (positive or negative) (p=0.16) and overall survival of the TMA 
population. Cases with a greater number of cells staining positive for S100A8 were, 
however, significantly associated with a better survival compared to those with low 
numbers (p=0.04, logrank test) (see Section 3.2.1.3).
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Emergency vs Elective
Kaplan-Meier survival estimates
0
Number at risk
20 40
analysis time
60 80
type = Elective 63 57 47 29 0
type = Emergency 15 9 6 5 0
type = Elective ------------- type = Emergency
Variable Median
Survival
(Months)
3 year 
survival
5 year 
survival
Logrank test Hazard ratio
Emergency 25 40% 40% Chi2=3.92
p=0.04
2.12
Elective - 85% 59%
Figure 26: Kaplan-Meir curves for TMA patients demonstrating survival 
according to mode of presentation
Mode of presentation and lymph node involvement, both well-known prognostic 
indicators, are shown to be of statistical significance in our TMA case series.
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Node: Positive vs Negative
Kaplan-Meier survival estimates
0
Number at risk
20 40
analysis time
60 80
node = 0 44 39 32 22 0
node = 1 37 26 20 11 0
node = 0 -----------  node = 1
p=0.03
Variable Median
Survival
(Months]
3 year 
survival
5 year 
survival
Logrank test Hazard ratio
Node Negative - 84 63 Chi2=4.72
p=0.03
2.0
Node Positive 47 60 40
Figure 27: Kaplan-Meir curves for TMA patients demonstrating survival 
according to lymph node involvement
Mode of presentation and lymph node involvement, both well-known prognostic 
indicators, are shown to be of statistical significance in our TMA case series.
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Resection: Clear vs Involved
p=0.36
Number at risk 
Complete 72 
Incomplete 9
60
5
48
4
30
3
Complete Incomplete
Variable Median
Survival
(Months)
3 year 
survival
5 year 
survival
Logrank test Hazard ratio
Clear 66 77 54 Chi2=0.85
p=0.36
1.55
Involved 30 44 44
Figure 28: Kaplan-Meir curves for TMA patients demonstrating survival 
according to resection margin involvement
Involved resection margins (Rl, TNM classification) tended to have a worse 
prognosis compared to clear (R0) margins, although this was not statistically 
significant.
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3.2.LI Emergency and Elective group analysis
Of the 81 cases suitable for analysis, 15 (19%) presented as an emergency whilst 66 
(81%) were admitted electively.
Associations were sought between mode of presentation and gender, age, tumour size, 
resection margin involvement, grade of differentiation, lymph node involvement (N 
Stage), depth of invasion (T Stage), and anatomical location. Only resection margin 
involvement differed significantly between groups with 92% of elective cancers 
possessing clear margins compared to only 73% of emergency cases (p=0.03) (Table 
6).
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Table 6: Association between mode of presentation and clinicopathological 
characteristics
Emergency and Elective groups
Clinical parameter All cases 
(n=81) 
(%)
Emergency
(n=15)
(%)
Elective
(n=66)
(%)
Significance*
Gender
Female 35 (43) 8(53) 27 (41) p=0.38
Male 46 (57) 7(47) 39 (59)
Age
^60 years 11(14) 1(7) 10(15) p=0.67
>60 years 70 (86) 14 (93) 56 (85) (FE)
Tumour size 
£3 0mm 23 (28) 5(33) 18(27)
>3 0mm 57 (70) 9(60) 48 (73) p=0.63
Unrecorded 1(2) 1(7) 0
Resection margin
Clear 72 (89) 11(73) 61 (92) p=0.034
Involved 9(11) 4(27) 5(8)
Degree of 
Differentiation
Well/Moderate 79 (98) 14 (93) 65 (98) p=0.33
Poor 2(2) 1(7) 1(2) (FE)
Nodal status
Negative (NO) 44 (54) 7(47) 37 (56) p=0.51
Positive (Nl/2) 37 (46) 8(53) 29 (44)
Depth of Invasion 
(T Stage)
T1 6(8) 1(7) 5(8)
T2 10(12) 3(20) 7(11) p=0.382
T3 52 (64) 7(47) 45 (68)
T4 13(16) 4(26) 9(13)
Colon/Rectum
Colon 49 (60) 8(53) 41 (62) p=0.53
Rectum 32 (40) 7(47) 25 (38)
* non parametric chi-squared test (2 groups), or chi-squared test (>2 groups). 
(FE) Fishers Exact test
Associations were also sought between mode of presentation and protein staining.
Neither S100A8 expression, nor the Hsp27 intensity (high or low combined index) 
was significantly associated with type of presentation (Table 7).
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Table 7: Association between presentation and protein staining intensity
Protein Expression All cases 
(n=81) 
(%)
Emergency
(n=15)
(%)
Elective
(n=66)
(%)
Significance^
S100A8
High 38(47) 5(33) 33 (50)
Low 41 (50) 9(60) 32 (48) p=0.30
Missing 2(3) 1(7) 1(2)
Hsp27
High 37 (46) 9(60) 28 (42)
Low 44 (54) 6(40) 38 (58) p=0.21
Hsp27
Positive 66 (81) 14 (93) 52 (79) p=0.19
Negative 15(19) 1(7) 14(21)
* non parametric chi-squared test (2 groups), or chi-squared test (>2 groups).
The association between Hsp27 expression, intensity and number of S100A8 positive 
cells, and survival was investigated for each mode of presentation (Figure 29). Hsp27 
expression tended to signify a worse outcome in elective tumours (Figure 29 A), 
whereas a high number of S100A8 positive cells displayed a better outcome in the 
emergency tumour group when compared to lower numbers (p=0.03) (Figure 29 D), 
Although significant, the number of emergency patients is very low and should be 
interpreted with caution
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High Hsp27 vs low Hsp27 in elective 
tumours
p=ns
Kaplan-Meier survival estimates
hsphilo - High 28 25 21 12 0
hsphilo > low 38 31 25 16 0
hsphrto ■ ------------ hspMo ■ Low
High Hsp27 vs low Hsp27 in emergency 
tumours
p=ns
Kaplan-Meier survival estimates
<N
§
o
Number at nsk 
hsphito * High 9 
hsphito * Low 6
20 40 60 80
analysis time
6 4 4 0
3 2 10
hsphik) = High ------------ hsphito * Low
High S100A8 vs low S100A8 in elective 
tumours
p=ns
Kaplan-Meier survival estimates
Number at risk
slOO«High 33 29 23 14 0
*100 = Low 32 26 22 14 0
*100 = High ---------- *100 » Low
High S100A8 vs low S100A8 in emergency 
tumours
p=0.03
Kaplan-Meier survival estimates
Number at risk
*100 = High 5 5 4 3 0
*100-Low 9 4____________2____________2 0
P ----- *100-High *100 - Low j
Figure 29: Kaplan-Meier curves for protein expression and survival in 
emergency and elective presentations
No significant relation between Hsp27 and outcome was demonstrated in 
emergency or elective CRC (A-B). The same is seen for S100A8 expression in 
elective tumours (C), but a lower numbers of S100A8 positive cell expression was 
significantly associated with poor survival within the emergency presentations 
(p=0.03), as demonstrated in curve D. Median survival with 3 and 5 year 
prognosis data is displayed in Table 8.
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Table 8: Survival figures and statistical data for K-M curves demonstrating 
protein expression in emergency and elective presentations
Analysis Median 3 year 
survival 
(%)
5 year 
survival 
(%)
Logrank
Test
HR
High vs Low Hsp 
in Elective
High 54 75 49 Chi2=1.67
p=0.20
0.62
Low - 87 60
High vs Low Hsp 
in Emergency
High 25 44 44 Chi2=0.31
p-0.58
1.45
Low 18 33 33
High vs low SI00 
in Elective
High - 84 61 Chi-1.21
p=0.27
1.51
Low 54 78 49
High vs low SI00 
in Emergency
High - 80 80 Chi2=4.78
p=0.03
7.72
Low 19 22 22
3.2.1.2 Hsp27 and Colorectal Cancer
Hsp27 intensity (high or low) was further investigated in relation to 
clinicopathological patient factors. Associations were sought between Hsp27 staining 
and gender, age, tumour size, resection margin involvement, grade of differentiation, 
lymph node involvement (N Stage), depth of invasion (T Stage), and anatomical 
location. High Hsp27 expression was significantly associated with involved (or 
incomplete) resection margins (p=0.006) (Table 9).
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Table 9: Association between clinicopathological characteristics and Hsp27 
intensity
Clinical parameter All cases Hsp High Hsp Low Significance
(n=81) (n=37) (n=44)
(%) (%) (%)
Gender
Female 35 (43) 17(46) 18(41)
Male 46 (57) 20 (54) 26 (59) p=0.64
Age
^60 years 12(16) 6(16) 6(14)
>60 years 69 (84) 31 (84) 38 (86) p=0.98
Tumour size
<3 0mm 23 (28) 9(24) 14 (32)
>3 0mm 57 (70) 27 (73) 30 (68) p=0.45
Unrecorded 1(2) 1(3)
Resection margin
Clear 72 (89) 29 (78) 43 (95) p=0.006
Involved 9(11) 8(22) 1(5)
Degree of
Differentiation
Well/Moderate 79 (98) 36 (97) 43 (98)
Poor 2(2) 1(3) 1(2) p=1.00
Nodal status
Negative (NO) 44 (54) 18 (49) 26 (59)
Positive (Nl/2) 37 (46) 19(51) 18 (41) p=0.34
Depth of Invasion
(T Stage)
T1 6(7) 2(5) 4(9)
T2 10(12) 5(14) 5(11)
T3 52 (64) 25 (67) 27 (61)
T4 13 (16) 5(14) 8(18) p=0.86
Colon/Rectum
Colon 49 (60) 22 (59) 27 (61)
Rectum 32 (40) 15 (41) 17 (39) p=0.86
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No statistical significance was demonstrated between Hsp27 intensity (high or low) 
(p=0.29) (Figure 30) or Hsp27 expression (positive or negative) (p=0.16) (Figure 31) 
and survival within the TMA population.
Hsp27 in CRC: High vs Low
Number at risk 
hsphilo = High 37 
hsphilo = Low 44
31
34
25
27
p=0.29
16
17
hsphilo = High hsphilo = Low
Variable Median
Survival
(Months)
3 year 
survival
5 year 
survival
Logrank test Hazard Ratio
High Hsp 27 54 67 48 Chi2=l.ll
p=0.29
0.71
Low Hsp 27 - 79 57
Figure 30: Kaplan-Meier curves for Hsp27 staining intensity and overall survival
This graph displays the Hsp 27 staining index and survival. No significant 
difference between high and low Hsp 27 levels and survival outcome are noted.
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Hsp27 in CRC: Negative vs Positive
Kaplan-Meier survival estimates
O
op -
O S------------------------ 1------------------------ 1------------------------ 1------------------------ r
0
Number at risk
20 40
analysis time
60 80
Negative 15 14 10 6 0
Positive 66 51 42 27 0
Negative ------------- Positive
p=0.16
Variable Median
Survival
(Months)
3 year 
survival
5 year 
survival
Logrank test Hazard ratio
Hsp 27 Negative - 93 67
Chi2=2.01
p=0.16
2.07
Hsp 27 Positive 66 69 49
Figure 31: Kaplan-Meir curves for Hsp27 positivity and overall survival
This graph displays the presence or absence of Hsp 27 staining and survival.
Although Hsp27 expression tends to be associated with worse survival, this 
association does not reach statistical significance.
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Although lymph node involvement acts as a prognostic indicator, variability in 
survival exists within this group (often attributed to differences in tumour biology). 
Further sub group analysis was undertaken investigating associations between Hsp27 
expression and lymph node involvement. No associations were demonstrated in node 
negative patients (Figure 32), but Hsp27 positivity was associated with poor survival 
in patients with node positive disease (p=0.02) (Figure 33).
Positive Hsp27 vs negative Hsp27 in node negative CRC (NO)
Kaplan-Meier survival estimates
40
analysis time
Number at risk 
hsp = Negative 7 6 3 2 0
hsp = Positive 37 33 29 20 0
hsp = Negative hsp = Positive
p=0.87
Variable Median
Survival
(Months)
3 year 
survival
5 year 
survival
Logrank
test
Hazard
Ratio
Pos Hsp vs
Neg Hsp in NO
Pos - 84 64 Chi2=0.03
p=0.87
0.89
Neg - 86 57
Figure 32: Kaplan-Meier curves for Hps27 expression in lymph node negative 
CRC
No significant difference in survival outcome is observed between groups.
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Positive Hsp27 vs negative Hsp27 in node positive CRC (Nl/2)
Kaplan-Meier survival estimates
analysis time
Number at risk 
hsp = Negative 
hsp = Positive
-----------  hsp * Negative ------------ hsp * Positive
8
29
8
18
7
13
p=0.02
Variable Median
Survival
fMonths)
3 year 
survival
5 year 
survival
Logrank
test
Hazard
Ratio
Pos HSP vs 
NegHSPin
Nl/2
Pos 34 49 30 Chi2=5.21
p=0.02
4.64
Neg - 100 75
Figure 33: Kaplan-Meier curves for Hps27 expression in lymph node positive 
CRC
Significantly worse outcome was observed for Hsp27 staining node positive 
tumours
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3.2.1.3 S100A8 and Colorectal Cancer
Associations were sought between S100A8 staining and clinicopathological 
characteristics. Protein expression and gender, age, tumour size, resection margin 
involvement, grade of differentiation, lymph node involvement (N Stage), depth of 
invasion (T Stage), and anatomical location are summarised in Table 10. No 
statistically significant association was demonstrated.
Correlation between number of positive S100A8 cells and survival was also assessed. 
Inferior survival was noted in the group with lower number of S100A8 expressing 
cells, and this did reach statistical significance (p=0.044, logrank test) (Figure 34).
Kaplan-Meier survival estimates
analysis time
Number at risk
slOO = High 38 34 27 17 1
s100 = Low 41 31 25 17 0
s100 = High ------------ slOO = Low
p=0.044
Variable Median
Survival
(Months)
3 year 
survival
5 year 
survival
Logrank test Hazard ratio
High s!00a8 - 83% 64% Chi2 = 4.06 
p=0.044
1.97
Low slOOaS 52 66% 44%
Figure 34: Kaplan-Meier curve displaying number of cells expressing S100A8 
and survival
A statistically significant difference in survival was observed between tumours 
expressing high and low numbers of S100A8 expressing cells..
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Table 10: Association between clinicopathological characteristics and S100A8 
expression
Clinical parameter All cases 
(n=79) 
(%)
S100A8 High 
(n=38)
(%)
S100A8 Low 
(n=41)
(%)
Significance
Gender
Female 34 (43) 14 (37) 20 (49)
Male 45 (57) 24 (63) 21 (51) p=0.28
Age
<s60 years 13(16) 8(21) 5(12)
>60 years 66 (84) 30 (79) 36 (88) p=0.26
Tumour size 
^3 0mm 22 (28) 14(37) 8 (20)
>3 0mm 57 (72) 24 (63) 33 (80) p=0.08
Resection margin
Clear 71 (90) 36 (95) 35 (85)
Involved 8 (10) 2(5)......... 6(15) p=0.26
Degree of 
Differentiation
Well/Moderate 77 (97) 38 (100) 39 (95) p=0.49
Poor 2(3) 0 2(5) (FE)
Nodal status
Negative (NO) 43 (54) 21 (55) 22 (54)
Positive (Nl/2) 36 (46) 17 (45) 19 (46) p=0.88
Depth of Invasion 
(T Stage)
T1 6(8) 3(8) 3(7)
T2 10(12) 4(10) 6(15)
T3 52 (66) 27 (71) 25 (61)
T4 11 (14) 4(11) 7(17) p=0.77
Colon/Rectum
Colon 47 (59) 26 (63) 21 (55)
Rectum 32(41) 15 (37) 17(45) p=0.46
Sub-group analysis was undertaken investigating S100A8 expression within lymph 
node positive and node negative CRC, A significantly worse outcome was observed 
in tumours expressing low numbers of S100A8 positive cells with lymph node 
involvement, (p=0.04, logrank test) (Figure 36), but this was not seen within node 
negative cancers (Figure 35).
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High S100A8 vs low S100A8 in node negative CRC (NO) p=ns
Kaplan-Meier survival estimates
d
op _
° Li----------------------------- 1----------------------------- 1----------------------------- 1------------------------------r
Number at risk
0 20 40
analysis time
60 80
$100 = High 21 21 15 10 0
s100 = Low 22 18 17 12 0
s100 = High -----------  $100 = Low
p=0.27
High slOO vs High - 90 71 Chi2=1.23 1.82
low slOO in NO Low - 82 59 p=0.27
Figure 35: Kaplan-Meier curve for S100A8 levels node negative CRC
No association was demonstrated between protein expression and survival in 
node negative CRC.
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High S100A8 vs low S100A8 in node positive CRC (Nl/2)
Kaplan-Meier survival estimates
analysis time
Number at risk
s100 = High 17 13 12 7 0
slOO = Low 19 12 7 4 0
s100 = High ----------- s100 = Low
p=0.04
High slOO vs High 34 76 56 Chi2=4.13 2.41
low slOO in
Nl/2
Low 64 45 22 p=0.04
Figure 36: Kaplan-Meier curve for S100A8 levels node positive CRC 
The number of positive S100A8 cells was significantly related to survival
outcome in node positive CRC.
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Section 4 Discussion
This study has demonstrated the application of 2D proteomic techniques using whole, 
undissected, human tissue, profiling protein expression between and within two 
distinct groups of colorectal cancer patients reflected by their respective emergency 
and elective type tumours. Careful tissue preparation and protein procurement 
enabled the production of reproducible gels and consequently well-preserved 
analytical protein maps, resulting in the identification of differentially expressed 
proteins using mass spectrometry and peptide mass fingerprinting. Whole tumour 
sections were utilised without protein enrichment. This allowed us to detect protein 
expression changes in the stroma as well as tumour cells.
Following the acquisition of well-resolved protein gel maps, automated computer 
mapping was undertaken. This, however, could not be relied upon for high 
throughput gel-to-gel analysis. Due to the variations in the dimensional separation of 
each IPG ship and SDS gel, overlay between the final stained gels was variable 
despite computer warping, and visual analysis using known points of reference 
(usually high abundance proteins) and pattern recognition were essential. In future, 
this variability could be minimised by incorporating DIGE technology as outlined by 
others223,266 and this may also contribute to economy of time.
Protein validation was undertaken using immunohistochemical analysis of paraffin 
embedded CRC tumour tissue sections within a microarray. Two core biopsies from 
each section of CRC tissue were included in our TMA. This was to accommodate for 
specimen heterogeneity; previous studies document a 95% concordance between 
TMA samples and whole cancer tissue with 2 core biopsies, with the rate increasing 
to 99% including 4 cores.281
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Over the last decade, early proteomic analysis of clinical material using two 
dimensional separation strategies mainly focused on differences between cancer tissue 
and adjacent health tissue 219’ 223,282, 283, non-lymph node and lymph node involved 
colorectal cancer284, and more recently sera, and sub-cellular compartments 285,286.251
This project highlights a unique approach investigating the differences in colorectal 
tumour proteome, and thus biology, assessing stage matched colorectal cancer tissue 
from different modes of clinical presentation using whole human tissue. No such 
study had been undertaken during my research time (2004-2006), and furthermore, 
associations had not been sought during this time between Hsp27 and S100A8 protein 
expression, clinicopathological variables, and survival within CRC. A group from 
Aberdeen undertook a study using similar methodology (2D PAGE, protein 
identification and TMA immunohistochemical validation) investigating colorectal 
cancer and adjacent normal mucosa. They identified an over-expressed protein, 
Mortalin, in the diseased state, the expression of which was associated with poor 
prognosis225. This protein, also a member of the heat shock family (Hsp70), 
correlated with advanced disease stage but its precise biological function in the 
clinical setting has yet to be elucidated.
We confirm that our cohort of CRC patients constituting the TMA demonstrated poor 
survival for both lymph node positive disease, and emergency type presentation (in 
keeping with the literature17, 108',10)s thus providing a representation of the wider 
population. Emergency cases, however, only accounted for 19% of our TMA sample 
and although this is within the observed range documented in other studies17,108-110, it 
is significantly less than the expected 43% noted within our previous study.106 This 
could be attributed to the collection process of the Liverpool Cancer Tissue Bank 
Research Centre; only cases undergoing surgery between 0900h and 1630h were
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collected and stored due to staffing provision. Tissue banking required the immediate 
processing of fresh tissue, and any cases resected outside these hours were preserved 
in formalin, rendering proteomic analysis difficult.
Hsp27 has been shown to regulate apoptosis via several pathways.287 Tumour cells 
demonstrating increased expression may acquire a survival advantage, and possibly 
increase their metastatic potential. Increased tumourigenesis of Hsp27 expressing cell 
clones have been demonstrated in animal models265, and more recently human CRC 
expressing Hsp27 has been associated with lymph node metastases.288 Our study 
demonstrates an association between Hsp27 expression and positive surgical resection 
margins, which may relate to a more aggressive tumour phenotype. Tumour 
involvement of the resection margin is also associated with a poor prognosis, but 
whether Hsp27 expression is an independent marker of margin involvement (and 
thence poor survival) or directly implicated in overall poor survival could not be 
addressed by this study. The number of cases were too few, and did not allow for 
meaningful multivariate analysis. As such, further investigation would be interesting.
The majority of our CRC (80%) overexpressed Hsp27, the extent of which was 
statistically unrelated to overall survival, hi tumours that had metastasised to lymph 
nodes (n=36), however, Hsp27 expression was of prognostic significance. The 
proportion of lymph node positive patients alive at 5-years was 75% for Hsp27 
negative patients compared to 33% for those with Hsp27 positive staining (p^O.03). 
Although the numbers are small and interpretation should be carried out with caution, 
this suggests that Hsp27 may have a role in guiding potential clinical management of 
stage III CRC. Further investigation is warranted with an appropriately powered 
study to investigate its use as a potential biomarker in the context of lymph node
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positive patients. The mechanism by which this might act is uncertain, and has not 
been addressed by this project.
Since this study was undertaken, several groups have identified Hsp27 as a 
differentially regulated in CRC284’ 288'2935 and indeed described associations between 
its expression and clinical outcome.291,294
Following on from this project, Miss Elizabeth Tweedle (research fellow, Division of 
Surgery and Oncology) further analysed the significance of Hsp27 in 404 cases of 
CRC, and found that its expression was strongly associated with poor cancer specific 
survival in rectal, but not colon cancer 295 It was suggested that this may reflect the 
biological differences between the anatomically distinct colon and rectum. In a 
similar study of 140 CRC cases, Wang et al. also noted poor survival with elevated 
Hsp27 expression, but this was observed in both colon and rectal tumours.294 Despite 
these discrepancies, it is evident that elevated Hsp27 may be indicative of more 
aggressive tumour characteristics.
Both Hsp27 and S100A8 expression are associated with inflammation. It is not clear 
whether Hsp27 expression is related to an acute phase response initiated by the insult 
of cancer microenvironment itself, or a consequence of genetic aberration, but 
interestingly, nearly all emergency tumours (90%) expressed Hsp27. The localisation 
of these proteins demonstrated by our TMA IHC would suggest that whilst Hsp27 
was expressed within the cytoplasm of tumour cells, S100A8 was specific to myeloid 
cells within the peritumoural stroma.
Myeloid cells within CRC stroma have been the subject of much investigation. 
S100A8, and its dimeric partner S100A9, are associated with both macrophages and 
monocytes, which are expressed at sites of inflammation.252 They contribute
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significantly to the host inflammatory response and are involved with leukocyte 
trafficking, adhesion and migration252, 296, which ultimately affects tumour growth, 
propagation and eventually metastasis. ’ The phenotypic makeup of tumour 
associated lymphocytes constituting the extracellular stroma has been linked to 
overall clinical outcome and relates to their functional plasticity. The presence of 
cytotoxic lymphocytes, identified by the surface cluster of differentiation (CD) 
marker CD3 and CDS are associated with tumour regression, reduced propensity to 
metastasise and a better prognosis.299 Tumour associated macrophages, on the other 
hand, promote tissue remodelling, angiogenesis and secrete growth factors which 
fundamentally influence aspects of tumour biology, often favouring tumour expansion
j • • 300,301and invasion.
Although our stromal cells possessed microscopic features typical of the macrophage, 
CD3 and CD68 IHC was not undertaken, and thus we were unable to further 
characterise these cells. Subsequent work undertaken by our group did however 
investigate S100A8 staining myeloid cells within CRC stroma, and found that they 
were CD14+/CD68' representing immature macrophages.302 In a study by Stulik et al. 
the differential expression of S100A8 and S100A9 was indentified between normal 
colon mucosa and CRC, with subsequent IHC confirming the co-localisation of these 
proteins at the invasive margin of tumour. They demonstrated CD68 positivity of 
these cells confirming a macrophage phenotype, although they did not undertake any 
correlation with clinical outcome.244,245 This differential expression was verified by 
2D DICE in a later study by Kim et al. who went on to demonstrate its expression 
using IHC within tumour infiltrating immune cells, but again without CD 
immunotyping or association with clinical outcome.251 They did however confirm the
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presence of this protein within the sera of affected CRC patients and suggested its 
implication as a potential biomarker of disease.
S100A8 expression has been shown to be of prognostic significance in cancers such 
as bladder303, leukaemia,304 and breast305 although to date, this has not been 
demonstrated in CRC. Our proteomic study would suggest that the clinical outcome 
of CRC is related to the number of S100A8 expressing cells present within the 
peritumoral stroma. Indeed, our subgroup of CRC patients who present with more 
severe symptoms, clinical signs of obstruction or perforation, or nodal disease was 
much better if high levels of S100A8 expressing cells were present in the stroma. 
This represents an exciting development in the investigation of tumour biology, and 
further studies are warranted.
Our work has highlighted protein differences between CRC tumour types, and 
discovered novel associations between their expression and clinical factors, which 
may one day find use in clinical practice. Whether S100A8 and Hsp27 expression are 
the cause, or effect of a more aggressive tumour subset remains unclear. They do 
however represent distinct biological differences and may serve as easily measurable 
biomarkers of disease prognosis. This may contribute to a tailored or focused 
selection of future adjuvant treatments available for CRC, such as those discussed at a 
multi disciplinary meeting for example. It also represents the early findings of a 
project set up from first principles, and a platform from which further research 
projects have developed. A comprehensive CRC database has been constructed as 
part of this project, which can continually develop and evolve, providing an ever more 
powerful analysis tool for future CRC research.
Finally, although the aims and objectives set out at the commencement of this project 
have been fully addressed, a vast number of individual protein spots were resolved on
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each analytical 2DE gel. Several additional spots of interest may be identifiable and 
provide targeted opportunities for future research into the biology and natural history 
of colorectal cancer.
Ill
Section 5 Conclusion
In conclusion, we have demonstrated the successful application of proteomic 
technology to the investigation of clinically distinct CRCs. This represents a unique 
approach to global proteomic analysis of CRC, as no previous comparative studies 
between emergency and elective colorectal tumours have been undertaken. 
Differences in protein expression between tumour cases reflect differences in 
underlying biology and hence clinical activity. Although the related mechanisms of 
action remain to be determined, this marks a progression in the understanding of CRC 
and its heterogenic clinical behaviour.
The quest for specific biomarkers of disease continues. This project, set up from first 
principles, was inspired by a “bedside to bench and back” ethos, and has provided 
valuable foundations for further work within the field of continuing cancer research.
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Age 28 | 43 37
Title Mr. Mr. Dr.
Post Held Research Registrar Consultant Surgeon Lecturer
(B) Details of Institution
Name: University of Liverpool, Division of Surgery and Oncology,
Address; 51h Floor UCD, Duncan Building, The Roya! Liverpool University Hospital, 
Daulby Street, Liverpool L69 3GA.
Telephone: 01S1 706 4180, EMai!;l.khattak@liv.ac.uk
(C) Title of Project
Colorectal Tumours: Comparative proteomie analysis of emergency versus elective 
patient tumours.
(D) Summary of Proposal
Colorectal cancer is one of the most common malignancies, accounting for 16,000 deaths in 
the UK in 2000.
CRC patients present either as emergency cases (with obstruction or peritonitis) or as 
elective patients. In a study of patients at Liverpool, we found that symptoms were present 
for a median of 11 days only in the emergency group compared to 32 days in patients 
presenting to clinic (Khattak and Rooney, 2004 submitted). Other work has shown that 
emergency cases present with inter stage disease. This short symptom period and 
advanced stage at presentation suggest that these tumours may be fundamentally different 
from those of patients presenting electively. The cancer specific mortality is 1.8 times higher 
for emergency cases compared to elective,
In this study, we will examine the protein expression profiles of stage selected tumours from 
both emergency and elective groups and determine whether there are fundamental 
differences in expressed proteins between specific Dukes' stages in the different groups. 
Proteins expressed differentially between these two groups will be identified by matrix 
assisted laser desorption ionisation (MALDI) mass spectrometry (MS) and selected 
examples will be validated by immunohistochemical analysis,
r,N> Vm .'w.n s fta rtiivnfjMsc) frau OLr [•VeSsiV uk
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(6) Summary of Support Requested
{NOTa: APPLICA TIONS FOP FUNDING >£C(W IVJLiL NOT BE CONSIDERED)
£
Staff
Running Costs £3600
Equipment £ 2400
TOTAL £6000 j
(F) Time-Table
Proposed starting date: Sept 2004 
Duration of project (months): 24
(NB: funding will only cover up to one year of the research project)
RESEARCH PROPOSAL
(1) Title of Project
Colorectal Tumours: Comparative proteomic analysis of emergency versus elective 
patient tumours.
(2) Background To Investigation
(To include (a) Present body of knowledge and work done on the subject: (b) Previous work 
done by applicants on this Or rotated area of research interest)
Colorectal Cancer (CRC) is the fourth most common cancer in the world. In 2000 it 
accounted for 16,000 deaths in the UK , making it the UK's second most common cancor. 
Patients can present with CRC in the elective setting (from the GP to the clinic) With 
symptoms such as recta! bleeding, weight loss, signs Of anaemia, or as an emergency 
cases (to casualty) with symptoms of intestinal obstruction and peritonitis (extreme 
abdominal pain) Previous work has found that tile spread of cancer, or stage, at 
presentation bears no relation to the duration of symptoms experienced by patients.^' 1 2
Similarly, despite a reduction in the time delay between diagnosis and treatment of patients 
with high risk symptoms, (as per the NHS cancer plan), no observed effect on Dukes' 
staging statistics was noted.'1
The cancer specific five-year survival, following "curative" resections, for patients in tiio 
elective group is far better than for stage matched emergency patients. Increased post 
operative mortality in the emergency group is documented;'Various explanations have been 
postulated including timing of surgery, experience of surgeon and age of patient.
It is not understood why the cancer specific mortntity of emergency cases is greater than 
that of elective pntsonts. We hypothesise that tile underlying biology of the respective 
tumours holds valuable clues. We will thorefore investigate the pattern of protein expression 
in stage-matched etective and emergency tumours. We anticipate that differences in the 
protein profiles between the two groups will be observed and that these differences will offer 
unique insight into the distinct biology of these tumours.
Ti’.’-'ai-f.iV. aiV'.f.'.t'.'M tin ai'a: b? [for.’.iMcW.WvT; owlVebs'.'C" mi'.*1 i<’-
Extensive genetic analysis of CRC has allowed Uie elucidation ot a model delineating the 
progression of this cancer.£ Recent technological advances have made the large scale 
analysis of proteins possible. Many cancers (notably ovarian and prostate and pancieas) 
have been investigated at a protoomic level leading to the discovery and identification of 
novel proteins present in the diseased state ',G s.
Using similar technology, colon cancers have been investigated and tumour related proteins 
have been identified.10 11 These proteins have been investigated with particular relevance to 
their use as a screening tool1^ and work is still ongoing. However, no proteontic studies 
designed to address the observed discrepancy in modality between emergency and elective 
patients have been reported. Proteins are the basis for cellular activity and therefore we 
postulate that cancers presenting as an emergency have a different biological activity, and 
hence a different protein profile, to elective ones. The identification of differentially 
expressed proteins will form a foundation for further research into investigating the 
differences between these tumour groups and potentially open up avenues for novel 
screening methods or treatments of CRC. The proposed work will apply advanced 
technology (laser capture micro dissection and mass spectrometry) to a clinical question
(b) Experience of the applicants with proteomic anais'sis.
Dr. Costello's group Iras previously undertaken proteomic analysis of cancer specimens. ‘ 
This included the detection and identification of proteins involving laser capture 
rnicrodissection (LCM), two dimensional gel electrophoresis (2-DE) and matrix assisted laser 
desorption ionisation - time of (light (f/iALDI-TOF) mass spectrometry (MS) and MAID!- 
TQF/TOF based MSfMS analysis. These protocols will be adapted for the analysis Of CRC 
specimens. Mr Khattak will work as part of this group. All of the expertise necessary for the 
execution of the project is in place.
The 5.vr?i Cfii? hp {fo.ivitaiitec/ favn cot
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(3) Aims of Study
The aims of the study can be set out as follows 
Part A)
i) to compare expressed proteins profiles in Duke’s stage-matched patients who 
underwent elective and emergency colorectal surgery for carcinoma.
ii) To identify proteins that are differentially expressed between these groups of patients, 
ii't) To validate the expression {using immunohistochemical or other relevant means) of
selected candidate difi'erentially expressed proteins.
{4) Plan of Investigation
(To include (a) Nature of work to he carried out' (b) Method(s) to be employed: (c) Research 
time-table to be implemented)
a) Our study will be carried out using human tissue. The tissue concerned has been deposited 
in the Cancer Tissue Bank Research Centre, University of Liverpool, following collection 
from selected cancer patients with their informed consent research. There will be no direct 
contact with the patients, and no further input from them is required
b) The project can be outlined as follows:
* Dukes B and Dukes C stage tumours from emergency and elective patients will be 
obtained from the Cancer Tissue Bank Research Centre
* Tumour cells will be dissected from non-tumour material. Whole, imdissected 
samples will also be used.
Proteins will be extracted from each sample and separated in two dimensions, as 
follows:
Gels will be loaded with a) limited material (< 30 micrograms protein) and silver- 
stained and b) with greater quantities of protein (> 250 micrograms protein) and 
Coomassie-Blue stained.
• Stained gels will be scanned and images analysed both visually and using 
imagsmaster 2D software.
» Protein spots unique to emergency patient tumours or elective patient tumours will be 
isolated from gels and identified by MALDI -MS or MS/MS based mass spectrometry.
• Validation of selected candidate proteins will be carried out by 1HC (immunohisto 
chemistry) on a large number of samples.
Detailed Plan
1. Selection of CRC tissues and enrichment of tumour ceils (
Twenty samples (10 each of Dukes’ stages B and C) from a) 5 emergency patients and b) 5 
elective patients will be selected and laser capture microdissection (LCM) carried out to 
enrich for tumour calls. Microdissected cells will be recovered directly into urea.fCHAPS- 
based lysis buffer. We will subject all samples to the same number of fraoze-thaw cycles 
(typically 6 per case). Whole, undissccted samples will also be used. This stage is very 
labour intensive hence the small numbers. Previous work on_the pancreas within the 
department has revealed significant findings using small numbers.’
2. 2-DE analysis of CRC cells.
Protein samples isolated from microdissected cells or whole tissue will be subjected to 2-DE 
analysis using immobilised pH gradient (IPG) strips (pH range 3-10 nonlinear and 4-7 linear) 
with in-gel rehydration. Protein concentrations in samples will be standardised so facilitating
77's utvAVv&Yi tYJO-'ic c>:Y,T:,'f:,'M'r.rt fraTat-vl-VccjiYj. jtJMwesed a- un
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comparisons of both silver stained gels and Coomassie Blue stained gels. Ge! images will 
be acquired and analysed, visually in the case of Silver stained gels, and by Imagemaster 
2D software. The patterns of the 2-D gel images from Dukes' stages B and C respectively 
obtained from emergency and elective patients will be compared and protein spots 
predominately seen on one and not the other will be prioritised for identification and 
validation, as described below.
3. Protein identification
Following analysis of profiles, relevant protein spots will be excised from gels and subjected 
to peptide mass finger printing by MALDI-MS. The peptide mass fingerprinting will provide a 
rapid first pass analysis Of the proteins and if it does not prove sufficient for the 
characterization of any individual proteins then subsequent MSrMS analysis will be carried 
out using tandem MSMS.
in our experience, identification of proteins from sitver-stained gels containing the low 
quantities of protein obtained fallowing LCM is difficult. Thus, we cannot rely solely on our 
analytical gels to yield sufficient quantities of protein for successful identification. We will 
therefore prepare preparative 2D gels from laser captured stromal specimens and 
Goomassie-blue stain them. These preparative gels will be compared with silver-stained 
gels containing protein from microdisseeled cells and protein spots will be matched (we are 
aware of the difficulties in matching spots from heavily loaded Coomas$ie-blue stained gols 
with silver stained gels). Material from the Coomassie-stained gels will be subjected to 
MALDI-MS or MS/MS for identification
4. Validation of the expression of identified proteins.
Because we anticipate some heterogeneity in observed protein alterations, a vital part of this 
study wnll be the validation of the protoin expression data we obtain. We will endeavour, 
using methods independent of 2-DE, to determine whether the observed changes in protein 
expression are maintained in a larger sample set. Where antibodies to protein candidates 
are available, we will carry out immunohistochemica! staining of CRC specimens {obtained 
from the Cancer Tissue Bank) and the results will bo scored by a specialist pathologist.
A CRC tissue microarray will be generated and will be used for this purpose.
c) Proposed research timetable:
0-12 months
1. Selection of appropriate samples and microdissection of tumour cells from non-tumour 
material. Preparation of protein extracts, quantification of protein.
3-15 months
2. 2-DE of a) limited material {< 30 microgram protein) and silver-stained and b) with greater 
quantities of protein (> 250 microgram protein) and Coomassie-Blue stained.
Scanning of stained gols and extensive image analysis (both visual and using Imagemaster 
2D software).
9-18 months
3. Protein spots unique to emergency patient tumours or elective patient tumours will be 
isolated from gels and Identified by MALDI -MS and (MALOi-ToF and MALDl-ToF/ToF)
z.'is fain can tie oew.sVM'fo flw «i.v Wefetite jSSirCr00' 'Ji:
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12*18 months
5. inimunohistochemistry of preserved CRC tissue specimens for the detection and 
verification of identified candidate proteins.
(5) Existing Facilities
a) Scientific and/or technical expertise and support
The proposed project will be carried out in the MRC Co-operative Gl and Pancreas 
Research Group, under the scientific supervision of Dr. Eithne Costello. Her group has 
recently developed considerable expertise in proteoniic analysis of cancer specimens, which 
will bo directly applicable to the proposed project. Her group is very active scientifically (see 
attached CV) and is a vibrant atmosphere for the research to be carried out in. All of the 
necessary scientific and technical support for the project is in place.
b) Accommodation available for research project
A designated laboratory space and research office are available for the purposes of this 
research.
c) Access or availability of equipment to applicants, required for research project
Equipment for the realisation of this project is in place. However, additional items for the 
persona! use of the appointee are also requested, including an eppendoif niicrofuge 
(£1,150) pipettes (Gilson Pipette Set, £850), a vortex mixer (ProGen Scientific, £130), and 
Pipette Aid (Pipette Boy Eppendorf, £220).
d) Additional funding obtained or applied for research project
No other grant applications are currently pending that relate to this research project. 
However, it is envisaged that future grant applications will be made.
Xlv* upixKcaKxx* fcr/n cat z.'sc- fru etap,™site6wr? gur lYetaCg MVMireaadag hr;
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(6a) Justification of Financial Support Sought
a) <taW cofrjg7 * ^ V
(Salary, Nl. superannuation)
(Disposables, animals, chemicals, etc)
Laser caoture mcrodissection reagents F1 440 (720 CapSure fi'm ca'ners fArcturus USA 
£4S0.'240 Caps)
Dtspcsable paste ware is estimated a: £800 (includes disoosable mpettes goves yellow 
and blue bps)
Mass spectrometry- associated costs including reagents ‘or digestion ;e g sequencing
grade trypsin). ZipTips for digest dean up are estimated at £1.360 £3 ggg
fi) qquHwnaqf^
fcppendor' microfuge (£1 *501 
pipettes iGilson Pipette Set, £850) 
vortex mixer (ProGen Scientific. £180)
P pette Aid (Pipette Boy Eppendorf £220)
» “ ; » 1 ’.
144
(6b) This application has been submitted through (i) The Head of Department and (ii) The 
Institution where the research will be undertaken
(i) Signature of Head of Dopartment (ii) Signature of Administrative Authority
Finance Qfftcer/Secreizr/ of institution 
(delete as appropriate)
Name {block capitals) and Qualifications
(printed)
Name (block capitals) {printed}
Address Address
Division of Surgery and Oncology.
Royal Liverpool University Hospital,
5'1 Floor UCD Building,
Daulby Street.
Liverpool,
169 3GA,
Senate (douse
University of Liverpool
L69 3BX
Official Stamp
Tftfi #iY>un>;wi fainj can .t.'.io i: aiv/TTitM'si) ftuw UtA' VVswiis. •«viv ;«tsr sv.v’A
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(7) Ethical Approval
(Funding will not bo provided without the necessary ethical approval, if appropriate)
a) Required: YES
b) Obtained; YES
(8) Possible Beneficial Outcome of Project
a) Principal Applicant
The project provides me with the opportunity to undertake and learn how research is carried 
out in reality. It enables me to expand my knowledge of cancer biology, in particular CRC. 
Moreover, the possibility to apply up to date techniques and to become familiar with the work 
involved in proteomlcs is exciting and I believe will be rewarding. Of benefit, the research will 
allow me to attain a higher degree by thesis.
b) Research institution
As there is no literature concerning the proposed research project in circulation, it follows 
that the institution will gain national and international recognition for novel work undertaken 
and presented at forthcoming conferences.
c) Scientific knowledge
The aim of the project is further understand the molecular biology of colon cancer Positive 
findings will contribute to both scientific and clinical fields allowing new applications to 
disease progression and detection.
Work undertaken during this project should act as a platform for further proteomic 
investigations into the biology of colon cancer.
d) Patient care
Patient care can be improved by oarlier detection of disease. Various screening tools have 
been investigated, but as yet there is no national screening facility in the United Kingdom. 
By identifying specific proteins associated with carcinogenesis new methods of screening 
may emerge allowing for earlier intervention of disease.
rp;i> flni>\r..ir.r.o Sjf.ti cad 3iS3 q-c* tfo-v.-imS?- .Vh m ow ivii^fasrL'.fo :i‘,
146
(9) Selected References [No more than 20 key references {detailed in fuli) to be cited]
1 www-cancefresearchuK.orq.
2 Holliday H. Hardcastle JD. Delay in diagnosis and treatment of symptomatic colorectal 
cancer, Tr?a Lancet 1979: 309-311.
3. Olsson L, Bergkvist L, Ekbom A. Symptom duration versus survival in non-emergency 
colorectal cancer. Scandinavian Journal of Gaslrcenteroiogy 2004;3fi(3}' 525-528.
4 Fiashman K, O'Leary DP. Senapati A, Thompson MR. The Department of Health’s "two 
week standard" for bowel cancer: is it working? 2G04;53: 387-391.
5. McCardl© CS, Hole DJ. Emergency presentation of colorectal cancer is associated with poor 
6-year survival, British Journal of Surgery 2004(91): 605-609.
6. Rajagopalan H. Nowak MA, Vogebtein B, Lengauer C. The significance of unstable 
chromosomes in colorectal cancer. Nature Reveiws Cancer 2003;3: 695-701.
7. Stiekovrh AR. Thompson CC, Prime W. Campbell F. Hamlett J, Herrington CS. Lemoine NR. 
CrnogoraoJurcevic T, Beuchler MW. Friess It Neoptolomos JP, Ponningotn SR, Costello 
E Application of laser capture microdissection combined with two-dimensional 
electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal 
adenocarcinoma. Profeom/ce 2003:2:1988-2001.
8. Stulik J. Hernychova L. Porkertova St Knizek J, Macola A, Bures J, Jandik P, Langridge J. 
Jungbiut PR. Proteome study of colorectal carcinogenesis. Eteutoopfiutesis 2001:22: 3019- 
3025.
9. Wulfkuhle J, Liotta LA, Petricoin EF, Proteomic applications for the early detection of cancer. 
Nature Reveiv/s Carreer 2003 ;3: 267-275
10. Friedman D, Hill S. Keller J, Merchant N. Levy S, Coffey R, Caprioli R. Proteome analysis of 
human colon cancer by two-dimensional difference gel electrophoresis and mass 
spectometry. Proteoniics 2004;4: 793-611.
11. Roblick UJ, Hirschberg D, Habermann JK Palmberg C, Becker S. Kmger S, Gustafsson M, 
Bruch HP, Franzen B, Ried t, Bergman T. Auer G. Jornvall H. Sequential proteome 
alterations during genesis and progression of colon cancer. Cellular and Molecular Life 
Sc/eoces 2004:61:1246-1255.
12. Mak T, Latloo F, Evans DGR, Hill J. Molecular stool screening for colorectal cancer. British 
Journal of Surgety 2004:91; 790-800.
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15 November 20C4 
Mr I yas Khattak
Divis on of Surgery and Oncology
Royal Live'oool University Hosplal
5"* Floor
UCD Bui:d ng
Oauiby Street
Liverpool
L69 3GA
Dear Mr Khattak
SMALL RESEARCH SUPPORT GRANT
TtvariK you for your application requesting funding which was considered 
at the Research Boarc meeting on Fnday 12 November Unfortunately 
your application was unsuccessfu on this occasion
I thank you for your interest and wish you every success n your research 
endeavours.
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Professor O Erorrn 
Chairman of the Research Boarc
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Appendix 2
Dote -B.m-aco* Hcteie*^ (M-oisos'G*
MHS R»scarch Ethics Commlnee|fc23
APPLICATION FORM______________________________________
Thi* form should be completed By the Chtet investigator stter reeding the guidance notes
$5C Glov-iry 'or clarrticat on r rtirr-ent tenr* m t-e auptmilnn loin __________
Short Tide and version number. !-m«irmn 70 ohi-actKS - th* w* hn irmeded ss hesde' yi a torn*, i 
Colorectal tjnrours GnmpaiaTve anaivss of vet sue «le:t v®
Hame ot M«S Research Ethic* Committee to which application tor ethlcsi review is being made:
Jverproi Local bites Conmticr
Proiect Reference number Inrxn above REC: 01'Qi
Submission Date: *5.~05.~2JC^_________ ______________________________ ______________________
At Title ot Research
PjH .j,|p Cotoiectai tunours Conp;».rlve iiioieDtn: an- vsit p* cmcnjnrcy versus eactive catient Wmoi-.
<ny werds Oboretts CpnEw.cnotecrrics. sympterr doMlcii. suivK*al
A3. Chief investigator
Tfc? Or
^crerurrC'IniHul'i bithne
Surname Ccsidb
Post LecTt'er,r Molecule' b olopv
Ojaidicarons 3.Sc. :Hors.im ^hc'TKicucyy. ^hO. »
Oganssito" Acaccn-•: Cepatlrrent ol Surpcn,. ivn
AtJdrcst: Sth F cor UOO
nu-.ai jve-poo' Hoscit-i
Pfcr*r.nl Slier
3OJt Cory L6D 3GA
t mail: rio*/ei<?t !V.ac -k
Tccphcne 01D1 7W.4-7a
Kax: CIS* .06 58^
iwf «v^ mjiyj Wu?
t S £ Mi A, WMl
A3 Proposed Study Oates and Duration
Star Date •S,08.’2Kc
Fidtiai*: *St>B.,20C9
Ourttim Mnullis SC: Years
N-tS REC Appcat Dh I o~< Vision <■ 1 AB.7622 1
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Dale: 16.-06.'2004 Feforerce (K^’CttSOS^M On 'te Form
A4 P»im«y purpose ot the research , ric* js
□ Or>T»wi:j orodu:t Or^ eircn^rii nro'ix Mreratr^ 
0 FublcK- urdrril I - .il Cf SC«nt‘C invesiiowipr
E tcucatona q.alifcain'i
(Z rMirt> sf ig a catabase oa s fROimy
□ Othyr
--------- ---------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------ 1
AS Tick the box It your research;
CD inrvovse tsslm; n mcrtinrmi piod.ct
ID bwovte inver^at 'a a r»ctli:;.-»i ilevioe
PI IrwDves .nlrliilorai -adiaton above •ha; renurmi (or cltr os) na
0 Invoves jsrig Kimeo '.ample* c- human biocgica! na rial <>.g bood ussuai
[~1 invo.ves itiing rsw sarreiof. ol iurran cioioc ca1 rnaiena1
E InvoK-m; arty aatent records creole w h m> iiHie' di'eci paflenl cor;&:l
I involves crisorinrs or o’lie'S in c.siod'i care
(D Involves aoults urafclo -.o oonsenl tai •he-nseves!' ■cuaB p-ysiriil nr m-nisf irosoacily 
(Cj Has *■« oirrary a Ti of be -fl edural nn;il y.tj a '•..oent crojecl or a crotocl o* rrsisi't.li nrnes&s'y lor a 
postp'aouale dogrt-r; rliocrrai
AS Oo you consider that Ibis research Ians vrtthln the category where there is no need lo appoint a Principal 
Investigator at each site?
Ove*
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Dare 16W2004 Rotofencfr 0*,OrfiOSa64 Ontr« Form
AT. What is the principal research questiorvobjocrivc? i»e .Vi •Jiijvape ccviip’eAensiO'e fc a iay nmof .•
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will be aracted by't durirq fioir Wet ivr Cress sec- coal and retrospoctv.; studies -avc shown -ha' trere are najo- 
dHtcrrrecs In rre ocst sug ca treEtrrcnt ov xoric of Itiusn paHerts y/ho have unde gone electve surtrrv wtun compared to 
nose w-io are sjbtectcc to ctrcrpr' cy siapery. I ie ca-ce- specific deaf rate at J> years .•rkmir.; 1 fi 'tries ughe- ? the 
enoigcncy casrs rwreri compensated '0' case m » and a hrywr post opsrat ve nortality; Although f o Tal onai .rve'jge b 
y- survival for a g ven staqo of r-«n er a weH mted. me emergencies often -"ai in the met end o' rre standard oevialior 
This iwivirles tfie tounda'io" tor our xscarrh cmp'':i why de some cancers d'esent as an emergency am what cMctstes. 
tretr pop- surmat'5
vre'h has beer uroertsker over re last 15 to ?0 years toosing at the preteir content of cel* The t -vT.in grnarie "as 
peer conpietso aid with that. Him* has been a well deecibed pe-orr c thco-y fo» foe prngiession ot CMC ►'rotei'1 
nvowlaaton atfows n'er^etatid' of ccJar -V-clio' ol a oosi tensorpriftal level rat is at a fonc-foial level rHctateo ay foe 
genetic oaoe Mary caiccfi inobsby ovarian ana prestate. hevo bcc- irvcslgiilcrl at a pioteomtc level leading to the 
c> sc every aro oent'oaHon of novo proirins pn-smi n the d seastc state
Using sinlla' teemobgy ccfon caiccht. t«ve her' irveahgated ano proto ia have been idc- iifod, out mere has been no 
wrrk or the ■tarenonionco Uifiic o e<piatr me observed dhcrcpc'-cy m iro"a 'y ‘toletriS are the bass ‘o' colt <u arivity 
and therefore- wr pos’L ate that cancers omscnimo ■r; »*■ emergency rave a dtfegrn brcfogte.it arttivtry which oar ce 
rttyesseo n ts c'otem proffo if iff. I* >d«nf tec me" a sourc ooomn -g fo' f irt"«» re^ewci no screenirc am treatment uf 
CRC W. oc ir p.tce Ihe p-eposed 'rverk wll app'v .nlv.iiii.r:! tecmol:-;.' rieser capf m micro rksrvrr.ltiMi am mass 
spectrometryi to a c nica) sljOy The skills am the expemneo wo have p.i nm) .vi:l w l cam wrl be made tva able fo ctrers 
ir the unveriety
A10. Give a brfol synopsis summary of methods and overview ot the planned reaaarch. including a brief explanation ol 
the theoretical framework which informs M H should Include a trial description of how piospecttve neeeerch
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parficlpantB and concerned communities (not nccesaaiHy gaographiciiti from vdilch tu&y are drawn have bcetr 
consulted over the design ond details ot the research.
flWtpw nfui'orrnaifi a ."atv cKart 0' (ft.y.Mn; ^'idl'.V,1 sL'^lfetf sciwraieiy. iY sfloura ue cfcar ojrachV ,v'lir'1 wW-baopsa fo mo 
reseH.w'rpafiit.'parii. fimv .‘tvi.'i/ fi'n’es nnf! m '.v.haf ysYcr,i.
This scclior- MUST tvs oompteiod in iiin:pMiji; o;rro ehe^snfe :e lire lay person. On ClilL s to y roprMuuj the prrrooa
li i;; it)'f!i)i lant to state bat bis is a atsdy using very sninll runrmsrs in which 'urran lissse -s to !«> invosl gated 
ratrc&toc-'.isi'.V- The [issue ccncornno is ;> rl ol lire Canaer Tisst.o Riint; Hi'.sir arch centra vrhish has &scn cyilluetad rerr 
selKrted can-nr pnliimis ivlb thetr consent rvri mKimsl.rnfJ sg :r.a: treir ’.issues >vitt ta; usad for t-e curprocs of cntxre- 
nv;p.-mTr, ’h&'s v.'ill be no direst f onl.rot wth tie pal onis, and rw fml wi Input 'tom tT-sm is 'vntiinsi
Ttrr; ptoect can bo out ned nr; ltrllo,/.is:
* Drc group v/ltt have Di-hcs n ri'ut Ducea C tjrraurs obtain to lomt tire Csvrkl e. emeigensy arc olxtivi: fralieirts;.
. "urnetii'ce^'i will t>-' Qlaaectsd Iron non-iun tiui m jt-r-ial. r! neses&arf'
■ I’rctsns vail be ostnir.iiN'i front each sample and scpni vm it too oin’ensions. as iollows
, „jlt pf. indeed with a) tirr tes nnlotipl (■: 30 nsor-grans cnoloin) mitt silvftr fttatnec c"d 01 •viti prentet guitriiities ot 
potato (.v iiuO ntic'esiums pwte o and GDS-na&sie-niue statned;.
* fjininiHt gels v.'ll be sc-r.-ncd anil images analysed both visutify m« usin; litagemastor 2D seilwR-c
■ Bruton spets .inii'iufr to ems-'goncy patiem 'ij-un.-fi'- nr etscllve patent lunours wit Im isolated rrc.Ti ges ara idcniifpd tiy
F.1ALPI -fits ^ ,
• Gob wit ’O r-mavaed rPful Bi with ,;i virr.-r to identlylnp prctc--ie but tu« tyfrioa1 ni spacrtlc Dukes atages,
■ Vail Paten of sofoshnl cmxridate cotsos oitl bo rcirriisi or.- by IHC (imnur^ism r.l-cmnlryi os a latte number of sa-npier..
• Cc.t'mI tissue, r tte.' aarvsom...-; m non cansera-^s. may nr-cd to be s.iivpled and asssa-sod in a siriiliv Insbion,
AllemarFk'e prater casco iTOiiyii;,ni ivethscs are e.eoorivisanrtcl
I. Seectiyt pf C“C ta-.sues s'd eiricTirrent ul umn.i' sella
SampliT'! f crach a? Dukes' str.-tyjs B nnrl Cj 1iom a) anierpp-rc«' pisliiints aro taj ective eat-s'its w>. t»:> mrilcied srd ebtainod 
trom bo Gtnc>:r TisStm dank. Llverpec1 Tnis lissi.i: i-.'ir, already teen cellosted from ofmss-'tec pElior. far the proposed ol 
reseajcfi Wo will easy out -as?' caplun: n'mrf.fllssaclion (LCMj, * rtoocccl nr neaole oissoeton to out oh for tmxtur cells. 
Mlraodsaected cels will bo recovered erectly ■net fcrn'Cl I'dk-i baaeo lys-s buifer Wo wilt tnibleat si samples to th; sumo 
numoar of frcuru-lhaw cyc.es (typerdy 0 cor nasei.
2.2 DE analysis of CUC cells. ... , , ., ,
Protoii’ ctiripts-a isolated 'rom rr-credisseetad cue:a cells v;i co snuccted to 2- DE anaysis usm;? iinniQbiliseo pH gradior.i 
llpai arps ipH run:.;:; S-to nsnlmeEr and 4-7 lirour) '.vtl- in gel rehydrstior 3rul<:in ctPTceitratloris in samples vrlt t>a 
stcnd iniisisi so fECilnetinn co-nptirifAtns ol potf silver slnkcd unis .mrl CtcornaESia Blue sUunud uuls. ctel images will be 
aoauireo End arinlysorl, vls.ially ir Iho case of Sllvor slnlnea gels, and by Irmpirim-iler 2D eoftwaro. The patlcrns os the 2-D 
[v.iges from Dukes sloguo B and u respsotivoly cbtainoa Imn emeigercy aid c’ccllvn pul enta wil be comoared iu-d 
pmtein spot!? prccumlnaiety soon on onu ;u>d n;it me ether wi oo p’urili!;:ut fur idemlficatior arc valitkilK^i n.s descnbEC- 
t>slow. In addtior, t-c omlmns o’ the 2-D gol irmnisi from Dukes’ stages 3 and C will m compared tor iho piruKsar. ot 
identifyii’u is-ntolns associated with CltC dsaass p'cgresEion
3. Pmleln ld£-nt.1ication [
Follov;irg antityun ol pm'i’es, relevant npms v.'ill bo oKciscd 'ton grtis and scC-ootod to ttciJidu irans Mgor pniimg
by MiV.Dh MS. The copied mnsf. Ilngerconting wll crovido a tapb lirst pass Evaiyais t"^ metons ard ti it dnc& not prove 
siTicioni b’ iliu CTar&r.terizatisr ut any iu:: v>.;.i;il pioloins ’Ten ovbowii'i'’ WU.'MS arinrysis will be curried out us eg tandpin
In ou'sxpsriorcc, dnnllta&lion of Drc-fo nu Kim mtver stain&d pc's L'onl.iinirg the tow quanttt&s cf proft;.e cbtanes followirg 
LGM is diflinitll. ihus. we earn'd roly sniaty cm dl' aialy.fcul iii-t'. to yield suf'lciont ouarilUes »t proton lor successful 
ktentihdatm. Wo w'l Huualnre precaro prcpiL’.:il '.':: 2D gels 'rerr Issor capluuKt stiamsi spoclmens ruid Cncn’assie -bluo 
stain tiigni n^fle preparatvo pels wi? l)fr comparsd v.'ilh celE containing prouv? liom mciKiESEclotj M-:Ur-
ard protein rpuic. will tit: milchod fwo ?,’e iv.va’ii of He dlhicuMos in rnairtilna f.pnta from, heavily loudw CnDr'nssale-tluo 
staincs; ;;dr. wlM silver stained prate'at troTi tho Csrnt'iisste stalnee cels will bo subyH-.tnri tc MALDI-MS or Miv Ab 
ror idoitrticaton
4. VaHcaticn cf thia cxp'osslon ol dontihed vVuteinR
BsdE'jsc wo nntldp&ts somo hcluuyurueliy in obsorvod pro'.cm n'Emtcns. a vital part u1 tt'-.s t'.lnrfy wii K Iho valulal*cri cr j
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Sbj cnjloin rixiif^'Miiun data v.'& oblain. Wc- oill ondsa^i.ir, i.ning •n^lh.'xis: lorfependen: or 2 Dt. lo detofnine vihothEr Hu? 
observed ehargos «• nroioii' raiiiMsinn me rraimair.so <« Rleigor sa-n-Josoi. Where Bi-iituaJius jo ruoteln CiintlBrates t'a 
avallaoe. \'ie wll oEry out unnuMO,*,E‘l!’::hi!nii.<1 j;iiii: i»j ot CHC spoiinens jchtauiod frerr rho C-~"czr Tisc-uo Diii k; »fii 
*hc rojiiUs '.vil htx -'i::utfcd by a. specialist paiho’cgist 
A CRC :i3EU0 rricrcnrir.y wit: hu nerarated and wll to used lo- this ojrptm
A16, What Is the expeciod total durolion of porilclpatlon in Ihe study tor each paniclpanl'? 
not a pa i table
AIG, V^hot on? the potenilal advaiae ettects, risks or hazards torresonreh partlciponls cither front giving orwSlhholdtng 
medlcatlans, davlceSi Ionising radiation, or from oilier Intervenllona <tnoiudlng non-clin1caT>?
Mot Epplicabo
At7. What Is the potential tor pain, discomfort, distress, inconvonleuce or changes to lifestyle for research 
participants'?
Not Btyilirnhle
Aid. With I is the potential for benetlt to rosoorch participants'? 
nk apoiicahle
A1B. v/hat Is the polentlnt tor adverse ellecls, risks or itazaida, paln,diBEomfort, disirc-os, or inconvenience id me 
resoarchers themselves? (<f i-.'hv
Mot {ipnicatilfi
A?0. How will potential participants tn tho study tac <!> identllied, (li^ approached and <tli( rscmlted?
GiVecte.'aiik for casss bnrf 5oni.fik iio/wrafay <>
toaln, lha is a relrospccl ve shkjV ;m:J so an o' lie above are nol surety rolcvnnl Inweviu:
(IJIdL'il 'Icstion of partciptv'ts win ha vis the aronymsw coh-oe.?: enneer I ssuu hnn« onto mss.
finite partoioants will ail nave Dc-cn hppmEehsd cdor to iheir surycry for coon ■csccllon, nml consent taks-n for kooring 
saclio-is ol urtuwr i.. ihe Canos- ' iee.s Bsnk Rosoareh Cwilm. All of he .ndivldusia on :hs data baso aro aware Ihi-.l thalr 
Speclrven wll to used for tt-c n..f|iriaefi at lunhe- research
glhThscBaes v:il be roriuilml nccofoing to nstarmg cntenon availaWw on H'e dam tease. Indlvlduaia here both arms 
Sdi'.nlivv. mnl enera=ncy> w b: r.s cksoV rmt-hcu Im nrjs, eev. tu-no^r size, site. grads, singe, and ro-rrothteUlss,
A2t. Whets research participants vrtll be rocruited vtn advoHlsement. give speolltc details. 
0 noi nppiicaoie
NHS RFC Application Fcn*r - Ve'S on I AB.'7622/f
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A22 Whal are the principal inclusion crttaria?'fVMW ivatifr}
l "e CiOC^tcal *i5E ja UTipcs used in -his slurly wM pe sravutna by ’b* Cnrew Tissue B&rrt ‘^esej'er Cer'ie iC BHCi 
f ry wi lx* liun paBenls w :h C HC and were ccntentod at the t rre pi operand" Ini -isr-je and mtewnni clw-il ri'anratun 
TO t>» StoreC in Ihn ham 'im nrSearOfi puiOCShi
I) nstterts aomned t* Ihe ^cya l s*crocol ‘-rwr. for ocln-rrcl.il <:»••*»?<■ :>:*rul <«» 
hi Selectio' fron the randHa es .MinacTy enlt?i«; if- Ihe data base
nil Dukes Ss*5e B C. «w!‘ r.maoe ^section arc stiije J 
rvj Tunidirs ol *h» colon
A23. What are the principal erciusion erttMta? Please ibstty?
I P.iiimif. who have died t'orr rc' cancer reiacec circunttaiccs
II -'allerrs wfe Bave not nad cu-atwc rescr cn?
A24. Will Ihe participants be from any of Ihe loiiowmg groups?! he* as SDcropr:*:*
□ DMdiei t-Tder it
O Adi is r.-ith Icarr np 'lir. it^iW ef
□ AduTS arfo E'e Lnocnacious or ve*y sevedy H
□ Adults wlio have a terrr iai nneas 
0 Aduts ? etwaoncy srlwrons
Q Mu as vim irentsl neta iparticularK' * deuined under Mental Hoallft l opistuinn)
□ Adults suffering f*orr dc ncr li;-.
O Pnsonons
□ Young Olende's
□ Multr- ir Scnffai*: r/ho ate untc«e to cpiseot tor tharraavw
□ Healfy Vo untsors
□ these vho could be cent cored to "*w s pf.-»culs*y *>rriK*fii iKTonK'p w*t the invest ga;y. e g those in care 
harries medical ttudw.:
D Orfer vt leraoe g*oups
J'usr.tv ft#M* iTIClViJiCin
3alicr*s jndPTiinno ener jency nesactio' B'« stabilized prer to surooiv wnie- mov lake ortywhene n ihe region font 6 to 24 
Pol's ir these c"C-mstanoss paNet ls havt* ijK'f Itielt consent n Ihe enercency settnp s'O rave dc-ne so with ihp 
apcropna c course* "ij and education yrit? a rsas cnabis 
araouat ot tine to na<e an ro-nco ccosio'
A25 Will any research participants be recruited who are involved in existing research or have recently been Involved «" 
any research prior to recruitment?
® Yes Ohio O Not K*’owi
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if Ymt give anUjugHfy Wit .r&'jt'ir, t* Nc: K’wr.. »'.iar swos w» voo .‘s>,e ft? fino oof^
Patents mav have tahn |»a'! in e?t*r clinon' Hals but they uiKle'qo ''o piioeJu'ei arc si* oriy aoc«oa;hec n trey are 
CMaented ry a aur; ce1 reaorce Al pnrticipnirs "avc reen consented tc have t*'eir Himof samples kcor in t^c tissue 
bum uiKt there'o'e thetr tasue may have bee- usee tor oner urrented esearch yoiect* previously All vrorK i this proeci 
is rfrrr<sosciive
A26 Will informed consent be obtained from the research participants?
® res O No
if Yes jjive c’era.Vs y a-nc »»' fs*p wmsenr snrf •viw n a-v t*r •Snap G.we oat^iis of ?~v eamo.’iK amos .•? p'ev.yfc .nfcmat.on 
(W aJUM.or- rc a nncen '.efoenanon s.'ieefi s a crJeos. inreracpvo rmtenai
if part'C'patvs am up fee rec't.vfetJ frrim .-ray c*f 'he po'cr\t!ff vvehccaMr pex.cs •'sretf .v: aaj, (teta^ of Clef's sfctvs Ifkvn 
ro assure fteiV ccorecfv^c yesciioe r.te arra^jei'w.trs re be n\srfe 'a' ocssATf fror a I'eskai raenesenrarf/e
ff conser? >s nef fc be c«ar?«f. pieaae ey,oi«.-.s *ny nor
All patents wMi l ssue in storase have bees corse-ye ope-.v vey An infc-nra’loc le.Vlw s provided tor the expis-.iron 
of tfooeed -gs and whs' w oecdtio of their tssi-=s A specially devised consent form rs m circulatior which rrur be agneo 
by the tfcudm, the pane-' and a wnness A ramcer oi the s-rgtcai team vaii also verbally le cerate ivsat ras been c-vered 
m t“e nformation loallot arc danfy c-v uncertain issues T-s is a siniln' prcccss to the p^’or-Tcnt consent 'o-tts used 
routlrvsly le coeraBve surae-y.
Ony t'inse wn am compos r rents ill!? rsHgnle l» r.Hjn ''C lot at. Di.e hi Ue r.Vi.'e til mrywiji'iicy ::nhv<:i:lal surpnry tfime K 
usua y piery or lime ’or me tatier D decide icon '.vietter or not to participate * tissue collect on
A27. Will a signed record ot consent be obtained?
@ Yes O Nu
AM How long wilt the participant have to decide
Vaiabe; it vril deoend on the prctocol in place ‘v aerr cling pa'ie- s lor surge-.-
to take part In the research?
A29 What arrangements have been made for participants who might not adequately understand verbal expUnations or 
written information given In English, or who have special communication needs? .e g rransfaben use of '.rferorevs 9K •
l rstsaters a e 'eadity avs able in tfe hdspta'
A30 What airangementa are In place to ensure participants receive any information that becomes available during the 
course of the research that may be relevant to their continued participation?
The prc-ect does not •ccuirc t-c<r ccHin^d cxiriic.pai on
A31. Does this study have or require approval of the Patient Information Advisory Group (PtAG) or other bodies with t 
similar remit?, see fne pv.xfanne .refest
O Ym ®No
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A32b. WHI the reeeetch perticipent* General Precmtoner be informed that they ar* taking pan In Ihe study?
Ovo* ©No
A32t> Will permission be sought from the research participants to mlorm their OP before this la done?
O Yes ® No
tf .Vo » efrw cvios^". vector iv.*iy njr 
'■lei'io.t tesp: ise to A32 r.'st tick box 
Nc*. appticahlc
nifvlous iMpcnae In A3? seo-tl tick bo* 
Candoatos E.rc ret roq. rod :o phvsici y psncipaie
% 'ZctOm.fm ft m ISoTauf 4 ..........
AJ3. Will individual research participants receive any payments for taking part In this research?
O Yes ® No
A34. Will Individual reaaaf ch participanta racalve rwmpweamanf of erpenaea or any othar /neersfive* or benefits tor 
taking pan In this research?
O Yea © No
A35. What arrangements have been made !o provide indemnity and.’or compensation in the event of a claim by, ®r on 
behalf of, participants tor nepJlpenf harm?
"at ecplicab*
A36. What arrangements have been made to provide Indemnity snd or compensation in the even! of a claim by. or on 
behalf of, participants for norr-noo/.oerTf harm?
No-, apdicablc
A17 Now Is H intended the results of the study will be reported and disseminated?T«ck S3 acgorcenaw
0 Peer renewed sctsnti'ic p.mals 
E Inter. -i. •nputl 
0 Goifenenrepreseriatcn 
0 Ctrei pubicanor 
□ SubTisi on K rsgulatorv a.:hc-t^s
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Q Access :o rev; data and nght to publish freely by all Invashgatcre In c'.tcy or by litdttp.'unfcnl ftiiwrin;! Cumniiiic^
MlV.Vf ul ft 1 it vftsliijftltjr:':
Q Wi'.iqn feedback to rrscnrcli ntitiicipnnic.
Q Preser/.ation to certicioanta or ’dovam conmunity j'oups 
Q Utiebnore ea Oschraie Hevievj. university t-ib'aiy
| A 33. How will the wish Its ol research be mode ovoibhlo to rosoftrch participants and communities tiom which they are 
‘ drawn?
All carrplcs am provide? wifoui psdcri icloniilios lanonymisod-. Intornation wll rct be passed to pailltipanls. If paclr.lpunis 
doapoy tormtomtatem snoul their cases tils will only bo ptovltlSit via l- e ■nMk;:it Icuni 'csbcriEbloVIhor care.
: A39- Will the research involve any ot the lollowlnp activities at any stag® (Including Idanmicatton cl potential research 
! participants)?fili;n‘s-s app.rcc>'iafe,i
□ fcsipmlrdtlM ft* ivodlent 'OCS'OS by thane nitfimln Pm Ml Ifi, gr wilhio Ho WHS by those who woufc ro: nor-nslly have 
nccoss
0 Elsctroi c transter by magnetic or optical nsola. e mat o'<tonipi.npr nrlwmi;:;
H Rl aiirv] i>t thil.i vjilh till'.::r 
0 Escpntt of cata pjtside Ho European Union
0 lisp nt pftnSMPl .trldrhsshs. pfififcnribs. ti'ixus u-rmils or 'e-cplin'm ’'urrbcrs 
0 Publication of esmot quotatens fron re;.:cnde--3 
0 P.iblkihlion ol cata thal night allow tteni 'innliun nl i"riiwilijii 
0 Uso ol audiaVtsua) rccor-d ng aowcos 
0 Sto'oge ot catsonai data cm any ot the fdinwlnm 
0M anual tiles -io .utlng X Ay£
0 NFS compincrs 
0 Home cr ether jersonal coti beta's
0 llni'.'UM.ily irc.-noilOfti
0 Prvr.tc oerre-any conpulots 
0 tepttp computers
rurtiir/.rfoJsvi1;;.
I he CfBHtf has p'Ovcfb.d these rvnrpieo wlhtcii! poliunl identity ami ti'omfcjrc nnorynous to t-c rcGoarch tosin.
A40. What moasures have boon put In place to ensure confidentiality of personal data? Give details ot whether any 
encryption or other anonymisation procedures hove been used and at what stage:
Too tesuo bs.ih is sn iHcnymisod rfr.ta base 4or tao puroesas ol cjr 'asearch. Tins stage happera prit-to our reseist ot any 
i snus- bank in'ormiie-''
A41. Where will Ihe analysis ot the data from Hie sludy take place and by whom will it bo undertaken?
At analysis will pl.-.Ci: in Hu? dniVntaiun; (it tannery hy Ihe rvGc;i>x.’’ IciMn and may roquira the ho'oc; the depstanenta 
atatfitlcian.
A42. Who vdll have control of and act as the custodian tor the data generated by the study?
WHS REC Application Form - Version A.1 9 A&7622-'!
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A43 Who will htve acc»u to th« data generated by I be aludy?
Only tbs rseearc-1 loam
A44 For bow long win data from the slvdy be stored?
Years M Mantra
CJ're o' *'»-e fhoy »v" !* storao rmo w bai-c accw* ■trio .”>e aMtocM* artar^jemcm® for iba rw'a.
Womatten w< be stored on the dro-vi-nn -ai conpulers and only the r~ar iru" team will have access to irtornnlmi tt s 
worthy to •’Ole thai .ill tro-rratior is i a no’ icterai'iittte pefsorajissd b'-n
A4S How has the scientific quality ol the research been assessed?, '.ok as sporop’Vr
[j lnc»^i»’ir:enl erterna review
C Review witht a company
C Review ivtr i a rHihi-o -i'ir- resea'Ch gro^c
B Interna r~.-i“w .e g irvolvinp ooiteog.iev academic suoarvsri
[~] None enerni 10 tlx; invns’gator
D Otht”, i! g nelhodocgica19-drtlii«f;
If yw on* no! in cosseas.on of srr referees Cf otter scenic znttntv reports .'eievanr so your p.Toosr.u xtixfy aoo 
oescitbs rbe ipWew process and oi-rcc -nr H .-nvinw Dse.i gnoetafeer t>V nor seen fty me researcbe'. giwi fnc ctefcufs o' 
ftp f-.fi'.'y w.?.c’; fta* tindertafirt ifm ne’/«w
A44 Has similar research on this topic been done before?
C Yes <8> No
A47 Have all existing sources of evidence, especially systematic reviews been fully considered?
®Vcs Onc
>< Yes. pease give <*».VS of sooren sm*«■ gy- used If .Vc, expfoVi wny not.
At ewersve sdarrfr .ts.*g r .iCMed -kiIiuoe wm undrttHr’ to explore toe wcdi done i« iiioo-mc assessmont o 
Coforcta Career Because protcomii3 sarela'ively •'ew dcvciopmrni suent'ie corns swem -see as siardard to acouire 
background informr.liim is a basis for the tope of rmosttr INS tope has -<r boor imsir.lgatec orov
A4B What H the primary outcome measure tor the study?
We Wil detect dtPerenccs in protein e ceres son crofilcs ociween errergercy std elociivo cases
A49 What ate the secondary outcome measures?’./ iry:
NHS REC Applicat on Form - Vu-ston 4 i 10 AE'7622/1
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A50 How many part»opent8 will be recruited? How many ol these participants will be in a control group?
A'C'ived •Issue f»on* 5C Mndi3a*es w be used lor pruicm mvost <3at on hor valtdalinu of rlilforentally exyosaeo enrteius 
as rarmy CRC saroos es oen be hera.ml •» r>c used A :»sue rticro anay s iioins fcored *or tits pcTiose. Cw—oi livs-^os 
wif be tseo tor antiboa, va u.ii on anrt'or other aspect* cf prcrei vnlirtferon
A51 Has Ihe sire oi the study been Inlormed by a formal statistical power calculation?
O Yes <S> No
AS2 Has a statistician given an opinion about the stalislical aspects of the researchi
O Yes <55 No
A53. Describe the stalislical methods and or other relevant methodological approaches (o g. for quailtaltva research) to 
be used In Ihe analysis of the results Give details of the methods ol randomisation proceas to be used it applicable
Because of the nature of Ihe mrbooclopy this resuwch procc uses O' y very sn-aii r jrrbcrs a"C Orel not reqairr- s atist'oa« 
Snulysis
A54. Where wifi the research take place?'TV.* as acpvconare.
0 UK
□ Other states in European _ lion 
C Other caunircr. ir ruiopoan Economic A'ea 
D Other
Give rf~'n‘s
A55. Has this or a almlllar application been previously rafscled by a Research Ethics Committee In the UK the 
European Union or lha European Economic Area?
O Yes (5) No
NHS REC Application Form - VeiSion 4.1 M AB76221
Da’*: 1B.'06.'2(X)4 Rp^pnancB: 04Q1505'C4 Online Form
ASS in how many ana what Type ol host oiganisallons (NHS or other) In tha UK la tt Intondad the proposed atudy will 
take place"?
Aiovcsia ?re lyoe of o’ffanisafwii t>* ,'KMini/ i,,.w Ixn a*>cf aaiitxwnafa >f knon-n
N^rrfcor ul 
orpansati^s
3 Acjtt lee:hir«3 NHS Truslr. t
□ Acute NHS I r-slE
□ NHS Cnmir mlt/ amor -‘rinarv Ga-g Trusts 
n NHS Trusts crpvidin; Mcnl.ll HMTcare
□ NHS Care Trusts
D Sacal Os-® OqstnsaHnns
□ i*re:n»
O indaoendeit hospitals
0 Ed-icatcnal cstabtis^i-ne-ts I
O i -aeoende" resoar :h jn«s
□ Olht- 15 s-e detain;
Oner
1_________
A57. What arrangements ere In place lor monitoring and auditing tha conduct ol the research?
No: apc-iuititr
Will a data monitoring committee be convened?
Ov8i Shto
stopping the trial or other research prematurely 7
A58 Has funding lor research been secured?
O ves <§) No
It No what arrangements ere being made to cover any coala ot tha reeeerch? It no eatemal funding Is being sought, 
please say so
Costs will initially be covered By T< Deps-neri of Sv’gcrv wr ic ’uniing is soug-t "ton vanoui sour:os______________
A59. Mas the lunder ot the reeeerch agreed to act as sponsor as set out In the Research Governance Framework?
<S> Yes O Mo O Not Know
NHS REC Application Form - Version 4 1 12 AE'7622' I
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Da’e ''G‘OG'2004 Mdetc^ce OA-Q1505-'6<I Onixy; Fotti
Mas th» amptoyw* ©♦ th» Chial Invastigator agraod to act as sponsor of the research?
®Ycs ONo Offt:l Km/*'!!
G.'.« dMstt of .**» atpanaatton wNr aa as the sconso* of ’'to
UK contact, 
rme
t-censTte'initialt 
Soutane 
Crjjtrifeot on 
AcWrass
U’’ v:'tiit> of I ivcrpool Orfuittrionl o' Sl'tjorv 
at* Floor UCD. Roval Uverpoc Hosplsl. 
i’leaco’ St'eet Llverpoo, Metseysce Ttrtephonp. 0t51 7C6 4170 
Fax Dial ?C6 6aZ6
A60 Has any responsibility for the research been delegated to n subcontractor?
O Yes ® Me
A61. Will individual rcsc.trchcrs receive any personal payment over and above normal salary tor undertaKinq this 
research?
A62 Win tndivtdual researcher* receive any other benefits or incentives lor taking part in this research?
C Ye*. ® Nn
A63 Will me host orgsntsatlon or the resesrchei's depsrtntent(s) or inttiluiion(e) receive 
excess of the costs ol undertaking the research?
A64 Does the Chief Investigator or any other invesligator collaborator have any direct personal Involvement (B.Q. 
llnanclai lhare-holding, personal relationship etc.) In the organisation sponsoring or funding the research that may 
give rise to a possible conflict of interest?
O Yes ® No
NHS REC Application Form - Version 4.1 ’3 A&7622-1
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Da-<? i6-'06.*2004 Referance: 04.-O' 505''5* Onlne Form
A6S Othet rH^vanl ttfefene* numbers If Known jive cW.'A'.V i'.a metfOtt ’KtitlOft is SCV3p<C3te'< 
Appiem M'nKj.nnteAdn's ms-' rrterenoe e.g. RChTI avaiaMe).
Spor$5-'S''y>5tCOy ryrrfccr 
Fu-Wa'* re'afenca *arrter
Inlet"afonai Siaroaid Knaoniseo Oor*.ra ed i-al MlTtrer S-tO Nt 
Tiwopnar ctnicai Trial* Database ifcus'acr:
Prt*i?c »"<»•?•
A66. Otbac Kay Invaatlgaloracol laborator* ocan <x>-*cp*c*rZt sKui'o ie itfra.
Tille: Misiet
Foronano'l'tttals Sjmsme Roo-ey
1*0*1: Contultait Coloreciai iu'geon
Cur-'cstiotts MT CltR TRCS DV
Ofp=nisaton Royal L vetpool and b'oadptsen N*- S 'rust
•Vid'e«i SC Lnk Unit -loyal uvepoo Hospital
Prrorol Siren Tolcchono 0131 706 3426
Liverpool t“8x
noslccde L7 8X1*
F-mai Pel RrirvyySB'lhtih' nhs tK
T’.lc Dm o'
Foror-irrc lnttals Etlhre 3urrA-ne. Coetello
1*0*1 Lecturer in Mciocula' Boogy
Qualrfca’crts BS«: PUC
OrgansBlior Depa*nerrt o' Surgery UniveraHy ol Lve-pool
Adores; Sth rnn» ur.D nrr/al iwpco'1 lr»sp ini
Hvizoi S‘re»- leepho'e CIS* 7D6 4178
Liverpool Fm
POSlUOlIt! LES 3GA
E-ma : e.oosrelL'* tv.ac .k
title Mate’
f oreratre.lnBii'ils yas Sisr-mv' ■OwIt.'lK
Poet Rosoaroh Fp on
OuAimcetcns MB CnB MKCS
O'uansalio'- lliiivninily ol l tvttrCOOl
Acdress bdiFoor JCO
Ruv.il Livrr|)u:; 1 lit'.(iil.il Tntept-crm 0151 700 4170
P'-escn Street. Jverpcc* Fax
Pocxoda U»3GA
t-Tiail l KrAdakrSmv ic.uk
AST. It ttta raaaarcb Involvaa a apacrftc irrtatvantion, <a.fl. a drug, madtcal davica, dtatary manipulation, litastyla cbanpa 
etc l whal arrangement* ana being made lor continued provision ol Hits lor tne participant (It appropriate) once me 
research has finished?
NHS REC ApplicaliO'i Fotm - vereto-) 4 " '* AB'7622’1
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Dale 16.06.-70CK Reference OA-Qi S05.-64 Online 10'ir
Q Net AeeHcafcte 
lot scplcaoe
A66 WTval do you consider to be toe mein ethical lesues or problems which may arise with the proposed study and 
what steps will be taken to address these'’
As this is a retrospect] /* stuoy usmp aicnived tissue tr.v has speortaiy tir*n cnllnctcrt with writon c^s^nt tor tt-e very 
pnmnsr cf irspa'irh, i» is hire to fr-n any cthiral muds fat can bo roister to *he proocsed case
A68. Do you need to add further information about certain questions In Part A7
This cueston & not appl»:abie far 'he on te venson COrtcC 'orri
NHS REC Application Fo'it Ve'Sion 4 I 15 AB/7622.1
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Dale 16.06.-200-! Reference: (M 'Q15DS.'fi4 O'ltne Form
BSw r X * T ^1 IT nfr • mr * - ^mJUBLP i •
1. What wnpies end how many will be included In the study'?
Soriptps wiB be wcclod fw the O'” verity 31 -ivcrpoc1'* list jo fcan< Canc>5r luste bank Mesearch Onf'e) "h«e will 
ncud* color, lyrron *odet 1*0 in'#' lectlo's
I r< rillial plan is lo invesiigaie up tc 5C psllert eases.i”di«ithn ii-itijCR'sjMrplos mill be obtained (c lion oerttircinco and 
qual fy coTfgl o' ;»>libi»dcs clc any I ssue anays
2. Whet testetecbniquMa will be carried out on the samples?
Tlrsr i«f m.Hii>rrl 1 psir. A hi.' wry briefly
c-o?on t astir ol "clovant tumours will bo oblair-so and proleic edraccec Iron oissedeo vid run rasseclcd samples Proteins 
wll be tepatifeci by 2 Dfc 1 or oChST appnoprafe r»?lliuils) and J 'ferrrx:rs n crof'os pin po rocs Imerastm; protwiswfl be 
idei' tleo by vadpLK rrru.iW'rs m litri 'fj -rv'ss sprciromoir/ amj va dated by innunoh alocnemstry or other appropriate 
methods
3 How will samples be labelled idenlifted 7
fnoveate ii'sacyv'w can te co.rfoei'eo fo oe 'iflerwiw ’ccoeo . de .uenrir.ei)' . "S'Kdymsnu' or •antmymous*. attfs: whaf 
scape iper.i'hft's a*e •vn'otna /See fte gtuUarvj? nmret for rif«iru»n»rs.'
At r'ari'arcn is anonymtnd prior to is recery l r s Is caired uul oy H e fos„c bank desarmer .CTBRC:
4. Mae specific consent been obtained previously to use stored samples lor this purpose?
®vei ONc
1 5 Does the research involve the analysis or usa of pane tic material from human biological materials?
{ O YM ©No
6 Would It be possible to link the results of any genetic anelysis back to the individuals?
OYeo <S>No
7. Is It intended to link the results of any genetic enelyela back lo individuals?
O Yes <5> No
8 It the samples are from an established tissue bank, give the name and location of the tissue bank, the organisation 
responsible tor it and the name of he manager
Canoef Tissue Ba'k Rasearc- Genre 
The Drivers iy of I ivorccc*
Department cf Heirtocgy 
D-ncar Bu cmp 
Caulby St.
Oeroool
L6B3QA
Orgonisr.Mon Rcsponniblr Unversity t>l I vtrpoo
NHS REC Apoticalion Form Version 4.' ’6 AB'7622 '1
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Data: 1 S'OG^Ofrt Rsfeieixo: 04,''Q1S05'S4 Oiling Forn
Miiimac^byW's W. Prinio OS“i FI5MS iS^nior ExpsKnrsiita] Cfllcarii
0, Slpnntura of the tisaue bank manager.
I cunlirm tiiat I ^avx; read dva nosaarcfi ouposal. I agre- to ‘h= use ot sentpiftfi r^n- Kiir- liwur bark fo* the purcosss stated :i 
Ns replication
Bgnaiure: ...............................
n?ilo (ckt'rm'.Vryvl
P-iri! Wiiirin:
NHS REG Application Form - Vorsion 4.1 AG.'7e22.'1
Oa-c 1B.D&700* Referpace C4'Qi5nS.ti4 OnMne Forrr
- The r‘p-na‘'3n fi this Inrn s to thr hest fry kntwdKJjc and belie* and I take fill resccnsibilrtV tor it.
- I .inrfcft.tkc In .nlmln liy Itir nMcJl onflcpsds ..ntlpilyinf; l*ir DcrUirnlinn o* Ho sinkj and QOOd practoe p.ideliret O" Ihe 
prooet condiitt e* nesearrh
It ll» rifSMa:!' ut appftMMl I utO*!il»kt- lu sO*mis uilliiml iH»:_r»wnl (Invialtin tc« (tio Sludv DXICCD. tf« lerns of tie fill 
appicaton c* lohich the main ^FfC hr.s piven a favourable and ary CMOiDons set tut by ihe nr an RtC in giving Ms 
fav^jra&e opmoi
- I unoertake to infcnr the rrain REG of anv cranpes in the onotcco ana to auo<n# annua ieoo-« setting out Ihe (mgress 
ot ihe reeearDi
- I an aware of ’nv ■ceocnebillty ta b? up tc date arc oompiy wtf tne neqi wens or tie aw and reevant g. aeunes 
real ig to secure-, arc contidenaaiity ol oate-v o' olhei personal data Mcdod hj itie nrre to -cote o* "ehc ncccsso vnf 
the? apryupun'r D.il.i P-iilotliiMi OTo-i
urnerstJind r-ar lesearch raoonlKdata may ne: ‘-.ubrstl o bnypeetton for audil pi —os-os 1 -sojired in fjt.re
urcerstand t-at peraona data abo.' ire as a nesearnhe*' in |-iis aaplic.it on will be hob bv the fote^ant RECs a-d :f«r 
ocwrEfio-a! ravage's and trat t-i* vvll oe ■na-ager acccrdirg to ”■« cone plec esiatoHstw*; in |n« Data ^roiccton Acl
tagnaune ______________ _ ____
Date idcArnntVywi
^irt Name
1. Do you need to add further Information about certain questions In pari B?
7>vs puestioe «.-.or an^VcabVe fa' r.*ie c.t»'ne version of COHtC form
NHS REC Appliuatiurt Form - VO'Sior 4 1 IB AB-7822-1
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Data: 16'0fr'2004 Reference: 04,-Ot 505-164 Online Form
1 ms term snnute ne conpipiM try in# *iincipa liv/es'iai-y Inr each «-•# (see (^rmeryi
Name of NHS Research Ethics Committee to which application tor ethical review is being made
Lverpcxj Local Reeeaxr Eftics Comn-tee
Project Reterenoe number Irom above REC 04 0' 505.154
Name of NHS REC responsible for SSA
livcrpod local Pcscarc*- Fthics Conrr nc
SSA reference (tor REC ottlce use onlyf:
Cueston* Cl. C-r. CO. C6, C7. C8 and C TJa ccrresponc to questions At. A2 A65. A10, At2 .M3 a-0 A29 on mam apb'canoo 
form respectively and w populate autc-TiatKally
Cl. Title of Research |Pcci“flreo' ^oer A1;
FuR Ulc Colo-ccLil umoc-s Co-npa'a-r.-o prc'SCTO anavsis & emerpe-cv versus eiectve patient ruinn.rs
Ke>- worts Colorectal Ca-cer proteonlc®. c.rnpton Ojiallot , su-vval
C2. Who Is the Principal Investigator lor mis study et mis site?
Title Mr. Forcnar'c.'lntlials Pa.
Post
O^anttcatons 
OgnnsaiiDi':
Address-
Co-si tarn Cocr-era St-geon 
ME C*ra l-HCSUM
Royal Livrrp:xji ant Dmiortgxcn N*-S '"rust 
5C L ik Csit, Roval Liverpoo Hospial 
I’rescar Street
Jvorpo:-
Post Code L7 8XP
E-rrail Pau Roonayt^rtuht n^.uk
leepfcne (P51 TOI 3426
Fat:
Suriame -tconey
19*#
03. Indicate the number ot trlela'projects within the organisation that the local t
Principal Investigator has been involved with in the previous 12 months;
How many are still current (active or recruiting)? t
Give details ol other members ot the local research team responsible to the local Principal Investigator
NHS REC Application form - Version 4 1 19
Date: 1Cv0Cv^O04 Rufuroncu: 04'Q15D&.‘G4 Online Fomts
C4. Chief Invesllgator fFopL'.'sri'S f-'cw Ai>)
~i'o Dr. Fore'aire'lniliala Slhne
Fcsl . nrt..'f:r n Mnlrc;iita'L Gtiicigy
Sum&me: Coste'c
Djalilicalions 3.Sc >;Hen5.)in Pha-naco^gy. ^hD. r pt-irnacolcgy 
C-i;i£rt£-i* i:-i Acadenic Depannoni c' Sur:ery. Liverpool l rv.-^s :y 
P/idress St^hlPOfUCD
L-vtn (XMI ilpapilal
“rescet Street 
t-'e&i Code: -63 3QA
C rV.ill tnsa^tjr.JP iv.fif: i.k
Tutejiiwid 01517n-r»4i7a
Fax: U15170S&S26
C5. Other relevant reference numbers if known iPrsrMuifco' ton .-tyvSi
^pptxjanta'orgar'&a'C'Ts ovrn roferoe;o number, o.g. HD;'- exstlafclei: 
Kfieri'.e-'Si'g'otoont ruivfcei 
Fculp-’e fefe'enex! ’mn'bnr
InternatonEt Slar^ard Raidamned Conreied Tral Nutiber IlSRC’Ni 
Eur:>;.:i:;ii' Clinpis1 Tiinli; Dnlnlni!;!; iEi>::iaCT| Mui’it.il’i 
Project websi'.e:
Off, Give n brief synopsis.'summary of methods and overview of tho planned resanreh. This should include a brief 
description of how prospective research parilcfpsiUS and concerned communities <not necessarily geographical) from 
which they are drawn have boon consulted ever tho design end details of tho research?
flWjere app;op!)a!s s t!cw efiart cv ABorram .o!.1,'vi x'.'reo st)p :v.-i if rtfiavWivj o'car r.-x.-ja'iy ivivr,' iv.v,' f/ir.'
resraiTfi cndibbr.r’. )xm mnny li'rncsaxxf w rvi’im citfcr/. iFtfpvtawofxxvAlO!
it is important to slato that this is n study using very smat nurrbors n v,'h>-h human tssuo is 10 bo nvEStigstod 
rolrospnclively. Urn tissuo owieeraefl fs port of Iho Oani«r Tissrm Han*, ^csctircft Cm: I to which has beer coHscled frem 
sslect-d conoor patents with tnelr oa-nsait and urderstaidinj that ihe;-tissues wit c« usK tor the purpoEes el cancer 
nj'Jun'i.:!' Ttiurc will III.: ttu UilUtt willl I'-t! ivithnly, :i;nl tm fi.rU cr 'i(jul hem them is required.
the preaee: can be outined aa IoIIet/.'s
■ Each group w il t*avc Oukcs fi ttixf Dukes C tumours obtained tro-n no fcankfi.o onctp:ney and aloctve pailsrta). I
■ Tumour cells v:i: be dissected from ro,i tumour matet'al It rocesEary.
■ Preleirs will be ext'acled fren- each sarrefe and srparated in two ri mc-isuns as lolle.vs-
• Gels will be tosded vhlh a) lirr.-ed matanal **t 20 *n«rog.tanis proten) and s :v&* statnsd are o; wnn nrealer quantities or -
protein i> 250 nticogrrms p-oten) u-id Csu-nas-iic-Duo stnincdi.
* Stalneo gels v/Ur be scanned and Images analysed fcolh vlsualy ar.h using Imagenasfer 2D satlware.
■ Preiein spets unique to emergen:/ patient umejre or eective psttenl lumoura wit m tsolaled from gels arcs Identified by *.
MALDI -fdS
■ Gets will here analysed (Pan B) wah a view to xantif/lng p-ateln; the I are typical of specif c Di.kes' singes. u
■ Ve.idotion of sooctod candidate ptolcins wi; to corri:d cut by IHC ! m.-nunghisls chemistry; on a 'argo number d sample?- J
- Conliol tssue. ellher cancerous O' run cancarous. nay seed to oe sampled and assessed i a aim. iar fashfei. f
Allamstlve protein bases araiyiical m&lhocts are also envisagM. ;
NHS REC Applicftiiori Form Version 4.1 20
169
Dale: Rnfcrencu: 04'Q1505:124 Online Form
1 SiiliKlum »l CRD llsft'.ifift firo e-.-tcimfr'it Qt lumour cells
Sarrclss I eac'i :4 D jlics* D and Cl Fun yj urrorgmxjv C\il nnlu n bl utoclivc pu’.ib'r'.s •’■'ill bu tctHclod and ubUiircd 
Fcim :h= Ce^Csc I iss jo Bans, LivLirp-o' Tus Bs-sua hss already seen «lloH*d Iron oonsorted pEllanl lor tlu* purcosad of 
rustMirri’i Wn '.'.ill carry mil as;>' cnpluro n'lcrcdlcs&cIlQi’i (LCMj. -1 needed, ur needle dler.eelidn :n unrlsh far limm.ir er*:s. 
Microdisaected ce‘!& svill bo rop-vp^d rjifnedy info p'OtvCHAPS-b-vst'o lyvi? biilfor Wo will subiosl al sarnplos *o Iho carco 
mi'DMi nr Itaeae.ihry.v ovdas fiyaealiy 6 pet casei
2.2-Ut analysis ol CRC oeia.
Prc::>n stvipius isulafad Trun 'nbrinkssnoted fli.v.l.il iMtilf; ivlll be f-.ilijncletl to 2-DE nnolyss usinij invnpwliauU pi I (iMdiyii 
(IPG| stnpE |pH range 3- to nonHoar and 4-7 linoa'l v/iih in-go’ ror/vraton. Prate i concenlf&iiQns ^ sampisa i.>iil be 
siandrjfciced s» inriiliar -ig conipsfaess of boih cnvac siainM jeic aro Dei-nnssie aine etainad gois.. Gel images win ca 
R:qi. --od ai>3 ?.iolyE>;o visually in bio coso of Silver slatnod po5, and by Irranomaste’ &D so'lwaro Tho paltamE of do 2-0 
gsi images Iron Uukes stages S and G sas emotively ctta ied from aTi&'gen:/ a-d a ecllve patsnta vrli be compared and 
protisri :;ixils iinxfnmiriiitctly fttmi OH OSli; mid not H«; :>!li»4 vjjll hi? prefi! sftvl 1m iiii>n|irt:;t|inr vjilidldio'i. ita ■deserted 
bcfoiv In add-lie-, b'o oatiorna of b'o 4>~r> nd inonos frorr DuBcs' slapos R and C vsill fco oompareo for tio purpMes of 
identifying aoteins associated wrth CRC essaae progression.
3. r’lpluiii ieenlilcallo''
Foilawng analysis c-' profllos, relevart proloin s-cots wli co excisod from .gel& era subjected !.d peolide mass. fing9f panting 
by MAI.DI-M5 'ho puptidn nnsn f ntjerpfi yirg win provide a mniil f :Vi:-.s muiypii; ol IIio proteins arid if il does rot P'tms 
sulfcent for tie cbsractenzalion of ary indyidiaJ croteins Hie1’ subso-jon! M&'MS analy&'-s w:i o& carnsd cut usin; lancem 
MS-MS.
In our o>;pedon:o, donbfcaiion of proto ns f'err silvor-atanod go'a ccntsminp tee ow quantdes c-; protein oKaired ftf lowing 
t.CM isdtllcnll. lliiis. we cor.-'nt i ety sft’eiy on nur rsMiyllcnl gels to yield siitifideni n.inntth.is nl p'oteie for fycwm'isfi.! 
idontif caiioi. Wo w!l tho re'ore p'oparo proaarabvc £D gob ?re-'n lasor capturod stromEt spocirrons sno Cor-rmssio-b'uo 
stain inem. "Inrsepififraialivegeawll oa compared will) aive' ataired gets cm.iaim-g u'eie.ri irnm -Pisirxievipclwt rietis 
snd protoin spots will bo ninttchrxi iV/r. nrn ruwtro of Iho diff cu'iioj in mipuhiryj spots from henviy londrd Cccma&sio-yuo 
stalnsc gels with £ ve- atamed gels). Material frem the Ccontass e-slEirgd gels will be sitjectecf to MALOI-MS or MS.VS 
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C9a. Give the name ol tne NHS or other organisation with which (he PI holds the necessary contract {substantive or 
honorary) to undertake tho research at this silo;
Academic Dopsrtmori of Surgery. Royal IK-orcool Toac iinp Hospital Trujl
C5b. Give Ihe name of the research site lor which the PI Is responsible, II dltierent from the above. {The alta may be a 
whole organisation, on individual unit, ora consortium):
C9c. Givotho name and contact details for the Research Governance lead lor the research site:
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C12b. Glue details ol vriio will be responsible lor oblslnlng informed consent locally, (heir qualifications and relevant 
expertise and training In obtaining consent (or research purposes;
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Translators are readiy available In tne l-oaateL
Ct3b. What local arrangements have been made to meet those requirements (where applicable)?
Tne hospital Tust has access to mteiorclo.'S for tlx> pinjotus c! wilten am verba1 consent.
C14. In addition to Informing the GP (il required), what arrangements have been made to Inform those responsible tor 
the care of the research partlcIpaniB In the host care organisation ol their Involvement in the research?
During the in tia; lissi,c bank consent process. Indvc'jals usually ctssuss the case with then next of kin. ft they tiyvi* ;.iny 
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CIS. Arc (ho Incllitlos and staffing available locally adequate to perform any necessary procedures or interventions 
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Appendix 3
Liverpool (Adult) Local Research Ethics Committee
Hamilton House 
24 Pall Mall 
Liverpool 
13 GAL
Tel: 0151 285 2097 
Fax: 0151 236 4493
21 July 2004
Private and Confidential
Dr £ Costello
Lecturer in Molecular Biology 
Academic Department of Surgery 
Liverpool University 
5th Floor UCD Building 
Royal Liverpool Hospital 
Prescol Street 
L7 8XP
Dear Dr Costello
Full title of sfwdy.* Colorectal tumours: Comparative proteomic analysis of emergency 
versus elective patient tumours 
REC reference number: 04/Q1S05/64
The Research Ethics Committee reviewed the above application ai the meeting held on 07 
July 20D4.
Ethical opinion
The members of the Committee present gave a favourable ethical opinion to the above 
research on the basis described in the application form, protocol ami supporting 
documentation.
The favoumbte opinion applies to the following research svfr?
Site: Royal Liverpool University Hospital
Principal Investigator Mr Paul Rooney
Conditions of approval
The favourable opinion is given provided that you comply with the conditions sot out in the 
attached document. You are advised to study the conditions carefully.
Approved documents
The documents reviewed and approved at the meeting were:
Documont Typo: Application. Version: 3.0, dated: 14/0'3f20Q4 
Date Received: 14/0&?2004
Document Type: Investigator CV - Eithno Costello, undated 
Date Received: 14/082004
*----------
G
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Document Type: Protocol. No Version Number. Undated 
Date Received. 14^Q&?20Ci'i
Document Type: Covering Letter, dated: t4i''06?2CCd 
Date Received: 14/06/2004
Document Type: Participant Information Sheet. No Version Number. Undated 
Date Received 14/06/2004
Document Type: Participant Consent Form. No Version Number Undated 
Date Received: 14/06)2004
Management approval
The study may not commence until final management approval has been confirmed by the 
organisation hosting the research
Ail researchers and research collaborators who will be participating in the research must 
obtain management approval from the relevant host organisation before commencing any 
research procedures. Where a substantive contract is not held with the host organisation, it 
may be necessary for an honorary contract to be issued before aporoval for tiro research can 
bo given
Membership of the Coimnirtco
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet.
Notification of other bodies
We shall notify tho research sponsor. Royal Liverpool University Hospital that the study has a 
favourable ethical opinion.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Comm Higgs (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
REC reference number: Q4/Q15Q5/64 Please qtioto this nutnbor on all correspondence
Yours sincerely
DrTej Purewal 
Chairman
Copy to Dr R Owen. Clinical Trials Centre, Royal Liverpool University Hospital
Ewr/nsoffis List of names and professions of members who were present af f/re meeting
and those who submitted written vomments
Slxmiurd approval conditions
List of Kamos and Professions of Members who wore Present at the Meeting or who
Submitted Written Commants
Or TeJ Purewal
Consultant Diabetes'fcndocnnology
Professor Simon Frostick
Consultant CMhopaedic Surgeon
Dr Derek Adams
Consultant in Restorat^e Dentistry
Mr Roy Farquharson
Consultant in Obstetncs 8. Gynaecology
Dr Alan Fryer
Consultant Geneticist
Dr Fred Mostafa
ConsuRan* Anaesthetist
Mrs Pauline Rowe
Lay Member
Mr Jonathan Herod
Consultant in Obstretncs and Gynaecology
Mrs Kathy Simons
Administrator
RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF 
INVESTIGATIONAL MEDICINAL PRODUCTS
Standard conditions of approval by Reseatbf) Ethics Committees
1. Further cpmmurntations wish the Researr.h Ethics Committee
1.1 Further communications during the trial with the Research Ethics Committee that 
gave the favourable ethical opin on (hereafter roforred to in this document as ,:thQ 
Committee") are the personal responsibility of the Chief Investigator
2. Commencement of the research
2.1 It is assumed that the research will commence within 12 months of the date of the 
favourable ethical opinion.
2 2 in the case of multi-site research requiring site-specific assessment, the research
may not commence at any srto until the Committee has nolifietl tho Chief Investigator 
that there is no objection from the relevant Local Research Ethics Committee or other 
approved local assessor.
2.3 The research may not commence at any site until the local Principal Investigator or 
research collaborator has obtained management approval from the relevant host 
aiganisation.
2A Should tne research not commence within 12 months, the Chief Investigator should 
gsva a written explanation for the delay. It is open to the Committee to allow a further 
period of 12 months within which the research must commence.
2 5 Should the research not commence within 24 months, the favourable opinion will be 
suspended and the application would need to be re-submitted for ethical review.
3 Duration of ethical approval
3.1 The favourable ethical opinion for the research applies for the excected duration of 
the research as specifiod in tho application form. If it is proposed to extend the 
duration of the study, this should be submitted for approval as a substantial 
amendment
4. Progress reports
4.1 Research Ethics Committees ere required to monitor research with a favourable 
opinion. The Chief Investigator should submit a progress report to the Committee 12 
months after the date on which the favourable opinion was given. Annual progress 
reports should be submitted thereafter.
4.2 Progress reports should be in the format prescribed by COREC and published on tho 
website (see www.corec.org.uiO.
4 3 Progress reports should include an annual list of any Serious Adverse Events 
occurring to research subjects (see paragraph 8.3 below).
4 4 The Chief Investigator may be requested to attend a meeting of the Committee or 
Sub-Committee to discuss the progress of the research
5 Amendments
5.1 If it is proposed to make a substantial amendment to the research, the Chief 
Investigator should submit a notice of amendment to the Committee.
5.2 A substantial amendment is any amendment to the terms of the application for ethical 
review, or to the protocol or other supporting documentation approved by the 
Committoe, that is likoly to affect to a significant degree
(a) the safety or physical or mentaf integrity of the trial participants
(b) the scientific value of the trial
(cl the conduct or management of fho trial.
5.3 Notices of amendment should be in the format prescribed by CORED and publishac 
on the website, and should ba personally signed by the Chief Investigator
5.4 A substantial amendment should not be Implemented until a favourable ethical 
opinion has boon given by the Committee, unless the changes io the trial arc urgent 
safety measures (see section 7) Tho Comnutlae is required to give an opinion within 
35 days of the date of receiving a valid notice of amendment.
5.5 Amendments that are not substantial amendments ('■minor amendments") may be 
made at anytime and do not need to be notified to the Committee.
5 Chancres to sites (muithsite studies requiring sitc-spccifia aasaRSttmi) nniy)
6 1 Where it is proposed to include a new ate in the research, there is no requirement to
submit a notice of amendment form to tho Committee Part C of the application form 
together with the Principal Investigator's CV should be submitted to the relevant 
LREC for site-specific assessment, tf no objection is notified, the Committee will 
extend the favourable ethical opinion to tho new site
6.2 Similarly, where it is proposed to make important changes in the management of a 
site {in particular, the appointment of a new Principal Investigator) a notice of 
amendment form is not required A revised Part C for the site (together with the CV 
for ihe new Principal Investigator if applicable) should bo submitted to the relevant 
LREC for site-specific assessment.
7. Urgent safety measures
7 1 The sponsor or the Chief Investigator, or Ihe local Principal Investigator at a trial site, 
may take appropriate urgent safety measures in order to protect research participants 
against any immediate hazard to their health or safety.
7 2 Tho Committee must bo notified within throe days that such measures have been
taken, the reasons why and the plan for further action. Notifications should be in the 
fomnat prescribed by COREC and published on the website.
8 Serious Adverse Events
8 1 Any Serious Adverse Event (SAE) occurring to a research subject must be promptly 
notified to trie Committee where it is considered possible that the event resulted from 
their participation in the research. An SAE is an untoward occurrence that
(a) results in death
(b) is lifo-throatening
(c) requires hospitalisation or prolongation of existing hospitalisation
fd) results in persistent or significant disability or incapacity
(e) consists of a congenital anomaly or birth defect
(f) is otherwise considered medically significant by the investigator
8 2 Reports of SAEs should be provided to tne Committee within 15 days of the Chief 
Investigator becoming aware of the event, in the format prescribed by COKEC and 
published on the website.
8.3 An annual list of SAEs occurring in the research should be provided to the Committee 
with the annual progress report.
8.4 The Chief Investigator may be requested to attend a meeting of the Committee or 
Sub-Committee to discuss any concerns about the hoaith or safety of research 
subjoefs.
8.5 There is no requirement to provide reports to other RECs in the case of multr-site 
studies
9 Conclusion or early termination of the trial
9.1 The Chief Investigator should notify the Committee m writing that the trial has ended, 
and provide a final report on tho roscarch, within 90 days of the conclusion of fhe 
research. The conclusion of the trial is defined as the final date or event specified in 
the protocol, net the completion of data analysis or publication of tne results
9 2 If the trial is temrinatod oarly, tho Chief Investigator should notify the Committee 
within 30 days of the date of termination. An explanation of the reasons *or early 
termination should be given.
9 3 Final reports, or reports of early termination, should be submitted in the form 
prescribed by COREC and published on the website.
10. Broach of approval conditions
10.1 Failure to comply with these conditions may lead to suspeivsion or termination of the 
favourable ethical opinion by the Committoo
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me Royal Liverpool ano f^/'g£j 
Broadgreen University Hospitals
ftoyii! Livf-nau^'
("eKCt >*ree: 
L•eroc5 
./
01 Jjly 20C4
Dr E thne Costello-Goidnry 
Royal Liverpool University Hosatal 
5th Floor UCD Building 
Daulby Street 
I iv«r[MM)l
L69 3GA
Dear Dr Eithno Costolio-Goldnng
Trust Project Ko 2S81 LREC no 04/Q1505/64
Colorectal tumours: Comparative proteomlc analysis of emergency versus elective patient
I am writing on behalf of the R&D Directorate and Clinical Tna s Unit of the Royal Liverpool 
& Broodgreen University Hospitals NHS Trust, we have peer info'mod by the Liverpool 
Flh rs Committee about the above study In order to proceed with the study, you must irst 
ootain Trust approval from us as stated on the ethic's approval letter
We would be very grateful rf you could pnDvide us with a copy of the protocol and completed 
ethics application. This w II enable us to complete our 'ecords and register all the necessary 
details on our database in ordor for your study to he progressed towards Trust approval
If you have the documentation in electronic form you could email it to my colleague
Cra fi.Bipgs^rlbuht.nhs.uk.
Many thanks.
Kind regards
Or Rod Owen 
R«-D Dirwctoratv
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North West Colorectal Chapter Meeting 
Liverpool Maritime Museum 
March 2008
Heat shock protein-27 predicts poor survival in rectal but not colon cancer 
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Publications
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cancer but not colon cancer.
Tweedle EM, Khattak I, Ang CW, Nedjadi T, Jenkins R, Park BK, Kalirai H, 
Dodson A, Azadeh B, Terlizzo M, Grabsch H, Mueller W, Myint S, Clark P, Wong 
H, Greenhalf W, Neoptolemos JP, Rooney PS, Costello E.
Gut. 2010Nov;59(ll):1501-10.
Smad4 loss is associated with fewer SI00A8-positive monocytes in colorectal tumors 
and attenuated response to S100A8 in colorectal and pancreatic cancer cells.
Ang CW, Nedjadi T, Sheikh A A, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park 
BK, Schwarte-Waldhoff I, Khattak I, Azadeh B, Dodson A, Kalirai H, Neoptolemos 
JP, Rooney PS, Costello E.
Carcinogenesis. 2010 Sep;31(9):1541-51.
Colorectal cancer—a prospective evaluation of symptom duration and GP referral 
patterns in an inner city teaching hospital.
Khattak I, Eardley NJ, Rooney PS.
Colorectal Dis. 2006 Jul;8(6):518-21.
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